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Summary 
 
Protein tyrosine phosphatases (PTPs) have been identified that mediate a range of 
physiological and pathological processes, such as proliferation and tumour metastasis. 
PTPRK and PTPRM belong to the same subfamily of PTPs. This study aims to 
investigate the role of PTPRK and PTPRM in cancer development and progression. 
 
Knockdown of PTPRK expression was performed in PC-3 and DU-145 cells. 
Functional assays were then carried out on these cells in order to determine any changes 
in their biological properties. Knockdown of PTPRK significantly reduced the growth 
and adhesion of both PC-3 and DU-145 cells. The experimental results suggested that 
reduction of cell growth is potential involvement of p53 and/or caspase-3 and -8 and its 
up-stream molecule JNK. 
 
The decreased expression of PTPRK and PTPRM are associated with poor prognosis 
and reduced survival. Knockdown of PTPRK resulted in increased adhesive and 
invasive abilities, and promoted cell proliferation and motility of breast cancer cells. 
Moreover, PTPRM knockdown resulted in elevated adhesion, invasion, and 
proliferation of breast cancer cells. Activation of ERK and JNK by tyrosine 
phosphorylation and consequent elevated MMP9 activity is involved in increased cell 
migration and invasion by PTPRM knockdown. 
 
These results suggested that PTPRK and PTPRM are involved in the disease 
progression of prostate and breast cancer by regulating a complex network of pathways 
and molecules. This provides further proof of the importance of the R2B subfamily, a 
subgroup of PTP superfamily, in cancer. In addition, it sheds some light on the use of 
PTPs as prognostic indicators of disease, aiding in diagnosis and treatment. The major 
effect is the promotion of motility and invasiveness of cancer cells via ERK and JNK 
pathways. However it can also impair the apoptosis mediated by JNK pathways in 
certain cancer cells, such as prostate cancer cells. Such contrasting effects on survival 
and motility require further investigation, and should also be considered when treating 
cancers by targeting these molecules. 
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1.1 Prostate and breast cancer 
1.1.1 Prostate cancer 
Prostate cancer is the most commonly diagnosed cancer in men in the UK. 
Approximately a quarter of new cancer cases diagnosed in men are prostate cancer. 
Several risk factors have been recognised in the development of prostate cancer, the 
most significant of which include; age, race, diet, family history and place of birth 
(Wynder et al., 1971).  
 
Around 95% of all prostate cancers are adenocarcinomas and the other 5% of prostate 
cancers are ductal adenocarcinoma, mucinous carcinoma, and signet ring carcinoma. 
These rarer prostate cancers are sometimes more difficult to distinguish between 
different types and they are usually less responsive to hormonal therapy (McWilliam et 
al., 1997). The most significant histological variant is the neuroendocrine prostate 
cancer, which is generally classified as either small cell carcinoma or a carcinoid 
tumour, and represents less than 2% of prostate cancer cases (Grignon 2004).  
 
Prostate cancer is graded by different methods such as the Gleason grading system and 
TNM (Tumour odal Metastasis) staging system. The Gleason grading system is the 
most common system for prostate cancer and was first described by Gleason and 
Mellinger in 1974. The grading is based on the histological pattern of the distribution 
and growth of the tumour cells in the prostatic stroma, and the degree of glandular 
differentiation in H&E stained prostatic tissue samples from either a biopsy, or if after 
radical prostatectomy, a whole prostate (Gleason and Mellinger 1974). The various 
growth patterns (Figure 1.1) are combined to form 5 basic grade patterns ranging from 
3 
 
1 (least aggressive) to 5 (most aggressive). A histological score ranging from 2-10 is 
then generated, by the addition of the primary grade pattern; the prevailing one in that 
area, to the secondary pattern, which is the subsequently most widespread pattern. 
However, if only one grade is present, or if the second grade covers less than 3% of the 
total tumour, its value is doubled in order to give a corresponding Gleason score. 
 
 
 
Figure 1.1 Schematic drawing of Gleason histological grading. Taken from 
(Humphrey at al., 2004). 
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1.1.1.1 Prostate cancer treatment 
There are many treatment mehods for prostate cancer including radical prostatectomy, 
radiation therapy, androgen ablation therapy and chemotherapy. Radical prostatectomy 
(complete surgical removal of the prostate) is usually carried out on patients with either 
early stage disease or those who have failed to respond to radiation therapy. It has also 
been indicated that it is beneficial for patients, who with locally advanced disease, to 
treat with adjuvant radiation therapy. In contrast, the operation is rarely recommended 
for elder men with a life expectancy of less than 10 years, because it proves to offer 
little benefit and can impose significant complications (Bill-Axelson et al., 2005).  
 
Radiation therapy is commonly used to treat all stages of prostate cancer or when 
surgery has failed. The method uses ionising radiation to damage cellular DNA, and 
although this occurs in both normal and cancer cells, the cancer cells are less capable of 
repairing the damage and therefore undergo apoptosis. There are two methods for 
radiotherapy, external-beam radiotherapy and brachytherapy. External-beam 
radiotherapy was developed by Bagshaw and colleagues (Bagshaw et al., 1969). They 
instigated the use of megavoltage linear accelerators as a means of directing a beam of 
high dose radiation towards the prostate, with lower doses being applied to the 
surrounding tissue. Possible side effects include inflammation of the bladder, rectum, 
and urethra, as well diarrhoea and dysuria (Bagshaw et al., 1977). Brachytherapy was 
introduced by Holm and colleagues (Holm et al., 1983). The procedure involves the 
insertion of approximately 100 small radioactive rods directly into predetermined 
positions within the tumour. The patient is placed in the dorsal lithomy position, and 
remains under general or spinal anaesthesia throughout the whole procedure. The 
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radioactive source of the rods can either be of the low-dose rate using Iodine-125 or 
palladium-103 as the source of energy, or as a high-dose rate with Iridium-192; 
uurrently, LDR is the most commonly used form of brachytherapy. 
 
Androgen ablation therapy of prostate cacner is a way to treat advanced and metastatic 
prostate cancer due to androgens is important for the cell survival and growth of 
prostate cancer cells. However, androgen therapy is rarely curative. This is due to the 
androgen insensitive cells that are present within the tumour, and although initial 
therapy will reduce tumour size, prolonged therapy can act as a selective pressure for 
the androgen independent cancer cells to thrive. These cells can then induce re-growth 
of a tumour which will no longer respond to hormonal therapy (Robson and Dawson 
1996). 
 
Chemotherapy is for hormone-refractory prostate cancers. These drugs are cytotoxic, 
they lead to kill both cancer and normal cells, resulting in considerable toxicity and 
undesirable side effects. However, scientists have found several newer combination 
therapies with lower toxicity have been developed. These drugs include Estramustine, 
Vincristine, Etoposide, Doxorubicin, and the taxanes, Paclitaxel and Docetaxel (Hudes 
et al., 1997). Other drugs such as Mitoxantrone in combination with corticosteroid are 
mainly used as a means of palliative treatment in patients with metastatic prostate 
cancer (Tannock et al., 1996). 
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1.1.2 Breast cancer 
Breast cancer, the same with prostate cacner, is the most common cancer in the UK and 
the lifetime risk of being diagnosed with breast cancer is 1 in 8 for women in the UK. 
Several risk factors have been recognised in the development of breast cancer such as 
age, race, diet, family history and obesity (Wang et al., 2013). 
 
The most common type of breast cancer is ductal carcinoma (70-80%) followed by 
lobular carcinoma (10-15%) and other type of breast cancers including Inflammatory 
Breast Cancer and paget's disease of the breast. Paget's disease of the breast is first 
described by Sir James Paget in 1874 accounting less than 5% of all the breast cancer. It 
is usually associated with an underlying in situ or invasive ductal carcinoma (Karakas 
2011).  
 
Breast cancer is usually graded using TNM staging system. The TNM classification of 
the prostate was first established in the 1940s by Pierre Denoix, but was updated by the 
American Joint Committee on Cancer and International Union against Cancer (UICC), 
in 2002. The system is based on primary tumour (T), lymph node (N), and metastases 
(M) categories, with each one being built on a series of clinical examinations, 
radiological imaging, biopsies, and biochemical analyses (Greene and Sobin 2002). 
Clinical T staging is the most important prognostic factor for clinically localised breast 
cancer. Regional lymph node metastases meanwhile are strong predictors of 
progression, and imaging using nomograms is essential for paitents who have a greater 
risk of developing metastases. The staging is described in full detail in Table 1.1. 
 
7 
 
Stage characterisation 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ; intraductal carcinoma, lobular carcinoma in situ, or 
Paget;s disease of the breast with no associated tumour 
T1 Tumour 2.0 cm or less in greatest dimension 
T1mic Microinvasion 0.1 cm or less in greatest dimension 
T1a Tumour more than 0.1 but not more than 0.5 cm in greastest dimension 
T1b Tumour more than 0.5 but not more than 1.0 cm in greastest dimension 
T1c Tumour more than 1.0 but not more than 2.0 cm in greastest dimension 
T2 Tumour more than 2.0 but not more than 5.0 cm in greastest dimension 
T3 Tumour more than 5.0 cm in greastest dimension 
T4 Tumour of any size with direct extension to chest wall or skin 
T4a Extension to chest wall 
T4b Edema or ulceration of the skin of the breast or satellite skin nodules 
confined to the same breast 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis to movable ipsilateral axillary lymph node(s) 
N2 Metastasis to ipsilateral axillary lymph node(s) fixed to each other or to other 
structures 
N3 Metastasis to ipsilateral internal mammary lymph node(s) 
Pathologic classification (pN) 
pNX Regional lymph nodes cannot be assessed 
pN0 No regional lymph node metastasis 
pN1 Metastasis to movable ipsilateral axillary lymph node(s) 
pN1a Only micrometastasis (none larger than 0.2 cm) 
pN1b Metastasis to lymph node(s), any larger than 0.2 cm 
pN1bi Metastasis in 1 to 3 lymph nodes, any more than 0.2 cm and less than 2.0 cm 
in greatest dimension 
pN1bii Metastasis ot 4 or more lymph nodes, any more than 0.2 cm and all less than 
2.0 cm in greatest dimention 
pN1biii Extension of tumour beyond the capsule of a lymph node metastasis less than 
2.0 cm in greatest dimension 
pN1biv Metastasis to a lymph node 2.0 cm or more in greatest dimension 
pN2 Metastasis to ipsilateral axillary lymph node(s) fixed to each or to other 
structures 
pN3 Metastasis to ipsilateral internal mammary lymph node(s) 
Distant metastasis (M) 
MX Presence of distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis present 
Table 1.1 The TNM classification for breast cancer. 
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1.1.2.1 Breast cancer treatment 
There are many treatment methods for breast cancer, basically are the same with 
prostate cancer treatments, including lumpectomy/ mastectomy, radiation therapy, 
hormone therapy and chemotherapy. Lumpectomy removes the tumor often along with 
lymph nodes in the armpit and it is suitable for treatment of small local breast cancer. 
Mastectomy includes total mastectomy and radical mastectomy. Total mastectomy 
involves removal of the whole breast and sometimes ipsilateral axillary lymph node and 
radical mastectomy removes the breast, chest muscles, all of the ipsilateral axillary 
lymph node and some additional fat and skin. Radiation therapy, includes external beam 
radiation (4-6 weeks) and brachytherapy (less common for breast caner treatment), is 
carried out following lumpectomy or mastectomy. 
 
In general, paitents with hormone receptor-negative cancers respond better to 
chemotherapy than paitents with hormone receptor-positive cancers. Adjuvant 
chemotherapy is administered following surgery and before radiation therapy. It has 
been also indicated that delaying chemotherapy more than 12 weeks after surgery may 
increase the risk of breast cancer recurrence and reduce the survival (Lohrisch et al., 
2006). For early-statge breast cancer patients, there are many drugs including 
doxorubicin, cyclophosphamide, fluorouracil, paclitaxel and methotrexate for thay as a 
combination therapies. Other drugs such as gemcitabine in combination with paclitaxel 
or capecitabine in combination with docetaxel are mainly used as a means of treatment 
in patients with advanced metastatic breast cancer (Ferguson et al., 2007; Watanabe 
2013). Moreover, combination therapy of trastuzumab, lapatinib and pertuzumab is for 
HER2-positive breast cancer patients (Dent et al., 2013).  
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Hormone therapy of breast caner is a way to prevent estrongen form stimulating breast 
cancer cell proliferation. It is used for patients whose breast cancers are 
hormone-receptor positive (either estrogen or progesterone receptors). There are three 
diffenet mechanisms to reach this goal; first of all, blocking estrogen receptors in cancer 
cells by tamoxifen; second, suppressing estrogen production in the body by aromatase 
inhibitors (Anastrazole, Exemestane or Letrozole); finally, destroying ovaries to 
produce estrogen by ovarian ablation (Chemical Ovarian Ablation or Bilateral 
Oophorectomy) (Coombes et al., 2007; Rao and Cobleigh 2012).  
 
1.2 Cancer metastasis 
Cancer metastasis is responsible for most of the mortality of patients with solid tumours. 
During metastasis, cells from the primary tumour follow a number of seemingly 
separate but highly related steps in order to acquire the properties necessary for 
successful metastasis. First of all after breaching the basement membrane, cancer cells 
need to be able to migrate and invade into the local tissues, which usually involves the 
process of EMT (epithelial-mesenchymal transition). The cells then invade into blood 
and/or lymphatic vessels (intravasation), which requires degradation of the ECM 
(extracellular matrix). The cells need to survive in the circulation until they reach a site 
conducive to colonisation (homing). In most cases, there is a temporal gap called the 
metastatic latency between the initial organ infiltration stage and the formation of new 
secondary tumours at a distant site. During this latency, tumour cells may enter a 
dormancy stage (Figure 1.1) (Aguirre-Ghiso 2007; Nguyen et al., 2009; Thiery et al., 
2009). 
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1.2.1 Sequential events during cancer metastasis 
1.2.1.1 EMT 
Cells from the primary tumour that are able to invade the surrounding tissues and 
disperse to produce metastases usually undergo EMT which provides epithelial cell 
plasticity. This process plays an important role during foetal and postnatal development 
and it is regulated by transcription factors such as Twist1, Snai1, and Slug, which 
inhibit E-cadherin (epithelial-cadherin) expression (Thiery et al., 2009). 
 
EMT contains essential features. First of all, cell polarity is reduced which includes the 
down-regulation of epithelial cell markers such as E-cadherin, ZO-1 (zonaoccludens-1), 
and β4-integrin, followed by reorganisation of cytoskeleton structures; following this, 
the expression of fibroblast markers and genes are up-regulated, such as vimentin, 
N-cadherin, Twist and α-SMA (α smooth muscle actin). Finally, there is an acquisition 
of stem cell-like properties and phenotype by cancer cells. The cells become isolated, 
motile and may also appear to be resistant to anoikis. Furthermore, cancer cells 
undergoing EMT have been found to show an increased resistance to apoptosis and 
some acquired traits reminiscent of those expressed by stem cells (Miyazono 2009; Xu 
et al., 2009; Singh and Settleman 2010). 
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Figure 1.2 The process of metastasis is characterised by several steps; breaching of 
the basement membrane, EMT, invasion, intravasation, anoikis resistance, extravasation, 
and finally organ colonisation of a secondary site. 
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1.2.1.1.1 EMT in prostate cancer 
EMT plays an important role in prostate cancer progression and expression levels of 
EMT markers are modulated. Decreased E-cadherin expression is correlated with 
disease progression and poor prognosis in prostate cancer, and is associated with 
tumour prognosis factors such as tumour grade, local invasiveness, dissemination into 
circulatory system and tumour relapse after radiotherapy. In contrast, markers of 
mesenchymal phenotype including N-cadherin, OB (osteoblast)-cadherin, and WFDC-1 
(WAP-type four disulfide core/ps20 proteins) are all up-regulated in certain tumour 
cells (Tomita et al., 2000; Loric et al., 2001; Mason et al., 2002; McAlhany et al., 2004; 
Jaggi et al., 2006; Ray et al., 2006). Increased levels of the extracellular domain of 
N-cadherin have also been shown in the serum of prostate cancer patients (Derycke et 
al., 2006). The decreased E-cadherin level in prostate cancer cells has been 
demonstrated to be associated with increased cell motility and protease expression 
(Chunthapong et al., 2004; Derycke et al., 2006). These changes of epithelial and 
mesenchymal markers and the loss of prostatic glandular structure are consistent with 
the general dedifferentiated phenotype of the aggressive prostate cancer cells.  
 
Various factors from the local microenvironment in the prostate are involved in the 
EMT process, including factors generated from the tumours cells themselves and 
tumour associated stroma cells. For example, HGF (hepatocyte growth factor) and EGF 
(epithelial growth factor) can induce EMT in the DU-145 prostate cancer cell line; the 
action of EGF on E-cadherin is due to its immediate calveolae-dependant endocytosis 
of E-cadherin and a subsequent up-regulation of Snai1 which in turn represses the 
transcription of E-cadherin. Such effects can be diminished by blocking EGF signalling 
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(Lu et al., 2003; Wells et al., 2005; Yates et al., 2007). The transcription factor Twist, 
represses E-cadherin expression and the up-regulates of N-cadherin levels in prostate 
cancer cell lines (Kwok et al., 2005; Alexander et al., 2006). Moreover, loss of the 
epithelium-specific transcription factor, PDEF (prostate-derived ETS factor) which is 
down-regulated by TGFβ (Transforming growth factor β), induces EMT in PC-3 cells 
(Gu et al., 2007). It has been further demonstrated that over-expression of PSA (prostate 
specific antigen) and KLK4 (kallikrein-related peptidase 4), both potential activators of 
pro-EGF and latent TGFβ2, leads to EMT in PC3 cells (Veveris-Lowe et al., 2005; 
Whitbread et al., 2006; Gu et al., 2007). Furthermore, the BMP-7 (Bone morphohenetic 
protein-7) developmental signalling pathway is re-activated in aggressive prostate 
cancer and can also induce EMT (Yang et al., 2005).  
 
PC-3 and DU-145 prostate cancer cell lines are popular choices for EMT studies and 
their expression of androgen receptor are absent or at lower levels. Cadherin expression 
and the invasiveness of prostate cancer cells are reported to be associated with 
androgen-independence. Inverse correlations between androgen receptor and a number 
of EMT-related signalling pathways have also been described (Zhau et al., 2008). 
Therefore, it is likely that the perturbation of the androgen receptor has a permissive 
effect on EMT, as aggressive prostate cancer cells exhibit increased plasticity and lose 
their luminal epithelial phenotype during tumour progression (Jennbacken et al., 2006). 
 
1.2.1.2 Migration/Invasion 
To enter the blood and lymphatic circulation and thus infiltrate distant organs, tumour 
cells need to invade through the surrounding tissues. There are a number of reasonably 
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well defined mechanisms that are associated with invasiveness, such as cell motility and 
basement membrane degradation, which have been indicated in the intravasation of 
tumour cells (Nguyen et al., 2009). MMPs (matrix metalloproteinases) are key proteins 
implicated in ECM remodelling and degradation by metastatic cells (Coussens et al., 
2002). For example, the expression of MMP-1, MMP-2, MMP-9, and MMP-13 have 
been shown to be linked to the aggressiveness of tumours and their expressions are 
mediated by p38 in prostate, breast, bladder, liver, and skin keratinocyte cell lines 
(Johansson et al., 2000; Xu et al., 2006; Hsieh et al., 2010; Park et al., 2011).  
 
1.2.1.3 Anoikis resistance 
Anoikis, derived from the Greek meaning 'homeless and death', defines the phenomenon 
of cells which undergo cell death or apoptosis after loss of cell-matrix adhesion. 
Tumour cells in the circulatory system need to survive in an anchorage-independent 
manner before they disseminate and colonise at a distant organ. Inhibitors of p38 have 
been shown to induce anoikis resistance in human breast cancer cells and murine 
mammary epithelial cells. The mechanism may be linked to the activation of 
mitochondrial Bax by the p38 pathway leading to cytochrome c release from 
mitochondria (Lagadec et al., 2009; Owens et al., 2009; Zhang et al., 2009). 
Furthermore, a recent study shows that p38α induced anoikis during mammary 
mophogenesis by increasing transcription of the death-promoting protein BimEL 
(Bcl-2-like protein 11) via the transcription factors ATF-2 (activating transcription 
factor 2) and c-Jun (transcription factor AP-1) (Wen et al., 2011).  
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1.2.1.4 Extravasation 
This process describes the process in which circulating tumour cells leave the blood 
stream by penetrating the vessel wall and is known to involve a variety of adhesion 
molecules, such as selectins, integrins, and cadherins. It can also be regulated by the 
MAPK pathways. For example, adhesion of colon cancer cells to E-selectin-expressing 
endothelial cells leads to the activation of the p38 pathway in both tumour and 
endothelial cells. This activation induces stress fibre formation resulting in endothelial 
remodelling by actin-polymerization-mediated phosphorylation of myosin light chain, 
thus allowing the extravasation of circulating cancer cells (Laferriere et al., 2001; 
Tremblay et al., 2006). Bone metastasis is the most common metastic site for prostate 
cancer and it has been reported α6 integrin plays an important role in bone metastasis. 
The α6 integrin cleavage permits extravasation of human prostate cancer cells from 
circulation to bone (Ports et al., 2009). 
 
1.2.1.5 Organ colonisation 
The ability of circulating cancer cells to colonise an organ depends on autonomous cell 
functions and the barriers imposed by the microenvironment at the site of metastases. 
Extracellular factors produced by the primary tumour have been shown to prime certain 
tissues for tumour cell engraftment by way of chemokine production. For example, 
LLC or B16 tumour cells implanted intradermally into nude mice release VEGF 
(vascular endothelial growth factor), TGFβ (transforming growth factor β), and TNFα 
(tumor necrosis factor α), which leads to the expression of the inflammatory 
chemoattractants S100A8 and S100A9 in lungs. The S100A8 and S100A9 produced by 
lungs induce p38-mediated migration of tumour cells (Hiratsuka et al., 2006). 
16 
 
Furthermore, activation of angiogenesis is also important for the establishment of 
metastatic tumours, which can provide tumour cells with nutrition and other necessary 
materials. For example, blocking of p38 pathway can regulate endothelial cell migration 
and angiogenesis induced by VEGF (Rousseau et al., 2000). 
 
1.2.1.6 Metastatic dormancy 
In some cases, there is a significant delay between tumour cell detatchment from the 
primary tumour to the colonisation of a distant organ. The time between primary 
tumour diagnosis and clinically detectable metastatic relapse is defined as metastatic 
dormancy, which can vary between days and years (Nguyen et al., 2009). Disseminated 
tumour cells are usually responsible for these distant metastases. When tumour cells are 
not able to colonise immediately, the cells may enter proliferative dormancy, i.e. an 
arrest at G0/G1 phase of the cell cycle. Alternatively, disseminated tumour cells may 
develop into a micrometastasis which is unable to spread, but has an acquired 
equilibrium between cell death and cell proliferation rates. For example, in human head 
and neck carcinoma cells, the ratio of ERK1/2 activity to p38 activity has been shownto 
be associated with the ability of tumour cells to proliferate or to enter a state of 
dormancy (Aguirre-Ghiso 2007). 
 
1.2.2 Key molecules and pathways involved in metastasis 
1.2.2.1 MAPK pathway 
In mammalian cells, 12 MAPKs (Table 1.1), 7 MAP2Ks, and 20 MAP3Ks have been 
identified. The MAPK (mitogen-activated protein kinase) pathway plays a key role in 
cancer development making it an important target for anti-cancer therapy. 
Dysregulation of the MAPK pathway is common in many human cancers, such as 
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breast, melanoma, and colorectal cancers (Fang and Richardson 2005; Lin et al., 2010; 
Leontovich et al., 2012). The three key molecules and signalling pathways of MAPK 
family, i.e. p38, JNK (stress-activated protein kinase JNK1) and ERK (extracellular 
signal-regulated kinase) have been studied extensively. These pathways are involved in 
the regulation of many important cellular processes such as cell proliferation, invasion, 
metastasis, survival and angiogenesis (Figure 1.2).  
 
MAPKs are evolutionary conserved enzymes, the activation of which requires dual 
phosphorylation on the Thr-X-Tyr motif which is catalysed by MAP2Ks. MAP2Ks are 
activated by up-stream MAP3Ks. Following the activation, MAPKs phosphorylate 
specific serine and threonine residues of the target proteins including other protein 
kinases and transcription factors. MAPKs are inactivated by both classic phosphatases 
and dual-specificit phosphatases and are further regulated by scaffold proteins which 
are usually specific for each of the three major mammalian MAPK pathways (Chang 
and Karin 2001; Morrison and Davis 2003; Avruch 2007).  
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Table 1.2 A list of MAPKs and their alternative names. 
Name Alternative names 
MAPK1 ERK2 (Extracellular signal-regulated kinase 2), p42-MAPK (MAP kinase 
isoform p42), MAPK2 
MAPK2 The same with MAPK1 
MAPK3 ERK1, p44-MAPK 
MAPK4 ERK4, p63-MAPK 
MAPK6 ERK3, p97-MAPK 
MAPK7 ERK5, BMK1 (Big MAP kinase 1) 
MAPK8 JNK1 (c-Jun N-terminal kinase 1), SPAK1c (Stress-activated protein kinase 1c) 
MAPK9 JNK2, SPAK1a 
MAPK10 JNK3, SPAK1b 
MAPK11 p38β, SPAK2b 
MAPK12 ERK6, p38γ, SPAK3 
MAPK13 p38δ, SPAK4 
MAPK14 p38α,SPAK2a, CSBP (Cytokine suppressive anti-inflammatory drug-binding 
protein) 
MAPK15 ERK7, ERK8 
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1.2.2.1.1 p38 signalling 
There are four genes encodinge p38 MAPKs which are MAPK14 (p38α), MAPK11 
(p38β), MAPK12 (p38γ), and MAPK13 (p38δ). Two alternative splicing isoforms exist 
for p38α. p38α and p38β are closely related proteins which may have overlapping 
functions. p38α is highly expressed in most cell types, whilst p38β seems to be 
expressed at relatively lower levels. The exact function of p38α in the p38 MAPK 
pathway is still unclear. p38γ and p38δ seem to have more specific functions due to 
their restricted tissue expression pattern in the body, where p38γ is expressed in skeletal 
muscle and p38δ in endocrine glands (Ono and Han 2000; Sanz et al., 2000; Cuenda 
and Rousseau 2007). p38 MAPKs are activated by up-stream MEK3 (MAPK/ERK 
kinase 3), MEK6, and sometimes MEK4; autophosphorylation can be also indicated in 
the activation of p38 MAPKs. There are two major groups of proteins that are regulated 
by p38-mediated phosphorylation. The first group are transcription factors, such as p53, 
ATF2 (activating transcription factor 2); and the second group are protein kinases 
including MK2 (MAPK-activated kinase 2; also known as MAPK2), MSK1 (mitogen- 
and stress-activated protein kinase 1), MNK1 (MAP kinase-interacting serine/threonine 
kinase 1), and MNK2. p38α acts as a tumour suppressor by both negatively regulating 
the progression of cell cycle and inducing apoptosis. However, p38α has also been 
reported to have oncogenic function due to its regulation of cancer progression 
processes such as invasion and angiogenesis (Ono and Han 2000; Bulavin and Fornace 
2004; Mittelstadt et al., 2005; Cuenda and Rousseau 2007; Hui et al., 2007). 
 
p38α can negatively regulate the cell cycle at both the G1/S and G2/M phases by 
several mechanisms including down-regulation of cyclins, up-regulation of 
20 
 
cyclin-dependent kinase inhibitors, and modulation of tumour suppressor p53 (Thornton 
and Rincon 2009). This phenomenon is highly conserved amongst different species and 
is important in many different cells including cardiomyocytes, hepatocytes, fibroblast, 
haematopoitic cells, and lung cells. This effect of p38α may be mediated by regulation 
of the JNK/Jun pathway or by down-regulation of the EGFR (epidermal growth factor 
receptor) pathway (Ambrosino and Nebreda 2001; Engel et al., 2005; Hui et al., 2007; 
Ventura et al., 2007; Thornton and Rincon 2009). Although p38α activation is usually 
associated with inhibition of cell proliferation, there are some reports shows that p38α 
can sometimes positively regulate proliferation in haematopoietic cells and certain other 
cancer cell types for example, prostate and breast cells (Neve et al., 2002; Platanias 
2003; Ricote et al., 2006). p38α also regulates apoptosis via transcriptional and 
post-transcriptional mechanisms which impact on the death receptors of survival 
pathways or on the pro- and anti-apoptotic Bcl-2 family proteins. Apoptotic stimuli 
sometimes trigger p38α activation by a secondary route, such as the production of ROS 
(reactive oxygen species). This mechanism is important for the suppression of tumour 
initiation by p38α, which triggers apoptosis in response to the expression of 
ROS-inducing oncogenes in some immortalised cells (Dolado et al., 2007). However, 
p38β has been reported as an anti-apoptotic factor in several cell lines for example, 
endothelial cells. Therefore, p38α is a dual regulator in cell growth and death: it is a 
general pro-apoptotic factor but acts as a pro-survival factor in certain other cells 
(Nemoto et al., 1998; Kaiser et al., 2004; Silva et al., 2006; Dolado et al., 2007). The 
pro-survival function of p38α is mediated by the induction of cell proliferation or 
anti-apoptosis inflammatory signals such as IL-6 (interleukin-6). In addition, p38α has 
been implicated in the G2/M phase checkpoint of the cell cycle process which leads to 
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cell cycle arrest and facilitates DNA repair. This action may diminish 
chemotherapy-induced DNA damage in cancer cells, which leads to the resistance of 
apoptosis (Thornton and Rincon 2009). Moreover, down-regulation of p38α in mice has 
a significant impact on lung homeostasis, probably reflecting the crucial function of 
p38α in the coordination of proliferation and maintaining the differentiation state of 
lung epithelial cells (Hui et al., 2007; Ventura et al., 2007). 
 
Several negative regulators of p38 signalling have been found in different human cancer 
cells, examples include the phosphatases PPM1D and DUSP26, the inhibitors of 
MAP3K ASK1 (apoptosis signal-regulating kinase 1), GSTM1 (glutathione 
S-transferase Mu 1) and GSTM2 (Bulavin et al., 2002; Li et al., 2002; Dolado et al., 
2007; Yu et al., 2007). In hepatocellular carcinoma, the activity of p38 MAPK and 
MEK6 are lower than in non-tumorigenic tissues, which supports the observation that 
increased p38 activity induces apoptosis in hepatoma cell lines. However, increased 
phosphorylated levels of p38α are also associated with certain malignancies, including 
head and neck squamous carcinoma, non-small cell lung cancer and breast carcinoma 
(Greenberg et al., 2002; Elenitoba-Johnson et al., 2003; Esteva et al., 2004; Pomerance 
et al., 2006; Junttila et al., 2007). These findings collectively suggest that cancer cells 
with pro-tumorigenic mutations in the p38 pathway have a selective advantage. 
 
1.2.2.1.2 JNK signalling 
The JNK proteins are encoded by three genes, MAPK8 (JNK1), MAPK9 (JNK2), and 
MAPK10 (JNK3), which are alternatively spliced to produce at least ten isoforms. 
JNK1 and JNK2 are widely expressed in almost all cell types. However, JNK3 is 
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mainly expressed in the brain (Gupta et al., 1996; Bode and Dong 2007; Cuevas et al., 
2007). JNKs can be activated by up-stream MEK4 and MEK7. While there are many 
down-stream substrates for JNK, the challenge remains to identify the molecular 
networks regulated by individual JNK family members (Karin and Gallagher 2005; 
Weston and Davis 2007; Rincon and Davis 2009). 
 
JNKs exert their effects on cell proliferation by interacting with the transcription factor 
AP-1, a well-known regulator of cell cycle progression (Eferl and Wagner 2003; 
Sabapathy et al., 2004; Weston and Davis 2007). AP-1 is a dimeric transcription factor 
complex which contains members of Jun, Fos, ATF and Maf protein families. In 
non-stimulated cells, JNK2 seems to mainly target c-Jun for degradation. However, in 
stimulated cells, JNK1 phosphorylates and stabilises c-Jun resulting in activation of 
transcription of the target genes. For example, JNK2-knockout fibroblasts grew slightly 
faster, whilst JNK1-knockout fibroblast cells grew slower compared with the wild-type 
fibroblasts. This was due to the effect on AP-1 activity and c-Jun phosphorylation. The 
contrasting impacts on proliferation between JNK1 and JNK2 have been observed in 
fibroblasts and erythroblasts (Sabapathy et al., 2004). Recently, the JNK pathway has 
been implicated in p53-dependent senescence using a conditional JNK1 allele. Such 
roles as a negative regulator of the p53 tumour suppressor also supports the idea that 
activated JNK has an oncogenic role in tumour models (Das et al., 2007). In addition, 
as cytoplasmic injection of cytochrome c rescues the apoptotic defects of JNK-deficient 
fibroblasts, JNK pro-apoptotic function is regulated by mitochondrial pathway. JNKs 
can phosphorylate and regulate the expression of several apoptotic molecules including 
BAX, BAD and 14-3-3 protein. Phosphorylation of 14-3-3 by JNKs releases the 
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pro-apoptotic factors BAX and FoxO1, to form inactive complexes leading to an 
increase of JNK-mediated apoptosis (Tournier et al., 2000; Weston and Davis 2007). 
Interestingly, inhibition of NF-κB in the mouse model of liver cancer leads to a 
sustained activity of JNK, increased cell death and cytokine-driven compensatory 
proliferation (Maeda et al., 2005). Activation of JNK pathway has also been indicated 
in the biphasic effect of TNFα on the cell survival. Transient activation of JNK was 
shown to promote cell survival whilst the late and sustained activation of JNK mediated 
TNFα induced apoptosis via caspase-8 (Ventura et al., 2006). 
 
An important role of the JNK pathway has also been indicated in prostate cancer 
development. The tumour suppressor PTEN (Phosphatase and tensin homolog) is one of 
the most commonly mutated tumour suppressors in cancer, and it is frequently lost in 
prostate cancer (Li et al., 1997). Loss of PTEN leads to Akt activation and increase JNK 
activity in various human cancer cell lines and human clinical prostate cancer samples. 
Analysis of gene expression has indicated that several members of the JNK pathway are 
up-regulated in prostate cancer. In contrast, Transcription factor Jun-B has been 
identified as an inhibitor of carcinogenesis in the prostate (Vivanco et al., 2007; Konishi 
et al., 2008; Ouyang et al., 2008).  
 
1.2.2.1.3 ERK signalling 
The ERK family is composed of ERK1 (MAPK3), ERK2 (MAPK1), ERK3 ( MAPK6), 
ERK4 (MAPK4), ERK5 (MAPK7), ERK6(MAPK12) and ERK7/8(MAPK15) 
(Bogoyevitch and Court 2004). ERK1/2 is expressed in virtually all the tissues in the 
body. In fibroblasts, it is activated by growth factors, serum, ligands which stimulate 
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heterotrimeric G protein-coupled receptors, cytokines, transforming growth factors, 
osmotic stress and microtubule disorganisation (Chen et al., 2001). Classic ERK1/2 can 
be activated by up-stream MEK1 and MEK2. MEK1/2 is activated by up-stream 
Ras-Raf family members. However, Ras is not the only activator of Raf. PKC (protein 
kinase C) has also been demonstrated to phosphorylate and activate Raf-1 (Kolch 2005). 
Nevertheless, the activation of the ERK pathway leads to the regulation of cell 
functions such as cell survival and apoptosis. 
 
Activation of ERK1/2 has been shown to inhibit apoptosis in response to a wide range 
of stimuli, some of the notable ones being TNF, Fas ligand, TRAIL (TNF-related 
apoptosis-inducing ligand), growth factor withdrawal, hydrogen peroxide and matrix 
detachment (Wang et al., 1998; Erhardt et al., 1999; Le Gall et al., 2000; Tran et al., 
2001). First of all, the anti-apoptotic function of ERK1/2 can be regulated indirectly by 
p38 signalling. Inhibition of p38 stimulates Raf and ERK activities and induces 
myoblast proliferation. Moreover, activation of p38 induces dephosphorylation of 
MEK1/2 and apoptosis in human skin fibroblast (Lee et al., 2002; Li et al., 2003). In 
mammalian cells, for example hepatocytes and leukaemia cells, the ERK1/2 pathway 
can block apoptosis at levels up-stream and down-stream, as well as events unrelated to 
the change in mitochondrial transmembrane protein and cytochrome c release. The 
inactivation of the pro-apoptotic Bcl-2 family member BAD is mediated by 
phosphorylation at Ser112 by ERK-activated p90 RSK (ribosomal S6 kinase) and at 
Ser136 by PI3K/Akt pathway. BAD phosphorylation at serine 112 by RSK suppresses 
BAD-mediated neuronal apoptosis and inhibition of ERK1/2 or Akt increases the extent 
of apoptosis. The ERK-downstream p70 RSK may also be involved in Ser136 
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phosphorylation and inhibition of BAD functions (Sturgill et al., 1988; Bonni et al., 
1999; Erhardt et al., 1999; Scheid et al., 1999; Hayakawa et al., 2000; Harada et al., 
2001; Qiao et al., 2001; Mabuchi et al., 2002; Shonai et al., 2002). In addition, it has 
been shown that inhibition of ERK1/2 up-regulates STAT3/5 phosphorylation and 
promotes cell apoptosis in melanoma (Krasilnikov et al., 2003). 
 
Although ERK1/2 is a pro-survival factor in MAPK family and regulates cell 
proliferation and differentiation, under some circumstances ERK1/2 also acts as a 
pro-apoptotic factor. In the neuronal system, ERK1/2 has been shown to be involved in 
neuroregeneration. Activation of ERK1/2 is associated with glutamate-induced 
oxidative toxicity in neuronal cells and the inhibition of ERK1/2 activation protects 
cells from glutamate toxicity. In addition, ERK1/2 activation promotes low 
potassium-induced neuronal degeneration predominantly through plasma membrane 
damage which occurs independent of caspase-3 (Stanciu et al., 2000; Cheung and Slack 
2004; Subramaniam et al., 2004). Furthermore, DNA damage also activates ERK1/2 in 
various cells and inhibition of ERK1/2 activation attenuates apoptosis or G2/M phase 
arrest. Additionally, suppression of ERK2 activity has been shown to sensitise ovarian 
carcinoma cells to cisplatin-induced apoptosis (Hayakawa et al., 1999; Persons et al., 
2000; Tang et al., 2002; Billecke et al., 2006). 
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Figure 1.3 The MAPK pathways including p38, JNK, and ERK pathways. 
 
 
1.2.2.2 TGF-β pathway 
The TGF-β superfamily regulates a broad range of cellular functions, including cell 
growth, differentiation, adhesion and apoptosis. Alteration of TGF-β signalling is 
involved in a number of pathological conditions, for example it plays a critical role in 
wound healing and cancer. Prior to tumour initiation and the early stage of cancer 
progression, TGF-β acts as a tumour suppressor. However, for the most part in the later 
stage of tumour development, TGF-β usually acts as a tumour promoter. 
 
TGF-β1 was discovered in 1983 as a protein regulating the cell growth of rat fibroblasts. 
It is now known that TGF-β1 belongs to a large protein family that has thirty-three 
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members, all of which have a common dimeric structure and a cysteine knot structural 
domain (Frolik et al., 1983; Galat 2011). The TGF-β superfamily has been divided into 
several sub-families, including TGF-βs, BMPs (bone morphogenetic proteins), GDFs 
(growth and differentiation factors), MIF (Mullerian inhibitory factor), activins, and 
inhibins. There are three isoforms of TGF-βs expressed in mammals, TGF-β1, TGF-β2 
and TGF-β3. The BMP family are expressed in both vertebrates and invertebrates and 
are known to exhibit a wide range of biological effects in different cell types. BMPs 
regulate the transcription of several genes involved in osteogenesis, neurogenesis and 
ventral mesoderm specification. GDFs (Growth/differentiation factors) are sometimes 
classified as part of the BMP subfamily. Activins are structurally related protein 
involved in the control of cell proliferation, differentiation, apoptosis, homeostasis and 
endocrine functions. Inhibins are crucial for normal reproductive and endocrine 
functions as they negatively regulate the synthesis of follicle-stimulating hormone (Lee 
1990; Roberts 1998; Stenvers and Findlay 2009; Xia and Schneyer 2009; Miyazono et 
al., 2010; Rider and Mulloy 2010). 
 
1.2.2.2.1 SMAD-dependent signalling pathway 
TGF-β binds to TGFβRI and TGFβRII (type I and II serine/theronine kinase receptors) 
and the receptors form heteromeric complexes after ligand binding. The co-receptors 
endoglin and β-glycan (also known as TGFβRIII) interact with TGF-β family ligands 
but are not directly involved in signalling. These co-receptors may regulate the access 
of ligands to TGFβRI and TGFβRII. Upon binding to the ligands, TGFβRII recruit and 
phosphorylates the glycine/serine-rich domain of TGFβRI which forms an activated 
ligand-receptor complex. The activated TGFβRI then phosphorylates down-stream 
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molecules such as SMADs (Mothers against decapentaplegic homolog) (Shi and 
Massague 2003; Kang et al., 2009; Gatza et al., 2010). 
 
The SMAD family are divided in to three groups; R-SMADs (receptor-associated 
SMADs), Co-SMADs (co-operating SMADs), and I-SMADs (inhibitory SMADs). 
R-SMADs are directly phosphorylated at two serine residues at their C-terminii by 
TGFβRI. The unphosphorylated R-SMADs are transcriptionally inactive and can be 
sequestered in the cytoplasm by specific proteins such as SARA (SMAD anchor for 
receptor activation) and endofin (Tsukazaki et al., 1998; Shi and Massague 2003; Ross 
and Hill 2008; Huminiecki et al., 2009; Miyazono et al., 2010). Five R-SMADs 
(SMAD1, SMAD2, SMAD3, SMAD5, and SMAD8) have been identified in humans. 
SMAD2 and SMAD3 are substrates for receptors activated by TGF-βs and activins, 
whilst SMAD1, SMAD5, and SMAD8 mediate pathways which are activated by BMPs. 
After phosphorylation of the R-SMADs, the phosphor-R-SMADs associate with 
SMAD4 (Co-SMAD). This complex translocates to the nucleus and collaborates with 
other transcription factors to regulate gene expression. There are two I-SMADs: 
SMAD6 and SMAD7 which are responsive genes to Smad signalling. The induced 
expression of these I-SMADs leads to a negative feedback regulation for TGF-β 
signalling. Furthermore, phosphorylation of R-SMADs can be inhibited by interaction 
of SMAD7 with type 1 receptors of TGFβ, activin and BMP. For example, SMAD7 
competes with R-SMADs for binding to TGFβRI and by recruiting E3 ubiquitin Smurf 
ligases to the activated receptor and targets this receptor for degradation. In the nucleus, 
the R-SMAD/Co-SMAD complex can bind to SMAD-binding elements in the DNA via 
the MH1 (Mad Homology 1) domain. SMAD1, SMAD5, and SMAD8 recognise a 
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non-consensus GC-rich domain. However, a 30-amino acid insertion in the MH1 
domain disables SMAD2 from individual binding to the DNA. The binding of SMAD 
complexes to DNA is crucial for the transcriptional activation of SMAD target genes, 
although this binding is low affinity. Additional interactions with other transcription 
factors are required to form large transcriptional complexes with high affinity for 
chromatin (Dennler et al., 1999; Shi and Massague 2003; Derynck and Akhurst 2007; 
Itoh and ten Dijke 2007). Figure 1.3 shows the overall SMADs signalling pathway. 
 
 
Figure 1.4 SMAD-dependent signalling pathway. 
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1.2.2.2.1.1 Mutation of SMADs in cancers 
Human chromosome 18q21, where SMAD2 and SMAD4 are located are often mutated 
in pancreas and colon cancers. The loss of SMAD4 disrupts the SMAD2/3/4 
heteromeric complexes and therefore affects TGF-β signalling. SMAD4 mutations are 
rare but are present in breast cancer, although. Recent studies have shown that aberrant 
germline mutation of SMAD4 may be more common in breast cancer than previously 
described. SMAD2 mutations have also been found at low levels in colon, head and 
neck and lung carcinomas. In skin cancer, SMAD2 expression is associated with SCC 
(squamous cell carcinoma) and BCC (basal cell carcinoma), while SMAD4 expression 
is only associated with SCC but not BCC (Kretzschmar 2000; Bellam and Pasche 2010; 
Yang and Yang 2010; Tram et al., 2011; Shao et al., 2012).  
 
SMAD3 mutations have not been found in any specific cancer but expression levels may 
vary in many cancers during disease progression. The growth of gastric cancer cells 
which lack SMAD3 expression can be inhibited by TGF-β. Furthermore, the reduction 
of SMAD2 and SMAD3 in human breast cancer cells resulted in enhanced 
tumourigenesis with an impaired metastatic capacity. These data show that SMAD 
mutations and aberrant SMAD expression can lead to the development of cancer and 
metastasis (Tian et al., 2003; Han et al., 2004; Arany et al., 2007). 
 
1.2.2.2.2 TGF-β pathway in cancer 
1.2.2.2.2.1 TGF-β-mediated growth inhibition 
TGF-β-mediated growth arrest can be mediated by the inhibition of CDKs 
(cyclin-dependent kinases) and the down-regulation of c-Myc. Cell cycle progression is 
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regulated by CDKs which is activated by cyclin binding and inhibited by CDK 
inhibitors. Cells are sensitive to TGF-β during the G1 phase of the cell cycle. If TGF-β 
is present after the G1 phase, the cell will complete the cell cycle and arrest at the 
subsequent G1 phase. In most cases, this arrest is reversible and it is associated with 
terminal differentiation or programmed cell death. TGF-β prevents or inhibits G1 
cyclin-CDK activation in a cell type-dependent manner via different mechanisms 
leading to pRb (retinoblastoma protein) dephosphorylation (Geng and Weinberg 1993; 
Slingerland et al., 1994; Donovan and Slingerland 2000; Liu and Matsuura 2005). In 
many cells, TGF-β results in a rapid inhibition of c-Myc transcription. Regulation of 
c-Myc protein is important for G1 to S phase progression. TGF-β induces the 
down-regulation of c-Myc expression and c-Myc promoter activity through a TGF-β 
response element. TGF-β mediates the c-Myc transcriptional repression via SMAD 
signalling. Upon SMAD3 signalling, the complex moves from the cytoplasm to the 
nucleus and the complex recruits the co-repressor protein, the pRb family member p107 
and the transcription factor E2F4. The complex then binds to the c-Myc promoter which 
is next to the E2F4-binding site and represses transcription (Massague et al., 2000; 
Chen et al., 2001; Chen et al., 2002; Yagi et al., 2002; Frederick et al., 2004). 
 
Another tumour suppression effect of TGF-β is its ability to induce apoptosis in a cell 
type-specific manner. SMAD signalling regulates the expression of several genes whose 
function is directly linked to the apoptosis pathway. Many pro-apoptosis target genes 
are controlled by the SMAD pathway, such as TIEG1 (TGF-β-inducible early-response 
gene), the death-associated protein kinases, and the SH2 domain-containing 
inositol-5-phosphatase.These pro-apoptotic molecules have been indicated as being 
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important in inhibiting proliferation and inducing apoptosis in different cells. The 
apoptotic response of normal cells is complex and incorporates both pro-survival and 
pro-apoptotic pathways. In all cases, the net decision of whether TGF-β will favour 
apoptosis or survival depends on the expression profile of relevant signalling molecules 
in certain receipting cells (Tachibana et al., 1997; Jang et al., 2002; 
Valderrama-Carvajal et al., 2002; Pardali and Moustakas 2007). 
 
1.2.2.2.2.2 TGF-β pathway in cancer progression 
Genetic and epigenetic changes in tumour cells are autonomous switch for TGF-β 
responses, from the inhibition of proliferation and survival to the promotion of growth, 
motility, and invasion. Interestingly, the p53 tumour suppressor seems to be able to 
switch the response (Adorno et al., 2009). In a number of human solid tumours, it has 
been indicated that TGF-β dysregulation has a significant effect on tumour progression 
and patient prognosis. The association of breast cancer with increased serum TGF-β 
levels has been reported. A complimentary study has subsequently shown that low 
levels of TGFβRII gene expression were correlated with an increased risk of breast 
cancer. Furthermore, endogenous over-expression of TGFβRII in the stromal 
compartment of human breast cancer is associated with poor prognosis (Gobbi et al., 
1999; Grainger et al., 1999; Yokota et al., 2000; Barlow et al., 2003). In addition, a 
study employing a tissue microarray of 310 colon carcinomas has indicated that stromal 
TGFβRII expression is an independent prognostic factor for cancer-related survival 
(Bacman et al., 2007). These observations collectively suggest that the autonomous 
effects of TGF-β signalling in tumour cell and stromal cell stimulation by TGF-β may 
contribute to the regulation of the adjacent epithelial cell population in human cancers. 
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In contrast to the tumour suppressor role of TGF-β1 during tumour initiation and early 
progression, TGF-β1 may actually promote cancer progression at a later stage (Robson 
et al., 1996; Tsushima et al., 1996). Moreover, TGF-β1 up-regulation is associated with 
angiogenesis, metastasis and poor patient prognosis in prostate cancer. Over-expression 
of TGF-β1 is associated with advanced prostate cancer (Wikstrom et al., 1998; Diener 
et al., 2010). These results show that TGF-β is able to mediate cell autonomous, local, 
and systemic responses that regulate the initiation, progression and prognostic outcomes 
in human cancers. 
 
TGF-β can induce EMT in embryonic epithelial cells. EMT is essential for normal 
embryonic development and its exploitation during cancer progression is thought to 
contribute to tumour invasion and metastasis. Tumour cells expressing mesenchymal 
markers have a greater tendency to be invasive and to metastasise than tumour cells 
expressing only epithelial markers (Xu et al., 2003; Han et al., 2004). A number of 
studies have indicated that TGF-β receptor/SMAD signalling and down-stream targets 
are important modulators of EMT. TGF-β signalling is known to down-regulate 
claudins, occludins and ZO1 followed by the degradation of tight junctions. It also has 
been indicated that R-SMADs interacts with EMT-associated transcription factors, such 
as Snai1 and AP-1 resulting in the formation of TGF-β-induced EMT-promoting SMAD 
complexes. The expression of E-cadherin is repressed by TGF-β via Snai1/2 (Zinc 
finger protein Snai 1/2), HMGA2 (High mobility group protein HMGI-C 2), and 
ZEB1/2 (Zinc finger E-box-binding homeobox 1/2). There is also evidence to show that 
TGF-β1-induced EMT leads to the loss of E-cadherin and cell-cell adhesion. 
TGF-β-induced activation of MAPKs is also important to induce EMT. For example, 
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activation of ERK pathway is important for TGF-β-induced EMT (Xie et al., 2004; 
Moustakas and Heldin 2007; Xu et al., 2009; Fuxe et al., 2010; Hills et al., 2012). 
Furthermore, the focal adhesion complexes including β1 and β3 integrins, Src, FAK 
(focal adhesion kinase), and p130Cas are activated by TGF-β. TGF-β can activate PI3K 
and its down-stream molecules, Akt and mTOR (Bhowmick et al., 2001; Galliher and 
Schiemann 2006; Galliher and Schiemann 2007; Lamouille and Derynck 2007; Wendt 
and Schiemann 2009; Wendt et al., 2009; Lamouille and Derynck 2010). Finally, it has 
been demonstrated that TGF-β stimulation induces the phosphorylation of PAR6 by 
TGFβRII, followed by degradation of RhoA (Transforming protein RhoA), a key 
molecule able to stabilise cell junctions. Meanwhile, microarray studies of human 
breast cancer show that PAR6 activation correlates with markers of the basal carcinoma 
sub-type in BRCA1-associated tumours. It has also been reported that destabilisation of 
p53 by MDM2 (E3 ubiquitin-protein ligase Mdm2) is a key step in the EMT of breast 
cancer and that the TGF-β1-induced expression of MDM2 is also related to the 
progression of metastatic breast cancer (Viloria-Petit et al., 2009; Araki et al., 2010). 
 
In summary, occurrence of the cancer metastasis is dependent on the success of 
inter-related multiple steps which are regulated by many different cytokines and factors. 
The phosphorylation of diverse receptors and intracellular signalling molecules is 
crucial for the effect induced by the cytokines and other protein factors. More 
interestingly, a group of proteins that are embedded in the cellular membrane or exist 
inside the cells can help to balance and coordinate such phosphorylation. These 
molecules are phosphatases which can deactivate phosphorylated proteins. 
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1.3 Protein tyrosine phosphatase (PTP) family 
Reversible protein phosphorylation is one of the major systems for regulating cell 
functions and it was implicated in signalling by paracrine or autocrine-acting growth 
factors and endocrine hormones such as insulin. PTPs are not only present in eukaryotes 
but also prokaryotes and viruses, for example, VH1 which is present in the vaccinia 
virus and the dual specificity enzymes IphP is present in the cyanobacterium Nostoc 
commune (Guan et al., 1991; Potts et al., 1993). This posttranslational modification is 
involved in many physiological and pathological processes, for example cell 
differentiation, survival (Fu 1992), cell adhesion and cell-cell contact (Volberg et al., 
1992). Current knowledge regarding the interactions between PTPs (protein tyrosine 
phosphatases) and their substrates is still limited. Contrary to the initial view of signal 
pathways being a simple linear arrangement of phosphorylation, it is now apparent that 
is is more complicated due to cross-talk and interactions existing among multiple 
signalling pathways which help to coordinate biological functions and responses to 
diverse stimuli. Kinases have been implicated in controlling the amplitude of signalling 
pathways and phosphatases are thought to play an important role in controlling the rate 
and duration of the response rather than just acting as passive housekeeping enzymes 
(Heinrich et al., 2002; Hornberg et al., 2005).  
 
PTPs are divided into the classical phosphotyrosine (pTyr) – specific phosphatases 
(Figure 1.4) and the dual specificity phosphatases (Figure 1.5) (Alonso et al., 2004; 
Andersen et al., 2004). Classical pTyr-specific PTPs include transmembrane 
receptor-like protein tyrosine phosphatases (RPTPs) that have the potential to regulate 
signalling through ligand-controlled protein tyrosine dephosphorylation. Each PTP is 
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composed of at least one conserved domain which includes an 11-residue motif (I/V) 
HCXAGXXR(S/T) G containing the essential catalytic residues, cystenine and agrinine. 
The sequences of PTPs are different with serine/theronine, acid, or alkaline 
phosphatases. The diversity in the structure of PTPs is due to the variety of 
non-catalytic sequences attached to either the NH2- or COOH- termini of the catalytic 
domain (Guan and Dixon 1991; Pot et al., 1991; Charbonneau and Tonks 1992). Many 
of the RPTPs are characterised by variable extracellular multiple domains, followed by 
a single transmembrane region and one or two intracellular phosphatase catalytic 
domains. RPTPs exhibit features of cell-adhesion molecules in their extracellular 
segment and have been implicated in cell-cell and cell-matrix contact via dimerisation, 
phosphorylation and reversible oxidation.  
 
RPTPs have been classified into eight subfamilies based on their phosphatase domains 
(Andersen et al., 2001). The eight subfamilies are R1/R6, R2A, R2B, R3, R4, R5, R7 
and R8. There are four subfamilies, R2A, R2B, R3 and R4 that play an important role in 
central nervous system development (Johnson and Van Vactor 2003). The members of 
the R2 subfamily have very similar protein structures including fibronectin type Ⅲ 
repeats, Ig-like domains, a siglen transmembrane region, a juxtamembrane domain, 
followed by one phosphatase domain and one pseudo-phosphatase domain. The R2 
subfamily is further divided into two groups. R2B subfamily members have an 
additional MAM domain (Meprin/ A5/ PTPRM) at the N-terminal of the protein 
(Beckmann and Bork 1993). 
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Figure 1.5 The classical PTPs are divided into two groups; receptor-like PTPs and 
non-transmembrane PTPs. Modified from (Tonks 2006; Soulsby and Bennett 2009) 
 
  
38 
 
 
Figure 1.6 The dual specificity phosphatases. Modified from (Tonks 2006; Soulsby 
and Bennett 2009)  
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1.3.1 Key members of PTP family 
1.3.1.1 PTP1B (PTPN1) 
The human placental protein tyrosine phosphatase non-receptor type 1 (PTP1B or 
PTPN1), a 35KDa soluble enzyme, was purified and its amino acid sequence was 
partially determined at 1980s (Charbonneau et al., 1988). The placental PTP1B can be 
activated by EDTA, spermine, spermidine and myelin. Its activity can be inhibited by 
different reagents including heparin and glutamate/tyrosine, via blocking the cysteinyl 
group which is an essential part for as PTPase activity (Tonks et al., 1988).  
 
The early identified placental PTP1B was a product with 321 amino acids and 
subsequently found to be the NH2-terminal portion derived from a full-length molecule 
of 435 residues. The conserved PTP domain of PTP1B contains residue 30 to residue 
278 and COOH-terminal non-catalytic extension acts as a regulatory function. The 
COOH-terminal 35 residues target the enzyme on the cytoplasmic surface of 
endoplasmic reticulum, whereas the preceding 122 residues are predominantly 
hydrophilic and contain sites for serine phosphorylation. The segment of PTP1B is 
phosphorylated on seryl residues by PKC in vivo and the pattern of phosphorylation is 
changed in cell cycle-dependent manner (Tonks et al., 1988; Guan et al., 1990; 
Frangioni et al., 1992; Flint et al., 1993). 
 
PTP1B regulates cell functions via different signalling pathways. For example, PTP1B 
expression and activity are increased in the mice hindlimb model of angiogenesis. 
PTP1B negatively regulates the activation of VEGFR2 (vascular endothelial growth 
factor receptor 2) via directly binding to the VEGFR2 cytoplasmic domain; and 
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stabilises cell-cell adhesion via decreasing tyrosine phosphorylation of VE-cadherin 
(Nakamura et al., 2008). PTP1B is positively implicated in the oncogenic properties of 
breast cancer cells by regulating ERK signalling in an ErbB2-induced breast cancer 
mouse model. The reduction of PTP1B expression in MCF-7 cells lead to decreased cell 
growth and ERK phosphorylation. Moreover, IGF-2-induced MCF-7 cell migration was 
also impaired by the reduced PTP1B expression, an effect independent of the ERK 
pathway (Julien et al., 2007; Arias-Romero et al., 2009; Blanquart et al., 2010). 
Down-regulation of PTP1B activity using small molecule inhibitors suppressed cell 
migration and spreading over fibronectin, increased Tyr
527
 phosphorylation in Src and 
decreased phosphorylation of FAK, p130
Cas
 and ERK1/2 in the integrin pathway of 
fibroblasts (Liang et al., 2005). Furthermore, PTP1B and androgen receptor were 
co-amplified in metastatic tumours and PTP1B amplification was associated with 
high-risk primary tumours. PTP1B depletion reduced the growth of 
androgen-dependent human prostate tumours and impaired androgen-induced in vitro 
cell migration and invasion (Lessard et al., 2012).  
 
1.3.1.2 SHP2 (PTPN11)  
SHP2 is an intracellular tyrosine phosphatase with two N-terminal Src-homology 2 
domains and two tyrosine phosphorylation sites at the C-terminal which are 
dephosphorylated by receptor and non-receptor PTKs. SHP2 promotes the activation of 
the Ras/ERK pathway by growth factors and cytokines in different animal models such 
as Xenopus and Drosophila and it is an essential component in several oncogene 
signalling pathways such as leukaemia, breast and gastric cancers (Hatakeyama 2004; 
Chan et al., 2008). It has been shown that SHP2 dephosphorylates and inhibits RasGAP 
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and sprout proteins, both being negative regulators of Ras activation. In addition, SHP2 
can directly or indirectly dephosphorylate Src kinase, thus negatively regulating the 
activation of Src and the subsequent Ras pathway (Neel et al., 2003; Hanafusa et al., 
2004; Zhang et al., 2004).  
 
Gain-of-function mutations of normal genes are called proto-oncogenes and they 
generate oncogenes which provide proliferation and survival advantages to the cells. 
However, loss-of-function mutations of tumour suppressor genes lead to dysregulation 
of cell proliferation and survival. SHP2 was found to be a proto-oncogene in leukaemia 
and its gain-of-function mutation has been detected in leukaemia and certain solid 
tumours (Xu et al., 2005; Zhou et al., 2008). Autosomal-dominant mutations in the 
human SHP2 have been detected in almost 50% of patients with Noonan syndrome who 
have higher risk of suffering JMML (juvenile myelomonocytic leukaemia), and somatic 
mutations constitutively activating SHP2 have also been found in several types of 
leukaemia (Tartaglia and Gelb 2005). However, SHP2 was also found to act as a tumour 
suppressor in hepatocellular carcinogenesis. SHP2 ablation enhanced 
diethylnitrosamine-induced hepatocellular carcinoma development which was 
diminished by deletion of both SHP2 and Stat3 in hepatocytes (Bard-Chapeau et al., 
2011). Furthermore, SHP2 is a predictive marker for good prognosis in colorectal 
cancer, which is in stark contrast to it role in promoting carcinogenesis in other 
malignancies (Yu et al., 2011). 
 
Certain pathways have been indicated in the escape of tumour cells from non-immune 
and immune surveillance system, particularly the PI3K/Akt and Ras/Raf/MEK/ERK 
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pathways (McCubrey et al., 2006). In gastric cancer, activation of PI3K by inhibition of 
PTEN leads to an increased cell growth and interferon-γ (INF-γ) resistance. Activation 
of Akt followed by inactivation of glycogen synthase kinase-3β (GSK-3β) promotes 
aberrant SHP2, which suppresses the INF-γ signalling and its inhibition on tumour 
growth. SHP2 also plays an important role in tumorigenesis (Tseng et al., 2012). In 
addition, reduced SHP2 expression in glioblastoma associates with decreased cell 
growth which may be due to an increase in cell population arrested at G1 phase (Sturla 
et al., 2011). 
 
1.3.1.3 LCA (PTPRC) 
Leukocyte common antigen (LCA, CD45, PTPRC, Ly-5, T200, or B220) is a type I 
glycoprotein containing a large extracellular domain, a single transmembrane domain, 
and a cytoplasmic portion that consists of a wedge-like structure followed by tandem 
PTP domains and a 79 amino acid C-terminal tail. Only the D1 domain has the enzyme 
activity, but both D1 and D2 domain are required for the optimal phosphatase function 
of PTP in vivo. The extracellular domain exists as multiple isoforms due to the 
alternative splicing of exons 4, 5, 6, and potentially 7; it can generate at least 8 different 
isoforms at mRNA level and five of these protein products have been detected in 
humans (Streuli et al., 1987; Charbonneau et al., 1988; Streuli et al., 1988; Thomas and 
Lefrancois 1988; Hermiston et al., 2003). Furthermore, due to the spatial orientations of 
D1 and D2 domains, D1-D1 interactions cannot be inhibited, suggesting the general 
inhibitory dimerisation may not be a mechanism for the regulation of receptor-like 
PTPs (Nam et al., 2005). 
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The structure of LCA suggests that it is a receptor-like PTP and its activities are 
controlled by the interaction with specific ligands (Streuli et al., 1989). LCA is 
composed of several isoforms with their size ranging from 180 to 220 kDa. They are 
produced by tissue-specific splicing (Streuli et al., 1987; Hall et al., 1988; Streuli and 
Saito 1989). Inactivation of an LCA protein in which the extracellular domain was 
replaced by EGFR led to similar results as with inactivation of EGFR which blocks 
TCR (T cell antigen receptor) signalling (Desai et al., 1993). LCA is thought to 
dephosphorylate tyrosine residues on the Lck, Fyn and Lyn protein tyrosine kinases. 
LCA can dephosphorylate both the C-terminal negative regulatory site (PY505 of Lck 
and PY508 of Lyn) and the positive regulatory site (PY394 of Lck and PY397 of Lyn) 
in the activation loop (Saunders and Johnson 2010). Lck, Fyn and Lyn are members of 
the Src family (non-receptor protein tyrosine kinases) and the activation of Src family is 
essential for initiating downstream signalling responses to the stimulation of T and B 
cell receptors (Koretzky et al., 1990; Justement et al., 1991). Furthermore, kinases in 
this family are inhibited by autophosphorylation of a particular tyrosine residue (Tian et 
al., 1991). However there are no studies indicated that LCA direct interacted with Src 
kinase family. Other substrates of LCA is Janus kinase (JAK) family. JAKs are 
hyperphosphorylated in LCA deficient T cells, B cells and most cells in response to 
IFNα, IL-3 and IL-4. Recombinant LCA D2 domain binds to JAK2 and 
dephosphorylates the kinase in vitro, suggesting that JAKs are direct substrates of LCA. 
Although Src family kinases do not directly affect JAK phosphorylation, Src family 
kinase can impact on the JAK/STAT signalling pathway and regulate cytokine 
signalling. This suggests that LCA plays a key role in regulating the activity of Src 
family kinase (Irie-Sasaki et al., 2001; Xu et al., 2005; Scapini et al., 2009).  
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1.3.1.4 PTPRM 
The human protein tyrosine phosphatase µ  (PTPRM) gene maps to chromosome 18 and 
locates p11.2 and predominantly expressed in lung, retina and brain (Suijkerbuijk et al., 
1993; Fuchs et al., 1998; Burden-Gulley and Brady-Kalnay 1999). In crystal structure 
analysis of PTPRM D1, the subunits interact and form a dimer with 2-fold symmetry. 
The PTPRM D1 domain has 46% similarity with the PTPRA D1 domain and the 
catalytic site of PTPRM D1 domain is unhindered and adopts an open conformation 
similar to the PTP1B (Barford et al., 1994; Bilwes et al., 1996; Hoffmann et al., 1997). 
 
The PTPRM protein has a similar structure to some cell-cell adhesion molecules and 
has been shown to exhibit homophilic binding and to confer cell-cell adhesion in cells 
including epithelia and cancer cells. However, PTPRM also binds with other subfamily 
members (PTPRK, PTPRT, and PTPRU) to mediate cell-cell aggregation (Becka et al., ; 
Brady-Kalnay et al., 1993). Some reports have indicated that the MAM and Ig-like 
domains are essential for homophilic binding. The MAM domain is the homophilic 
binding site of PTPRM and contains independent cis and trans interaction sites; these 
two different interaction sites play an important role in the promotion of dimerisation of 
PTPRM at the cell membrane (Cismasiu et al., 2004). Furthermore, the Ig-like domain 
also contains a homophilic binding site to control the localisation of the enzyme; 
deletion of Ig-like domain reduced the localisation of PTPRM to the cell-cell contacts 
in endothelial and epithelial cells (Del Vecchio and Tonks 2005). 
 
Like other PTPs, PTPRM is regulated by the balance between the actions of protein 
tyrosine kinases (PTK) and PTPs. PTPRM associates with E-cadherin/ α-catenin/ 
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β-catenin complexes in rat heart, lung and brain tissues. Previous studies have shown 
that the levels of tyrosine phosphorylation of cadherin/catenin complexes are related to 
the adhesive capacity of the cadherin. PTPRM is associated with the cadherin/ catenin 
complexes of homotypic cell adhesion molecules. Treatment of cells with PTP inhibitor 
can result in an increase of tyrosine phosphorylation of cadherins and catenins. It 
suggests therefore that PTPRM can help to maintain the unphosphorylated state of the 
cadherin/catenin complexes (Cheng et al., 1997). In fact PTPRM can directly bind to 
intracellular domain of E-cadherin rather than α-catenin or β-catenin to regulate the 
phosphorylation of E-cadherin (Brady-Kalnay et al., 1995; Hiscox and Jiang 1998; 
Freiss and Vignon 2004).  
 
The association of RACK1 (Receptor of activated protein kinase C 1) with protein 
kinase c (PKC) δ and PKCδ activity, BCCIP (BRCA2 and CDKN1A-interacting 
protein), and IQGAP1 (Ras GTPase-activating-like protein IQGAP1) are involved in 
the PTPRM-dependent axonal migration. PKCδ, BCCIP, and PLCγ1 (phospholipase C γ 
1) have been reported to be PTPRM substrates. PTPRM regulates cell migration by 
dephosphorylation PY783 of PLCγ1, resulting in the enzyme being inactive and 
blocking cytoskeletal changes which are required during cellular migration (Mourton et 
al., 2001; Rosdahl et al., 2002; Ensslen and Brady-Kalnay 2004; Phillips-Mason et al., 
2006; Phillips-Mason et al., 2008; Phillips-Mason et al., 2011). Furthermore, reduced 
expression of PTPRM resulted in an increased phosphorylation of tyrosine 992 of 
EGFR (pY992) by EGF, a docking site for PLCγ1 to activate PLCγ1 thus leading to 
increased cell migration in both scratch wounding assay and chemotaxis assay 
(Phillips-Mason et al., 2008; Hyun et al., 2011). 
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1.3.2 PTPRK 
Protein tyrosine phosphatase kappa (PTPRK or PTPκ) belongs to the MAM-subfamily 
(R2B subfamily). The protein contains a MAM (Meprin/A5/ PTPRM) domain in the 
extracellular region followed by an Ig-like domain and four fibronectin type III repeats, 
the typical structure in CAM (cell adhesion molecule) proteins. It is also a putative 
neuronal recognition molecule. The post-translational modification of this molecule is 
cleavage of its extracellular domain (Streuli et al., 1988). The MAM-subfamily has two 
cytoplasmic PTP domains and an intracellular juxtamembrane region homologous to 
the intracellular domain of cadherin (Zondag et al., 1995). There are four members in 
this subfamily, PTPRM, PTPRK, PTPRT and PTPRL, with just a few variations in the 
length of their exons. The number and phases of exon/intron junction are highly 
conserved. It is at the juxtamembrane domain where the biggest variability in genomic 
organisation and the majority of alternatively spliced exons are found. This domain is a 
critical region for PTPRK in the regulation of signal transduction. The phylogenetic 
analysis of complete sequences shows that PTPRM and PTPRT are the most closely 
related, followed by PTPRK. PTPRL is the most distantly related member in this family 
(Figure 1.6) (Besco et al., 2004). 
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Figure 1.7 Exon sizes of the marine R2b subfamily extracellular and 
juxtamembrane domains. Boxed numbers indicate the number of nucleotides in each 
exon; interconnecting horizontal lines represent introns. The numbers between exons 
indicate intron phase. TM: transmembrane; JM: juxtamembrane. Adapted from (Besco 
et al., 2004) 
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PTPRK is widely expressed in normal tissues such as spleen, prostate, ovary, brain, and 
has also been found in melanocyte and keratinocyte epidermal cell lines with a 
post-translational cleavage site in extracellular region. Moreover, PTPRK is not 
expressed in peripheral blood leukocytes and hematopoietic cell lines (Jiang et al., 1993; 
McArdle et al., 2005). Recent studies have shown that PTPRK is up-regulated by 
TGF-β and is probably involved in TGF-β dependent anti-proliferation and cell 
migration effects (Yang et al., 1996). Furthermore, co-localisation of PTPRK with 
β-catenin at adhesion junctions has been revealed in human embryonic kidney cells 
(HEK293) which stabilises the E-cadherin/β-catenin complex. This suggests that 
β-catenin might be a substrate of PTPRK-mediated phosphatase activity. The 
stabilisation of the β-catenin/E-cadherin complex can suppress wnt/β-catenin-induced 
transcription of target genes such as cyclin D1 and c-Myc, leading to an inhibition of 
proliferation and migration in cancer cells. It suggests that PTPRK may be a potential 
tumour suppressor (Novellino et al., 2008). 
 
In addition, it has also been demonstrated that PTPRK can dephosphorylate EGFR or 
ErbB1 which belongs to PTKR (receptor protein-tyrosine kinase) superfamily. 
Abnormal regulation of EGFR has been shown to promote multiple tumourigenic 
processes by stimulating proliferation, angiogenesis and metastasis. EGFR and its 
ligands play important roles in some of the most common human cancers (Salomon et 
al., 1995). It has been shown that PTPRK directly dephosphorylates EGFR in vitro and 
that increased PTPRK expression decreases both basal and ligand-stimulated EGFR 
tyrosine phosphorylation. Reduced PTPRK expression leads to an increase in EGFR 
tyrosine phosphorylation (Xu et al., 2005). Despite the aforementioned biochemical and 
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cellular functions for PTPRK, the influence that PTPRK may have on cancer and cancer 
development remains largely unknown. To date, some PTPs have already been shown to 
act as tumour suppressors, such as PTEN (MMAC1, is a tumour suppressor and is 
mutated in various human cancers) and PTPρ (PTPRT, potential tumour suppressor in 
colorectal cancers) (Tonks 2006). Recent studies have shown that PTPRK may possibly 
act as a putative tumour suppressor in primary central nervous system lymphomas 
(Nakamura et al., 2003). 
 
1.3.2.1 The PTPRK Gene 
The mouse PTPRK gene maps to chromosome 10 and 19.0 centimorgans (cM) from the 
centromere and to be highly expressed in liver and kidney. The mouse PTPRK sequence 
has a 5’ untranslated region (1,072 bp), an open reading frame (4,371bp) and a 3’ 
untranslated region (338 bp). The translational initiation codon is identified by a 
standard environment for initiation of translation (Kozak 1983) and there is an upstream 
in-frame stop codon (position: -252) which is followed by a hydrophobic region that 
functions as a signal peptide. The second hydrophobic region is found from amino acid 
residues 753 to 774. This is followed by a series of predominantly basic residues, which 
function as a stop transfer sequence. These features show an extracellular region of 752 
amino acid residues and an intracellular part of 683 amino acid residues, a PTP domain 
repeat. The structure is homologous to most PTPRs identified so far. A special feature 
of PTPRK is the extended distance between the transmembrane segment and the start of 
the first phosphatase homology domain. This segment is around 70 amino acid residue 
longer than any other PTPRs with PTPRM being the only exception (Gebbink et al., 
1991).The first 170 amino acids of PTPRK show 26% similarity to a region in Xenopus 
50 
 
neuronal cell surface protein A5 (position: 30-193). The A5 protein is a class I 
membrane protein containing two different internal repeats in the extracellular region 
and is expressed in retinal ganglion cells and visual centre neurons. It is homologous to 
complement components and coagulation factors in the blood. This protein has been 
shown to be involved in recognition between input and target neurons in the visual 
system (Takagi et al., 1991). This domain is followed by an Ig-like domain (C2-type 
immunoglobulin domain) (position: 195-280) and four putative fibronectin type Ⅲ 
repeats (position: 290-688). These fibronectin type Ⅲ domains are similar to those in 
PTPRM (receptor- like protein tyrosine phosphatase μ), LAR (PTPRF, receptor- like 
protein tyrosine phosphatase F), Drosophila PTPRs DLAR and DPTP10D and 
Drosophila neuroglian (Streuli et al., 1988; Bieber et al., 1989; Streuli et al., 1989; 
Gebbink et al., 1991; Tian et al., 1991; Yang et al., 1991). The extracellular domain of 
PTPRK contains the HAV sequence (histidine, alanine and valine; position: 340-342 
within the first fibronectin repeat.), a domain seen in most of the Type I cadherins and is 
central to the cell-cell contact formed by members of cadherin family (Blaschuk et al., 
1990). In addition, its extracellular domain contains the RTKR sequence 
(arginine-threonine-lysine-arginine; position: 640-643), which is the same cleavage site 
(RXK/RR, arginine-X-lysine/arginine-arginine) for processing by endoprotease furin 
and PC3. These endoproteases are mammalian homologues of the yeast precursor 
processing endoprotease Kex2, and are Ca
2+
-dependent serine proteases. In endocrine 
cells, the sequence is only cleaved by PC3; however, in non-endocrine cells, furin 
enhances the precursor cleavage (Hosaka et al., 1991). Other potential post-translational 
modification sites are the 12 potential N-linked glycosylation sites (position: 100, 139, 
210, 415, 423, 435, 461, 551, 585, 589, 606 and 689) and SG (serine-glycine) 
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sequences which are candidates for chondroitin sulphate attachment (position: 172, 176, 
277, 333 and 662) (Kjellen and Lindahl 1991). PTPRK shows a highly similar sequence 
to mouse PTPRM, with over 77% similarity in their amino acid sequences (Gebbink et 
al., 1991). There is an 80% sequence similarity in the first PTP homology domain and 
74% similarity in the second PTP homology domain (Jiang et al., 1993). 
 
The human PTPRK gene maps to chromosome 6 and locates to q22.2-23.3 and is 
predominantly expressed in the spleen, prostate, ovary and also expressed in the thymus, 
testis, small intestine and colon. Peripheral blood leukocytes are exceptional and 
express very little of this PTP. The human PTPRK gene has a 98% similarity to the 
murine PTPRK gene. The human PTPRK gene contains an open reading frame 
(4,317bp) coding 1,439 amino acids which includes an extracellular region (position: 
27-752), a transmembrane region with a stretch of 22 hydrophobic amino acids 
(position: 753-774) and a cytoplasmic region (position: 775-1439). The extracellular 
region of human PTPRK contains a MAM domain (position: 31-194), an Ig-like 
C2-type domain (position: 196-281), four fibronectin domains (position: 291-680) and 
twelve potential N-glycoylation site (position: 101, 140, 211, 416, 424, 436, 462, 552, 
586, 590, 607 and 690). These features are similar to the cell adhesion molecule (CAM) 
family. The cytoplasmic region contains two repeats of PTPs (position: 887-1141 and 
1173-1435).  
 
1.3.2.2 PTPRK Protein Structure 
The molecular weight of the PTPRK protein is 210 kDa. Following posttranslational 
modifications, it is divided into two subunits, which are a secreted N-terminal 110 kDa 
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product including most of the extracellular domain and a 100 kDa product including the 
intracellular sequence and about 100 amino acid residues of extracellular sequence. The 
potential cleavage site was investigated using furin, a processing endopeptidase. It has 
been confirmed that the cleavage site, RTKR (position: 640-643) is located 113 amino 
acids upstream of the transmembrane sequence. This also shows that the RTKR region 
is the proteolytic cleavage signal for processing of the PTPRK proprotein (Jiang et al., 
1993).  
 
The crystal structure of PTPRM D1 domain shows the subunits associate to form a 
dimer with two-fold structural symmetry. This dimerisation has been proposed to be a 
result of crystallisation because the protein are monomeric in solution. The dimer 
exhibits no obstruction to the catalytic site. However, the crystal structure of PTPRA 
has also been shown as a crystallographic dimer, their active sites occupied by a 
helix-turn-helix wedge motif of its dyad-related partner (Bilwes et al., 1996) which 
blocks substrate access to the catalytic site. Although PTPRK belongs to the same 
subfamily of PTPRM, the PTPRK D1 domain is a monomer in both solution and crystal 
structure. Furthermore, the crystal structure of catalytically active, monomeric D1 
domain of PTPRK is at 1.9Å . The structure of the PTPRK D1 domain and the same 
domain of other PTP family members has an overall classical PTP structure which 
comprises twisted mixed β-sheets flanked by α-helices in which the catalytic important 
WPD (Trp1049-Ala1058) loop is in an open conformation. As in all tyrosine 
phosphatases, the active site cysteine (Cys1083) is located in the well-conserved 
phosphate binding loop and an acetate molecule bound to it might reduce the phosphate 
binding opportunity (Eswaran et al., 2006). In PTPRK, Ile1123 and Asn1124 are 
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present in the corresponding positions and Asn1124 seems to accommodate the 
phosphopeptides with a small amino acid in the pY+1 position. The N-terminal β-strand, 
formed by βx association with βy, is conserved between PTPRK, PTPRM, PTPRA and 
most of PTPRs. This feature has been suggested to distinguish D1 domain of RPTPs 
from the cytosolic PTPs and is conserved in the PTPRK structure forming a β-strand at 
the N-terminal (Bilwes et al., 1996; Hoffmann et al., 1997; Eswaran et al., 2006).  
 
1.3.2.3 Role of PTPRK in physiology 
1.3.2.3.1 Role of PTPRK in cell growth/development 
PTPRK has been indicated in T cell development. The rat PTPRK gene shares 98% 
similarity with the human and mouse PTPRK gene and it is expressed abundantly in the 
CD4
- 
CD8
- 
double-negative stage. Reduced PTPRK expression using RNA interference 
method has shown a similar phenotype of T helper immunodeficiency which leads to T 
cell mutation from CD4 and CD8 double-positive to CD4 single positive cells in the 
thymus (Kose et al., 2007). Furthermore, there is an approximate 380 kb deletion in 
chromosome 1 of LEC rat (which has a spontaneous mutation in the T helper 
immunodeficiency) where the PTPRK gene is located. It is noted that PTPRK plays a 
critical role in CD4 single-positive development in thymus (Asano et al., 2007). Most 
importantly, inhibition of PTPRK suppresses ERK1/2 phosphorylation in T cell 
hybridoma. PTPRK regulated CD4
+
 T cell via ERK1/2 signalling pathway and ERK1/2 
activity is crucial for CD4 and CD8 T cell. Inhibition of PTPRK suppresses ERK1/2 
phosphorylation in T cell hybridoma. ERK1/2 is phosphorylated by MEK1/2. Moreover, 
PTPRK affects c-Raf (MAP3 kinase) phosphorylation which generally phosphorylates 
MEK1/2. It has been shown that PTPRK can directly dephosphorylate β-catenin and 
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EGFR. Although EGFR signalling affects the ERK1/2 pathway, there is no evidence 
showing EGFR to be involved in the regulation of CD4
+
 T cell development 
(Erdenebayar et al., 2009). In addition, PTPRK stimulates growth factor receptor 
bound-2 (Grb2), a multi-purpose adapter molecule and its down-stream MAPK 
cascades (Ras/Raf/MEK/ERK) to promote neurite outgrowth from cerebellar neurons 
whilst EGFR is not required in this event (Drosopoulos et al., 1999).  
 
As already discussed in previous sections, the transforming growth factor-β (TGF-β) 
family plays an important role in a variety of physiological functions including cell 
proliferation, adhesion, differentiation, morphogenesis, motility, tissue repair and other 
functions in many different types of cells. In fibroblasts and epithelial cells, TGF-β1 
shows a reversible growth arrest. However, in mesenchymal cells it increases cell 
proliferation and also up-regulates the expression of several extracellular matrix 
components and protease inhibitors. Human keratinocytes require EGF and TGF-α for 
proliferation, whilst TGF-β1 exhibits an inhibitory effect (Shipley et al., 1986; Coffey 
et al., 1988). Keratinocytes treated with TGF-β1 have a decreased expression of c-myc 
gene transcript (Pietenpol et al., 1990). Additionally, TGF-β1 inhibits cell growth via 
phosphodiesterase-mediated hydrolysis of phosphatidylcholine (Diaz-Meco et al., 
1992). Moreover, TGF-β1 inhibits proliferation of hamster lung fibroblast in which 
protein kinase C and polyphosphoinositide breakdown are not involved (Chambard and 
Pouyssegur 1988).  TGF-β1 also induces PTPRK mRNA expression in HaCaT cells, 
leading to an inhibition of proliferation of the human keratinocyte cell line. This can be 
suppressed by sodium orthovanadate (tyrosine phosphatase inhibitor) and H7 
(serine/threonine kinase inhibitor) but not genistein (tyrosine kinase inhibitor) (Yang et 
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al., 1996). RNA interference (RNAi) of PTPRK can accelerate cell cycle progression 
and enhance the response to EGF-induced EGFR tyrosine phosphorylation which leads 
to increased downstream ERK activation and abrogates TGF-β-mediated 
anti-mitogenesis effect. Activation of EGFR is necessary for the induction of signalling 
pathways including mitogen-activated protein kinases (MAPKs), phosphatidylinositol 
3-kinase (PI3K)/ Akt and phospholipase C/ protein kinase C (PKC). Endogenous 
PTPRK associated with EGFR and HER2 (ErbB2), leading to the suppression of basal 
and ErbB ligand-induced proliferation and receptor phosphorylation (Wang et al., 2005; 
Xu et al., 2005). Moreover, activation of EGFR can prevent UV-induced apoptosis via 
activation of PI3K/ Akt pathway in which PTPRK plays an important role in the 
antioxidant action by directly interacting with EGFR (Xu et al., 2006). PTPRK 
expression is reduced in EBV (Epstein-Barr virus) infected Hodgkin lymphoma cell 
lines due to the expression of EBNA1 (Epstein-Barr nuclear antigen-1) and decreased 
SMAD2 protein expression. EBV infection presses TGF-β induced expression of 
PTPRK which leads to an increase of in cell proliferation and survival. It has thus been 
suggested that PTPRK is a putative tumour suppressor in Hodgkin lymphoma (Flavell 
et al., 2008).  
 
PTPRK, an N-linked glycoprotein, has been identified as a substrate of 
N-Acetylglucosaminyltransferase V (GnT-V) in colon cancer (Kim et al., 2006). GnT-V 
overexpression does not only change the glycosylation of PTPRK but also decreases its 
protein expression. PTPRK is involved in the regulation of β-catenin signalling and 
downstream target genes such as c-myc and cyclin D1 which may promote the 
proliferation of human hepatoma SMMC-7721 cells (Wang et al., 2010). However, in 
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melanoma cells, PTPRK exhibits an inhibition of β-catenin protein expression and a 
disruption of the β-catenin/Tcf-mediated cyclin D1 expression, resulting in a reduction 
of cell proliferation (Novellino et al., 2008).  
 
1.3.2.3.2 Role of PTPRK in cell-cell/cell-matrix adhesion 
The extracellular region of PTPRK contains one Ig-like domain, four fibronectin type 
Ⅲ repeats and a MAM domain. A combination of fibronectin type Ⅲ repeats and 
Ig-like domains are often highly expressed in epithelial and neuronal tissues and 
PTPRK behaves similarly to members of the N-CAM family. Some proteins of the Ig 
superfamily can mediate both homophilic and heterophilic interactions by the presence 
of MAM domain. However, it is very interesting to note that PTPRK fails to interact 
with PTPRM, which belongs to the same subfamily of PTPs. PTPRK only promotes 
homophilic interactions such as cell aggregation and cell-cell adhesion. Furthermore, it 
has been reported that PTPRK-mediated intercellular adhesion does not need PTPs 
activity or post-translational modification of PTPRK protein and it is also calcium 
independent (Sap et al., 1994; Brady-Kalnay and Tonks 1995; Zondag et al., 1995). 
 
GnT-V overexpression down-regulates cell calcium-independent adhesion and increases 
the tyrosine phosphorylation of β-catenin (Wang et al., 2010). The increased tyrosine 
phosphorylation level of β-catenin can lead to a decrease of cadherin-bound β-catenin, 
and an increase of β-catenin in the cytoplasmic and nuclear pool (Gujral et al., 2008). 
β-catenin in the nuclear pool has been found to serve as a key component in the Wnt 
pathway in which it interacts with Tcf (T-cell-specific transcription factor 1 )/ Lef 
(lymphoid enhancer factor) family to activate target genes such as, c-myc and cyclin D1 
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(He et al., 1998; Tetsu and McCormick 1999). PTPRK can negatively regulate 
β-catenin transcriptional signalling in melanoma cells. PTPRK is also able to re-locate 
β-catenin/E-cadherin complexes to cytoskeleton-linked phase alongside cell-cell contact 
surface and to inhibit cytosolic and nuclear accumulation of both wild type β-catenin 
and the oncogenic form of β-catenin (Novellino et al., 2008). 
 
1.3.2.3.3 Role of PTPRK in cell motility 
Previous studies have shown that excess production and activation of TGF-β in tumour 
cells can accelerate cancer progression by a combination of autocrine and paracrine 
mechanisms which include enhancement of tumour cell motility and survival, increase 
in tumour angiogenesis, production of extracellular matrix and peritumoral proteases 
and inhibition of immune responses in tumour host (Derynck et al., 2001; Wakefield 
and Roberts 2002). It has been reported that SHP-1 and SHP-2 are activated by TGF-β 
to regulate T cell functions and PTPRK is also activated by TGF-β to reduce 
keratinocytes cell proliferation (Yang et al., 1996; Choudhry et al., 2001). Moreover, 
TGF-β pathway not only regulates cell proliferation but also other cell functions. The 
negative effect of TGF-β-induced PTPRK expression on Src and HER2 signalling plays 
a profound role in coordinating the cell motility and adhesion (Wang et al., 2005; Kim 
et al., 2006). 
 
Overexpression of GnT-V induces an addition of β1, 6GlcNAc branch to N-glycan of 
PTPRK and also decreases the protein level of PTPRK. This change of PTPRK leads to 
an increased phosphorylayion of EGFR at tyrosine 1068 and subsequently increased 
phosphorylation of ERK and FAK which results in an increase in cell migration. 
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Glycosylation of PTPRK tends to be aberrant in the GnT-V overexpressed cells and 
glycosylated PTPRK is easy to be broken by proteolytic cleavage. All these events 
would lead to an enhanced cleavage of PTPRK and reduced capacity of the homophilic 
binding which eventually results in an increase in cancer cell migration. (Wang et al., 
2009). 
 
1.3.2 PTP family in cancer/disease 
There have been overwhelming reports on the abnormalities of a number of the PTP 
family members in human cancer, ranging from gene mutations, abnormalities in gene 
expression at message and proteins levels. Tables-1.2 to 1.4 summarise some of the key 
observations in various human cancers. The following sections discuss some of the 
most interesting members of this family in cancer. 
 
1.3.2.1 PTPs and apoptosis 
Apoptosis, also known as programmed cell death, can be induced by both internal and 
external pathways. TNFs (tumour necrosis factors) and their receptors trigger apoptosis 
via the external pathway and its down-stream transcriptional factors are also involved in 
the internal pathway of apoptosis. The Bcl-2 superfamily plays a crucial role in the 
control of apoptotic signalling in mitochondria. Moreover, Bcl-2 and anti-apoptotic 
family proteins such as the Bax/ Bak subfamily promote cell survival. The Bax/ Bak 
subfamily is able to mediate apoptotic signalling and also help to release the 
pro-apoptotic factors such as cytochrome c and Smac/ Diablo, from mitochondria 
(Adams 2003; Roset et al., 2007).  
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The intrinsic mitochondria pathway of apoptosis is regulated by several molecules, for 
example XIAP (inhibitors of apoptosis) and the Bcl-2 family. Activation of Bcl-2 family 
members leads to mitochondrial outer membrane permeabilisation; cytochrome c is 
released and bound with APAF-1 and caspase-9 to form an apoptosome (Siu et al., 
2008). After apoptosome formation, caspase-9 is activated and there is also regulation 
of down-stream molecules such as caspase-3 (Ohtsuka et al., 2003). Tumour cells can 
inhibit apoptosis by regulation of anti-apoptotic mechanisms such as upregulation of the 
apoptotic suppressors Bcl-2 and Bcl-XL and downregulation of the caspase cascade 
(Elmore 2007). The extrinsic pathway involves the promotion of apoptosis via the 
ligand-activation of death receptors (Wallach et al., 2008). For example, TNF-α binding 
to its receptors leads to the formation of two complexes; one can lead to activation of 
the pro-survival NF-κB pathway and another one activates the apoptosis pathway 
through FADD (Fas associated death domain) and activation of caspase-8 (Wajant and 
Scheurich 2011). 
 
PTPs deficiency leads to several physiologic abnormalities such as embryonic 
developmental defect (PTP-PEST), impairment of the immune system (TC-PTP) and 
inhibition of tumourigenesis and metastasis (PTP1B) (Sirois et al., 2006; Bourdeau et 
al., 2007; Julien et al., 2007). Dysregulation of apoptosis by PTP deficiency may play a 
profound role in these disorders. PTP-PEST makes cells more sensitive to anti-Fas and 
TNFα induced apoptosis. PTP-PEST is cleaved by caspase-3 which increases its 
catalytic activity and changes its protein structure. Furthermore, PTP-PEST proteolysis 
facilitates cellular detachment during apoptosis (Halle et al., 2007). Unlike PTP-PEST, 
PTP1B has no caspase cleavage site and is not cleaved by caspases during apoptosis. 
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However, there is a report showing activated PTP1B contributes to STAT3 
dephosphorylation and induces apoptosis in human glioma cells (Akasaki et al., 2006; 
Halle et al., 2007). PTP1B and its catalytic activity are required for IRE1 
(inositol-requiring kinase 1) signalling which activates JNK and p38 MAPK, XBP-1 
(X-box-binding protein 1) splicing, and EDEM (ER degradation-enhanced 
α-mannosidase protein) transcription. Moreover, ER-induced apoptosis is decreased in 
cells lacking PTP1B and PTP1B null mice are resistant to Fas-induced liver damage 
because of absence of PTP1B-mediated suppression of pro-survival NFκB and ERK 
signalling (Gu et al., 2004; Sangwan et al., 2006). In addition, p53 is required for 
TC-PTP overexpression induced apoptosis. In MCF-7 breast cancer cells, the 
accumulation of p53 in response to TC-PTP overexpression directly increases the 
expression of Apaf-1 and the pro-apoptotic α-isoform of caspase-1 (Radha et al., 1999; 
Gupta et al., 2002). SHP-1 disrupts anti-apoptotic pathway through the regulation of 
Lyn, Tyk2 and PI3K upon death receptor stimulation. In addition, SHP-1 favours Bim/ 
Bod expression and c-jun phosphorylation, resulting in increased apoptosis. However, 
SHP-1 dephosphorylates TrkA which in turn inhibits NGF-mediated PLC1 and Akt 
phosphorylation, thus producing a reduced TrkA survival signal (Marsh et al., 2003; 
Yousefi and Simon 2003). 
 
1.3.2.2 PTPs and cancers 
Tyrosine and serine/threonine phosphorylation are important in the regulation of 
biological functions and is mainly regulated by kinases and phosphatases. Many 
phosphatases have been reported to participate in the regulation of cancer development. 
Furthermore, it has been shown that some phosphatases are tumour suppressors, such as 
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PTEN (deletion in many cancers) and PTPRH (down-regulation in hepatocellular 
carcinoma). However, some of them are thought to act as proto-oncogenes/oncogenes, 
for example SHP2 (leukaemia) and PTPRF (over-expression in thyroid and breast 
cancers). Other examples will be discussed in the following sections. 
   
1.3.2.2.1 PTPRJ 
PTPRJ (DEP1) was initially identified as a potential tumour suppressor in breast cancer. 
This was demonstrated when re-expression of PTPRJ in breast cancer cells resulted in a 
five- to ten-fold reduction of cell proliferation. Similar findings in pancreatic, thyroid 
and colon cancers were reported later (Keane et al., 1996; Trapasso et al., 2000; Iuliano 
et al., 2003; Trapasso et al., 2004). 
 
Loss of heterozygosity, occurring in the absence of acquired mutation in the remaining 
allele has been found in breast, colon, lung and thyroid cancers, implying that PTPRJ 
alone may not be sufficient as a transforming mechanism in cancerous cells. According 
to those reports, different allelic variants of PTPRJ have been identified, which result in 
different structures in the extracellular domain of PTPRJ variants. In colon cancer, 
analyses of tumours of heterozygous patients indicated that the preferential loss of one 
of those alleles (Q276 of the Q276P polymorphism) occurred during tumour growth, 
suggesting functional differences may exist between these alleles (Ruivenkamp et al., 
2002; Ruivenkamp et al., 2003; Iuliano et al., 2004; van Puijenbroek et al., 2005). 
However, similar experiment in patients with thyroid cancer failed to detect any loss of 
the Q276 allele. The D872allele (D872E polymorphism) has been detected more 
frequently in patients with thyroid carcinoma. The D872 variant may increase the 
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ability to form dimmers resulting in an inhibition of PTP function (Iuliano et al., 2004). 
Furthermore, a significant association has been demonstrated between breast cancer risk 
and the PTPRJ haplotype which does not require Q276P allele (Lesueur et al., 2005). 
Various signalling pathways have been implicated in the function of PTPRJ. PTPRJ 
plays an antagonistic role in growth factor signalling pathways; it can directly 
dephosphorylate PDGFR, VEGFR and cMET (Kovalenko et al., 2000; Grazia 
Lampugnani et al., 2003; Palka et al., 2003). In addition, PTPRJ substrates including 
Src, p120 catenin and PLCγ, have been indicated in its tumour suppressing action. 
Another tumour suppressing mechanism of PTPRJ is that it promotes G1 phase arrest 
via acyclin-dependent-kinase-inhibitor p27. Additionally, a pro-apoptotic effect has also 
been indicated in the anti-cancer functions of PTPRJ (Holsinger et al., 2002; Trapasso 
et al., 2004; MacKeigan et al., 2005). 
 
1.3.2.2.2 PTPRA 
PTPRA (PTPα) is a member of the transmembrane subfamily of PTPs and is widely 
expressed in various human tissues. PTPRA participates in the regulation of several 
pathways controlling cell proliferation and differentiation. For example, PTPRA can 
down-regulate insulin-increased prolactin gene activity via a dephosphorylation of 
insulin receptor (Jacob et al., 1998). Over-expression of PTPRA in rat embryo 
fibroblasts leads to activation of ERK and -Jun (Zheng and Pallen 1994). Therefore, 
PTPRA plays a critical role in the proliferation and differentiation of different cell 
types. 
 
PTPRA may have an oncogenic role in gastric cancer progression by promoting 
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migration and anchorage-independent cell growth, an effect achieved by 
dephosphorylation of proteins that are involved in these processes (Wu et al., 2006). 
PTPRA is required for the activation of SFKs (Src family kinases) following integrin 
ligation, an event necessary for adhesion to occur. PTPRA binds to integrin α5β3 and 
regulates integrin signalling and cell migration via the dephosohorylation of Src on 
pY527, which increases the association of Src with FAK (Harder et al., 1998). PTPRA 
can also potently transform mouse fibroblasts (Zheng et al., 1992). Furthermore, 
over-expression of PTPRA has been found in late-stage human colon carcinoma and 
breast cancer (Tabiti et al., 1995; Ardini et al., 2000). However, it has been 
demonstrated that PTPRA over-expression is correlated with low tumour grade and 
positive oestrogen-receptor expression. PTPRA has also been shown to inhibit 
transformation of breast cancer cells associated with increasing accumulation in G0 and 
G1 phases leading to a delayed tumour growth and metastasis (Ardini et al., 2000). 
 
1.3.2.2.3 PTEN     
PTEN (phosphatase with tensin homology) is a recognised tumour suppressor in many 
cancers and it has been identified as a gene mutated in many tumour types. PTEN is a 
dual specificity phosphatase; it not only has dephosphorylated tyrosine but also 
dephosphorylated serine/threonine residues (Myers et al., 1997). PTEN has been shown 
to act as a tumour suppressor by negatively regulating the PI3K pathway, an important 
route for the regulation of cell proliferation and cell survival (Stambolic et al., 1998).  
There are two important subunits of PI3K required for activation of the downstream Akt 
signalling pathway (to protect cell from apoptosis and increase cell proliferation), which 
are a 85 kDa regulatory subunit (p85 subunit) and a 110 kDa catalytic subunit (p110 
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subunit). There are a number of ways for PI3K to activate downstream pathways. The 
first is direct binding of the p85 subunit to phospho-YXXM motifs of the RTK which 
then activates the p110 subunit. Another route requires an adaptor protein, GRB2 
(Growth Factor Receptor-bound protein 2) for binding to the RTK phosphor-YXN 
motifs and then GRB2 binds to the scaffolding protein GAB (GRB2-associated binding 
protein) which subsequently binds to the p85 subunit (Domchek et al., 1992; Ong et al., 
2001; Pawson 2004). The p110 subunit of PI3K can be activated by interaction with 
Ras (Rodriguez-Viciana et al., 1994). In endometrial tumours and melanoma cell lines, 
mutations of Ras and PTEN genes are mutually exclusive. In comparison wit PTEN 
mutations, Ras mutations are more commonly seen in pancreatic, lung and colon 
cancers. Such mutations have seldom been found in glioblastomas. In the mouse model 
of chemically-induced skin carcinogenesis, Ras mutations are increased in PTEN
+/+
 
mice and decreased in PTEN
+/-
 mice. Tumours that lack Ras mutations tend to lose the 
wild-type PTEN allele. It has been suggested that Ras activation and loss of PTEN may 
have a similar impact during tumorigenesis (Liu et al., 1997; Ikeda et al., 2000; Tsao et 
al., 2000; Simpson and Parsons 2001; Downward 2003; Mao et al., 2004). 
The tumour suppressor p53 activates PTEN and functions as a negative regulator of the 
PI3K signalling pathway (Stambolic et al., 2001). Down-regulation of the PI3K 
pathway by p53 activation is due to p53-mediated transcriptional inhibition of the gene 
encoding the p110 subunit of PI3K. Transcriptional regulation of the PI3K pathway by 
p53 eliminates PI3K-mediated cell survival and proliferation and provides additional 
protection for DNA replication in the presence of genotoxic stress (Singh et al., 2002). 
p53 mutation is one of the most common mutations in human cancer and the p53 
apoptotic response requires the down-regulation of the PI3K pathway via the 
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transcriptional activation of PTEN (Stambolic et al., 2001). Meanwhile, inhibition of 
the PI3K pathway and activation of apoptosis by p53 downstream signalling might have 
synergistic effects. Moreover, drug induced activation of p53 or Ras may also 
synergistically increase the anti-tumour effects of drugs that target PI3K or TOR (Cully 
et al., 2006). 
 
 
Table 1.3 Receptor-like PTPs and Cancers.  
 
Receptor-like PTPs  
PTPs Negative regulator Positive regulator Reference 
PTPRA Breast
↓
 Colorectal
↑
, head and 
neck
↑
, gastric
↑
 
(Tabiti et al., 1995; Berndt et al., 1999; 
Ardini et al., 2000; Wu et al., 2006) 
PTPRB   Glioma
↑
, gastric
↑
 (Foehr et al., 2006; Wu et al., 2006; 
Hagerstrand et al., 2008) 
PTPRD Glioma*, melanoma*, 
colorectal
↓
, liver*, 
head and neck*, lung* 
 (Nair et al., 2008; Solomon et al., 2008; 
Veeriah et al., 2009; Laczmanska and 
Sasiadek 2011; Nalesnik et al., 2012) 
PTPRF Colorectal* Thyroid
↑
, breast
↑
 (Yang et al., 1999; Levea et al., 2000; 
Konishi et al., 2003; Laczmanska and 
Sasiadek 2011) 
PTPRG Head and neck*, 
breast
↓
, ovarian
↓
, 
lung
↓
, gastric, 
lymphoma 
Glioma
↑
, gastric
↑
, 
lymphoma
↑
 
(van Niekerk and Poels 1999; Liu et al., 
2002; Wang et al., 2004; van Doorn et al., 
2005; Vezzalini et al., 2007; Wang and 
Dai 2007; Cheung et al., 2008) 
PTPRH Liver
↓
 Gastrointestinal
↑
, 
colorectal
↑
 
(Matozaki et al., 1994; Seo et al., 1997; 
Nagano et al., 2003) 
PTPRJ Breast*, lung*, 
colorectal, thyroid 
 (Ruivenkamp et al., 2002; Iuliano et al., 
2004; Ding et al., 2010; Mita et al., 2010) 
PTPRK Melanoma
↓
, 
lymphoma 
 (Zhang et al., 1998; McArdle et al., 2001; 
Nakamura et al., 2003) 
PTPRM Glioma
↓
, melanoma
↓
 Ovarian (McArdle et al., 2001; Gyorffy et al., 
2008; Burgoyne et al., 2009; Burgoyne et 
al., 2009) 
PTPRO Breast, lung, 
leukaemia, colorectal 
 (Mori et al., 2004; Motiwala et al., 2004; 
Motiwala et al., 2007; Motiwala et al., 
2009; Ramaswamy et al., 2009) 
PTPRS Colorectal*  (Korff et al., 2008) 
PTPRT Colorectal*, gastric*, 
lung* 
 (Wang et al., 2004) 
PTPRZ  Glioma
↑
, melanoma
↑
, 
gastric
↑
 
(Goldmann et al., 2000; Ulbricht et al., 
2003; Foehr et al., 2006; Wu et al., 2006; 
Hagerstrand et al., 2008) 
*: deletion or mutation of gene.
↓
: expression decreased. 
↑
: expression increased. 
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Table 1.4 Non-transmembrane PTPs and Cancers.  
 
Non-transmembrane PTPs  
PTPs Negative regulator Positive regulator Reference 
PTPN1 Oesophageal
↓
 Breast
↑
, ovarian
↑
, 
gastric, pancreatic, 
prostate
↑
 
(Wiener et al., 1994; Wiener et al., 1994; 
Warabi et al., 2000; Mahlamaki et al., 
2002; Yang et al., 2005; Wu et al., 2006) 
PTPN2 T cell acute 
lymphoblastic 
leulaemia* 
 (Kleppe et al., 2010) 
PTPN3 Breast*, lung*, 
colorectal* 
Gastric
↑
, 
oesophageal
↑
 
(Warabi et al., 2000; Wang et al., 2004; Wu 
et al., 2006) 
PTPN5 Colorectal*  (Korff et al., 2008) 
PTPN6 Gastric, prostate, 
lymphoma, 
myeloma, leukaemia 
Ovarian
↑
 (Oka et al., 2002; Zapata et al., 2002; Chim 
et al., 2004; Reddy et al., 2005; 
Cariaga-Martinez et al., 2009; Ksiaa et al., 
2009) 
PTPN7 Lymphoma
↓
 Leukaemia
↑
 (Zanke et al., 1994; Fridberg et al., 2008) 
PTPN11 Liver
↓
 Leukaemia* (Chan et al., 2008; Bard-Chapeau et al., 
2011) 
PTPN12 Breast*, kidney*  (Streit et al., 2006) 
PTPN13 Breast
↓
, colorectal*, 
lung, liver, 
lymphoma 
 (Lee et al., 1999; Wang et al., 2004; Yao et 
al., 2004; Yeh et al., 2006; Ying et al., 
2006; Korff et al., 2008; Revillion et al., 
2009; Mita et al., 2010) 
PTPN14 Breast*, lung*, 
gastric*, colorectal* 
 (Wang et al., 2004) 
PTPN18 thyroid  (Guimaraes et al., 2006) 
PTPN21 Colorectal* Colorectal* (Korff et al., 2008) 
*: deletion or mutation of gene. 
↓
: expression decreased. 
↑
: expression increased. 
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Table 1.5 Dual specificity phosphatases and Cancers.  
 
Dual-specificity phosphatases  
PTPs Negative regulator Positive regulator Reference 
PTP4A1  Pancreatic
↑
, 
oesophageal
↑
, 
colorectal
↑
 
(Wang et al., 2007; Liu et al., 2008; 
Stephens et al., 2008) 
PTP4A2  Pancreatic
↑
, 
colorectal
↑
 
(Wang et al., 2007; Liu et al., 2008; 
Stephens et al., 2008) 
PTP4A3  Head and neck
↑
, 
oesophageal
↑
, 
breast
↑
, gastric
↑
, 
ovarian
↑
, lung
↑
, 
liver
↑
, colorectal
↑
, 
glioma
↑
, myeloma
↑
 
(Saha et al., 2001; Bardelli et al., 2003; 
Kato et al., 2004; Peng et al., 2004; Wang 
et al., 2006; Kong et al., 2007; Miskad et 
al., 2007; Fagerli et al., 2008; Mollevi et 
al., 2008; Zhao et al., 2008; Ren et al., 
2009; Xing et al., 2009; Zhou et al., 2009) 
DUSP1 Liver
↓
, ovarian
↓
, 
prostate 
Nead and neck
↑
, 
breast
↑
, grastric
↑
, 
pancreatic
↑
, 
bladder
↑
, ovarian
↑
, 
prostate
↑
, lung
↑
, 
colorectal
↑
 
(Loda et al., 1996; Magi-Galluzzi et al., 
1997; Bang et al., 1998; Denkert et al., 
2002; Manzano et al., 2002; Liao et al., 
2003; Wang et al., 2003; Vicent et al., 
2004; Rauhala et al., 2005; Tsujita et al., 
2005; Colombo et al., 2009) 
DUSP2 Leukaemia
↓
 ovarian
↑
 (Kim et al., 1999; Givant-Horwitz et al., 
2004) 
DUSP3  cervical
↑
 (Henkens et al., 2008) 
DUSP4 Breast* Breast
↑
 (Wang et al., 2003; Armes et al., 2004) 
DUSP6 Pancreatic, ovarian
↓
  (Furukawa et al., 2003; Xu et al., 2005) 
DUSP7  leukaemia
↑
 (Levy-Nissenbaum et al., 2003; 
Levy-Nissenbaum et al., 2003) 
DUSP16 Prostate*  (Kibel et al., 2004) 
DUSP26 Glioma
↓
 thyroid (Yu et al., 2007; Tanuma et al., 2009) 
CDKN3 Glioma Breast
↑
, prostate
↑
, 
liver* 
(Lee et al., 2000; Yeh et al., 2000; Yu et 
al., 2007) 
MTMR6  leukaemia
↑
 (Vallat et al., 2003) 
*: deletion or mutation of gene. 
↓
: expression decreased. 
↑
: expression increased. 
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1.4 Aims and objectives 
Cancer metastasis is a complicated and fatal problem. Although there have been an 
increasing number of studies with a focus on cancer metastasis, understanding of the 
essential molecular and cellular mechanisms involved remains poor. Metastasis is a 
multi-stage process involving EMT, angiogenesis, cell invasion/migration, intravasation, 
extravasation and organ colonisation. To accomplish metastasis, many signalling 
pathways are involved as they participate in the regulation of different cell functions. 
Such pathways are the PI3K, ERK, EGF and HGF pathways, etc. kinases and 
phosphatases also play crucial roles in the regulation of these pathways.  
 
The PTPs family is a group of these key regulators which can dephosphorylate the 
target molecules and inactivate certain critical pathways involved in cancer progression. 
PTPRK is one member of this family and has been indicated as a possible tumour 
suppressor in primary central nervous system lymphomas and colorectal cancer. Recent 
studies have shown that PTPRK participates in both TGF-β and EGFR pathways in the 
regulation of cell growth. Furthermore, PTPRK also performs homophilic interaction to 
promote cell aggregation and cell-cell adhesion. PTPRM belongs to the same subfamily 
with PTPRK and has been indicated regulation of cell migration via PLCγ in glioma. 
The implication of PTPRK and PTPRM in prostate and breast cancer remains unknown. 
 
Therefore, this study determined to characterise the role played by PTPRK and PTPRM 
in the development and disease progression of prostate and breast cancer. 
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The aims of this study were: 
1. To screen and identify the expression profile of PTPRK and its associated 
down-stream molecules in different prostate cancer cell lines. 
2. To construct hammer-head ribozymze targeting human PTPRK and to establish 
PTPRK knockdown cell lines for examining the influence of PTPRK on the biological 
functions of cancer cells. 
3. To understand how PTPRK regulates apoptosis in prostate cancer, such as the 
expression of the apoptosis relevant genes in the PTPRK knockdown cells and to 
elucidate the potential pathways involved in the effect by PTPRK using small 
inhibitors. 
4. To screen and identify the expression profile of PTPRK and PTPRM in breast cancer 
cell lines and breast cancer tissues and carry out a clinical cohort study.  
5. To establish PTPRK or PTPRM knockdown in breast cancer cells and to investigate 
the in vitro cell functions and possible downstream signalling pathway of cancer 
metastasis involved in the effect by PTPRK or PTPRM knockdown in breast cancer. 
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Chapter 2 
 
Methodology 
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2.1 Materials 
2.1.1 Cell lines  
The current study used seven prostatic cell lines, two breast cancer cell lines and one 
fibroblast cell line. PC-3, MRC5, MDA-MB-231 and MCF-7 were acquired from the 
European Collection of Animal Cell Culture (ECACC, Salisbury, UK). DU-145, 
CA-HPV-10, LNCaP, PZ-HPV-7, BT474 and BT482 were all obtained from the 
American Type Culture Collection (ATCC, Rockville, Maryland, USA) and PNT-1A 
and PNT-2C2 were generously given by Professor Norman Maitland (University of 
York, England, UK). Full details of these cell lines are supplied in Table 2.1. Cells were 
maintained in DMEM-F12 Media supplemented with 10% foetal bovine serum (FBS) 
and 1X antibiotics.  
 
2.1.2 Collection of human prostate and breast cancer tissues 
Fresh tissue samples were collected immediately after surgery and stored at -80°C until 
use, with approval of the Bro Taf Health Authority local research ethics committee. All 
patients were informed and participated with written consent. All the specimens were 
verified by a consultant pathologist. Breast cohort study please refers to section 2.9. 
 
2.1.3 Primers 
All the primers used in the current study were designed with the use of the Beacon 
Design Programme (Biosoft International, Palo Alto, California, USA) and were 
synthesised by either by Invitrogen (Paisley, UK) or Sigma (Poole, Dorset, UK). Details 
of the primers used for PCR and qPCR are provided in Table 2.2. Details of the primers 
used for generating hammerhead ribozymes are found in Table 2.3.  
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Cell line Origin Cell 
morphology 
Tissue type Metastatic site Hormone seceptors 
PC-3 62 year old 
Caucasian male 
Epithelial Adenocarcinoma (highly tumourigenic) Bone Androgen receptor negative 
DU-145 69 year old 
Caucasian male 
Epithelial Carcinoma Brain Androgen receptor negative 
LNCaP 50 year old 
Caucasian male 
Epithelial Carcinoma Left supraclavicular lymph node Androgen and Estrogen receptor positive 
 
CA-HPV-10 63 year old 
Caucasian male 
Epithelial Non-tumourigenic cell line 
derived from prostatic 
adenocarcinoma, transformed 
HPV18 transfection 
 Androgen receptor negative 
PZ-HPV-7 70 year old 
Caucasian male 
Epithelial Non-tumourigenic epithelial cell line 
transformed through HPV18 transfection 
  
PNT-1A 35 year old 
Caucasian male 
Epithelial Normal prostatic epithelial cell line, 
transfected and immortalised with SV40 
DNA with a defective replication origin. 
 Androgen receptor positive 
PNT-2C2 33 year old 
Caucasian male 
Epithelial Normal prostatic epithelial cell line, 
immortalised with SV40 
DNA 
 Androgen receptor negative 
MRC-5 14 weeks gestation 
Caucasian male 
Fibroblast Normal lung fibroblast cell line   
MDA-MB-231 51 year old 
Caucasian female 
Epithelial Adenocarcinoma (tumourigenic) pleural effusion Extrogen receptor negative 
MDA-MB-436 43 year old 
Caucasian female 
Epithelial Adenocarcinoma (non-tumourigenic) pleural effusion Extrogen receptor negative 
MCF-7 69 year old 
Caucasian female 
Epithelial Adenocarcinoma pleural effusion Extrogen receptor positive 
BT474 60 year old 
Caucasian female 
Epithelial ductal carcinoma (tumourigenic)  Extrogen receptor positive 
BT482 23 year old 
Caucasian female 
Epithelial ductal carcinoma (tumourigenic)  Extrogen receptor positive 
Table 2.1 Details of cell lines used in this study. 
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Table 2.2 Primers for conventional RT-PCR and Q-PCR (Primers were designed 
using Beacon Design programme (Palo Alto, California, USA) and were synthesised by 
Invitrogen (Paisley, UK) and Sigma (Poole, Dorset, UK)). 
Gene Primer name Primer sequence (5’-3’) Product 
size (bp) 
GAPDH GAPDHF8 GGCTGCTTTTAACTCTGGTA 475 
GAPDHR8 GACTGTGGTCATGAGTCCTT 
GAPDH GAPDHF2 CTGAGTACGTCGTGGAGTC 93 
GAPDHZR2 ACTGAACCTGACCGTACACAGAGATGATGACCCTTTTG 
PTPRK PTPRKF11 AATTACAATTGATGGGGAGA 427 
PTPRKR11 CCACTTTTCCACCTGAAGTA 
PTPRK PTPRKF11 AATTACAATTGATGGGGAGA 90 
PTPRKZR11 ACTGAACCTGACCGTACATATTGTGTGACGATGAAAGC 
PTPRM PTPRMF8 TGCAGGAAACCATCTATGA 500 
PTPRMR8 CTCTGTTTGCACCATGTTC 
PTPRM PTPRMF1 CCTTCTCCCCTATAAAAGCTA 87 
PTPRMZR1 ACTGAACCTGACCGTACAGCCACTTGGACACAGTCTAT 
c-Myc Myc1F TGCTCCATGAGGAGACAC 450 
 Myc1R TTTCATTGTTTTCCAACTCC 
c-Myc Myc1F TGCTCCATGAGGAGACAC 128 
 MycZR ACTGAACCTGACCGTACATGATCCAGACTCTGACCTTT 
ID1 ID1F1 TCAACGGCGAGATCAG 57 
 ID1ZR ACTGAACCTGACCGTACAGATCGTCCGCAGGAA 
p53 p53F2 ATCCTCACCATCATCACACT 85 
 p53ZR ACTGAACCTGACCGTACACAGGACAGGCACAAACAC 
Caspase-3 Cas3F1 GGCGTGTCATAAAATACCAG 115 
 Cas3ZR1 ACTGAACCTGACCGTACAACAAAGCGACTGGATGAA 
Caspase-8 Cas8F1 AGAAAGGAGGAGATGGAAAG 113 
 Cas8ZR1 ACTGAACCTGACCGTACAGACCTCAATTCTGATCTGCT 
Caspase-9 Cas9F1 AAGCCCAAGCTCTTTTTC 102 
 Cas9ZR1 ACTGAACCTGACCGTACAGTTACTGCCAGGGGACTC 
MMP9 MMP9F1 AACTACGACCGGGACAAG 357 
MMP9R1 ATTCACGTCGTCCTTATGC 
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MMP9 MMP9F1 AACTACGACCGGGACAAG 106 
MMP9ZR1 ACTGAACCTGACCGTACAGGAAAGTGAAGGGGAAGA 
 
Table 2.3 Primers used for ribozyme synthesis. 
Gene Primer 
name 
Primer sequence (5’-3’) 
PTPRK 
ribozyme-2 
PTPRKrib2F CTGCAGGATGATAGGACCATCGCCAATCTGATGAGTCCGTGAGGA 
PTPRKrib2R ACTAGTGATCCAACTAAATGCCAACTCGATTTCGTCCTCACGGACT 
PTPRK 
ribozyme-3 
PTPRKrib3F CTGCAGTTTGCTCTTTTTTACAATTAATATCTGATGAGTCCGTGAGGA 
PTPRKrib3R ACTAGTTCATCCTCCTTCTCCTAGTTGTTTCGTCCTCACGGACT 
PTPRM 
ribozyme 
PTPRMribF CTGCAGCCTGTCTCCTGCCACGGTCCTGCCCTGATGAGTCCGTGAGGA 
PTPRMribR ACTAGTGCTACCTTCCAGTGCAGTGCCATTTCGTCCTCACGGACT 
pEF/His 
TOPO TA 
plasmid 
vector 
T7F  TAATACGACTCACTATAGGG 
BGHR TAGAAGGCAGTCGAGG 
Ribozyme 
clone 
verification 
RbBMR TTCGTCCTCACGGACTCATCAG 
RbTPF CTGATGAGTCCGTGAGGACGAA 
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2.1.4 Antibodies 
2.1.4.1 Primary antibodies 
Full details of primary antibodies used in this study are provided in Table 2.4. 
2.1.4.2 Secondary antibodies 
The secondary antibodies used for Western blotting were horseradish peroxidise (HRP) 
conjugated anti-goat IgG, goat anti-rabbit IgG, and rabbit anti-mouse IgG antibodies, all 
supplied by Sigma (Poole, Dorset, UK). Those used for immunofluorescent studies are 
goat anti-rabbit IgG TRITC conjugated secondary antibodies, and FITC conjugated goat 
anti-rabbit IgG FITC conjugated secondary antibodies, which are all supplied by Sigma 
(Poole, Dorset, UK). 
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Table 2.4 Primary and secondary antibodies used in this study. 
Antibody name Molecular weight 
(kDa) 
Supplier Product code 
Mouse anti-GAPDH 37 SANTA CRUZ 
BIOTECHNOLOGY 
SC-47724 
Rabbit anti-PTPRK 162 SANTA CRUZ 
BIOTECHNOLOGY 
SC-28906 
Mouse anti-p38 38 SANTA CRUZ 
BIOTECHNOLOGY 
SC-7972 
Rabbit anti-JNK 46 SANTA CRUZ 
BIOTECHNOLOGY 
SC-571 
Rabbit anti-ERK1/2 42/44 SANTA CRUZ 
BIOTECHNOLOGY 
SC-93 
Mouse anti-c-Myc 48 SANTA CRUZ 
BIOTECHNOLOGY 
SC-70465 
Rabbit anti-ID1 15 SANTA CRUZ 
BIOTECHNOLOGY 
SC-734 
Rabbit anti-Caspase-3 32 SANTA CRUZ 
BIOTECHNOLOGY 
SC-7148 
Mouse anti-Caspase-8 57 SANTA CRUZ 
BIOTECHNOLOGY 
SC-70501 
Mouse anti-Caspase-9 46 SANTA CRUZ 
BIOTECHNOLOGY 
SC-17784 
Mouse 
anti-Phosphotyrosine 
Dependent 
on protein 
SANTA CRUZ 
BIOTECHNOLOGY 
SC-508 
Mouse anti-Phosphoserine Dependent 
on protein 
Sigma-Aldrich P-5747 
Mouse 
anti-Phosphothreonine 
Dependent 
on protein 
Sigma-Aldrich P-6623 
Rabbit anti-mouse 
IgG peroxidise conjugate 
 Sigma-Aldrich A-9044 
Goat anti-rabbit 
IgG peroxidise conjugate 
 Sigma-Aldrich A-9169 
Rabbit anti-goat 
IgG peroxidise conjugate 
 Sigma-Aldrich A-5420 
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2.2 Standard reagents and solutions 
2.2.1 Solutions for use in cell culture 
0.05M EDTA 
1g KCl (Fisons Scientific Equipment, Loughborough, UK), 5.72g Na2HPO4 (BDH 
Chemical Ltd., Poole, England, UK), 1g KH2PO4 (BDH Chemical Ltd., Poole, 
England, UK), 40g NaCl (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) and 1.4g 
EDTA (Duchefa Biochemie, Haarlem, The Netherlands) were dissolved in 5L distilled 
water, adjusted to pH of 7.4, autoclaved, and stored until further use. 
 
Trypsin (25mg/ml) 
500mg trypsin was dissolved in 0.05M EDTA and then filtered through a 0.2μm 
minisart filter (Sartorius, Epsom, UK). This solution was aliquoted and stored at -20⁰C 
until further use. When trypsin was required for cell culture work, 250μl of the trypsin 
stock was diluted in 10ml 0.05M EDTA and used to detach the cells. 
 
Balanced Saline Solution (BSS) 
79.5g NaCl, 2.1g KH2PO4, 2.2g KCl and 1.1g of Na2HPO4 were dissolved in 10L of 
distilled water, and the pH adjusted to 7.2, using NaOH (Sigma-Aldrich, Inc., Poole, 
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Dorset, England, UK). 
 
100X Antibiotics 
5g streptomycin, 3.3g penicillin and 12.5mg amphotericin B in DMSO, were dissolved 
in 0.5L of BSS and filtered. 5ml of the antibiotics was then added to a 500ml bottle of 
DMEM media. 
 
2.2.2 Solutions for use in molecular biology 
Tris-Boric-Acid-EDTA (TBE) 
TBE solution (5X) (1.1M Tris; 900mM Borate; 25mM EDTA; pH 8.3) was made by 
dissolving 540g Tris-HCl (Melford Laboratories Ltd, Suffolk, UK), 275g Boric acid 
(Melford Laboratories Ltd, Suffolk, UK) and 46.5g of EDTA in 10L of distilled water. 
The pH was adjusted to 8.3 using NaOH and then stored at room temperature. It was 
diluted in distilled water to 1X TBE for preparing agarose gel and DNA electrophoresis. 
 
DEPC water 
250ml Diethyl Pyroncarbonate (DEPC) (Sigma-Aldrich, Inc., Poole, Dorset, England, 
UK) was added to 4.75ml of distilled water and then autoclaved . 
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Loading buffer (used for DNA electrophoresis) 
25mg of bromophenol blue (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) and 4g 
sucrose (Fisons Scientific Equipment, Loughborough, UK) were dissolved in 10ml of 
distilled water and stored at 4
o
C. 
 
Ethidium Bromide 
The stock solution of 10mg/ml ethidium bromide was prepared by dissolving 200mg of 
ethidium bromide powder (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) in 20ml 
distilled water. In order to protect the solution from sunlight, it was stored in a tube 
covered with aluminium foil. 
 
2.2.3 Solutions for gene cloning 
LB agar 
LB agar was prepared by dissolving 10g tryptone (Duchefa Biochemie, Haarlem, 
Netherlands), 5g yeast extract (Duchefa Biochemie, Haarlem, Netherlands), 15g agar, 
and 10g NaCl, in 1L of distilled water then adjusting the pH to 7.0 and autoclaving the 
solution. The solution was melted antibiotics added and solution poured into 10cm
2
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Petri dishes (Bibby Sterilin LTd., Staffs, UK). These dishes were left to cool and harden 
before use. 
 
LB broth 
10g tryptone, 10g NaCl and 5g yeast extract were dissolved in 1L of distilled water. The 
pH of the solution was adjusted to 7.0 and then autoclaved. After cooling down, 
antibiotics were added and the solution stored at 4
o
C until use. 
 
2.2.4 Solutions for Western blot 
Lysis Buffer 
This was made up by dissolving NaCl 150mM (8.76g), Tris 50mM (6.05g), Sodium 
azide 0.02% (200mg), Sodium deoxycholate 0.5% (5g), Triton X-100 1.5% (15ml), 
Aprotinin 1µg/ml (1mg), Na3VO4 5mM (919.5mg), Leupeptin 1µg/ml (1mg) in 1 litre 
of distilled water. The solution was then stored at 4
o
C for further use. 
 
10% Ammonium Persulphate (APS) 
1g APS was dissolved in 10ml distilled water and then stored at 4
 o
C for further use. 
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Tris Buffered Saline (TBS) 
10X TBS (0.5M Tris, 1.38 M NaCl, pH 7.4) stock solution was prepared by dissolving 
606g of Tris and 765g of NaCl (Melford Laboratories Ltd., Suffolk, UK) in 10L 
distilled water. The pH was adjusted to 7.4 using HCl and stored at room temperature. 
 
10X Running buffer (for SDS-PAGE) 
10X running buffer (0.25M Tris, 1.92M glycine, 1% SDS, pH8.3) was prepared by 
dissolving 303g of Tris, 1.44kg of Glycine (Melford Laboratories Ltd., Suffolk, UK) 
and 100g SDS (Melford LaboratoriesLtd., Suffolk, UK) in 10L distilled water. It was 
diluted to 1X running buffer with distilled water before use. 
 
Transfer buffer 
15.5g Tris and 72g glycine were dissolved in 4L distilled water. 1L of methanol (Fisher 
Scientific, Leicestershire, UK) was added to make a final volume of 5L. 
 
Ponceau S stain 
Supplied by Sigma. 
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2.2.5 Solutions for use in immunocytochemical staining 
Diaminobenzidine (DAB) chromagen 
2 drops (approximately 50µl) of wash buffer, 4 drops of DAB (Vector Laboratories, Inc., 
Burlingame, USA) and 2 drops of H2O2 were added to 5ml of distilled water and mixed 
well before use. 
 
ABC Complex 
The ABC complex is prepared by using a kit provided by Vector Laboratories Inc. 4 
drops of each reagent A and B were added to 20ml of wash buffer before being mixed 
thoroughly and left at room temperature for 30 minutes before use. 
 
2.2.6 Solutions for use in galetine zymography 
Wash buffer 
This was made up by 2.5% Triton X-100 and 0.02% NaN3 
 
Incubation buffer 
This was made up by 50mM Tris-HCl, 5mM CaCl2 and 0.02% NaN3. The pH was 
adjusted to 8.0 and stored at room temperature. 
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Destain buffer 
This was made up by 100ml Acetic acid and 250ml Ethanol in 1 litre of distilled water. 
 
2.3 Cell culture, maintenance, and storage 
2.3.1 Preparation of growth media and cell maintenance 
• Dulbecco’s Modified Eagle’s medium (DMEM/ Ham’s F-12 with L-Glutamine; 
Sigma-Aldrich, Inc., Poole, Dorset, England, UK), pH 7.3 containing 2mM 
L-glutamine and 4.5mM NaHCO3, supplemented with 10% heat inactivated Foetal 
Bovine Serum (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) and antibiotics, 
was used to routinely culture the cells. 
• Cell lines transfected with the pEF6/His plasmid or constructed plasmid vectors 
were subjected to a selection of 2 weeks using 5μg/ml blasticidin (Melford 
laboratories ltd, Suffolk, UK), the resultant transfectants were then cultured in 
medium supplemented with 0.5μg/ml blasticidin for maintaining purpose. The 
transfectants were then verified and used for subsequent studies. 
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• All the cell lines were cultured in 25cm2 and 75cm2 culture flasks (Greiner Bio-One 
Ltd, Gloucestershire, UK) with a loosed cap in incubator at 37
o
C, 95% 
humidification, and 5% CO2. 
• Cell confluency was visually measured with a light microscope and estimating the 
percentage of cells covering the surface of the tissue culture flasks. If needed for 
experimental work, the cells were left to grow until they reached sub-confluency 
(2-3 days). All handling of cells was carried out using a Class II Laminar Flow 
Cabinet with autoclaved and sterile equipment (manufactor). Cells were routinely 
sub-cultured when they had reached a confluency of 80-90% as explained in section 
2.3.2. 
 
2.3.2 Trypsinisation (detachment) of adherent cells and cell counting 
Once the cells had reached a confluency of approximately 80-90%, the medium was 
aspirated then briefly rinsed with sterile EDTA BSS buffer in order to remove any 
remaining serum which has an inhibitory effect on the action of trypsin. 
• Adherent cells were then detached from the tissue culture flask using 1-2ml of 
Trypsin/ EDTA (0.01% trypsin and 0.05% EDTA in BSS buffer) and incubating the 
cells at 37
o
C for approximately 5 minutes. 
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• Once detached, the cell suspension was then collected into 30ml universal 
containers (Greiner Bio-One Ltd, Gloucestershire, UK) and centrifuged at 1,780rpm 
for 8 minutes in order to collect the cell pellet. 
• The supernatant was removed and the cell pellet resuspended in an appropriate 
amount of medium. Cells were either counted for using in immediate experiments, 
or transferred into fresh tissue culture flasks for re-culturing. 
• Cells were counted with a Neubauer haemocytometer counting chamber 
(Mod-Fuchs Rosenthal, Hawksley, UK) using a light microscope at a magnification 
of 10x10 (Reichert, Austria). A haemocytometer allows for the calculation of the 
number of cells in a predetermined volume of fluid in order to obtain the quantity of 
cells per millilitre, and an accurate estimation of cell density for use in in vitro and 
in vivo cell function assays. 
• The haemocytometer chamber is divided into 9 squares with dimensions of 1mm x 
1mm x 0.2mm. For consistency of cell density, three of these 9 squared areas were 
counted. This allowed for determination of cell number by using the following 
equation:  
Cell number/ml= (number of cells in three 9 squares÷ 6) x (1 x 10
4
). 
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2.3.3 Storing cells in liquid nitrogen and cell resuscitation 
Cell stocks of low passage number that needed to be stored were done so in liquid 
nitrogen. 
• Cells were trypsinised as described in section 2.3.2 and resuspended in medium 
with 10% Dimethylsulphoxide (DMSO; Fisons, UK) at a cell density of 
1x10
6
cells/ml. 
• This cell suspension was then divided into 1ml aliquots and transferred into 
pre-labelled 1ml CRYO.S
TM
 tubes (Greiner Bio-One, Germany) and the tubes were 
wrapped in protective tissue paper, stored overnight at -80
o
C, and then transferred to 
liquid nitrogen tanks for long term storage . 
• In order to resuscitate the cells, they were removed from liquid nitrogen and left to 
rapidly thaw before being transferred into a universal container containing 5ml 
pre-warmed medium and incubated for 10 minutes at 37
o
C. 
• This was followed by centrifugation at 1,600 rpm for 5 minutes to remove any 
excess DMSO, before re-suspending the cells in 5ml media. The cell suspension 
was then transferred into a fresh 25cm
2
 tissue culture flask and kept in an incubator. 
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2.4 Methods for RNA detection 
2.4.1 Total RNA isolation 
There are three types of Ribonucleic acid (RNA) in the cytoplasm known as; ribosomal 
RNA (rRNA), transfer RNA (tRNA), and messenger RNA (mRNA). Despite its critical 
role of carrying the genetic information required for specific protein formation, cellular 
mRNA only constitutes 1-2% of the total cellular RNA. It is this type of RNA that is 
normally used in research, and is used in this study. 
• The protocol followed for RNA isolation was using the Tri Reagent kit 
(Sigma-Aldrich, Inc., Poole, Dorset, England, UK). 
• Cells were grown in a monolayer of 85-90% confluency before the medium was 
aspirated and replaced with RNA reagent (1ml per 5-10 x 10
5
 cells), in order to 
induce cell lysis. 
• This homogenate was transferred into a 1.5ml eppendorf, and incubated at 4oC for 5 
minutes. 
• This was followed by the addition of 0.2ml (per 1ml of RNA reagent) chloroform 
(Sigma-Aldrich, Inc., Poole, Dorset, England, UK), 15 seconds of shaking, and 
incubated at 4
o
C for 5 minutes. 
• The resulting homogenate was centrifuged at 12,000rpm for 15 minutes at 4oC 
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(Boeco, Wolf laboratories, York, UK). Under these acidic conditions, the 
homogenate separated into three phases; a lower pink organic phase contains protein, 
an inter phase contains DNA, and an upper aqueous phase contains RNA. 
• The aqueous phase should constitute around 40-50% of the total volume, was  
carefully transferred into a fresh eppendorf, then  an equal volume of isopropanol 
was added (Sigma-Aldrich, Inc., Poole, Dorset, England, UK) and incubated for 10 
minutes at 4
o
C. After centrifuging the samples at 12,000rpm for 10 minutes at 4
o
C, 
the RNA precipitates as a white pellet on the bottom of the eppendorf. 
• The supernatant was discarded, and the RNA pellet washed twice with 75% ethanol 
in DEPC water. Each wash was carried out by adding 1ml 75% ethanol, vortexing 
and centrifuging the samples at 7,500rpm for 5 minutes at 4
o
C. 
• After the final wash, the RNA pellet was briefly dried at 55oC for 5-10 minutes, in a 
Techne, Hybridiser HB-1D drying oven (Wolf laboratories, York, UK), to remove 
any remaining traces of ethanol. 
• The final step was to dissolve the RNA pellet in 50-100μl (dependent on pellet size) 
of DEPC water by vortexing. DEPC is used as it is a histidine specific alkylating 
agent and inhibits the effect of RNAases, which require histidine active sites to 
carry out their function. 
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2.4.2 RNA Quantification 
• Once RNA isolation was completed, the concentration and purity of the resulting 
RNA was measured with the use of a UV1101 Biotech Photometer (WPA, 
Cambridge, UK). This spectrophotometer had been previously set to detect single 
strand RNA (μg/μl) at a dilution of 1:10, measuring the difference of absorbance 
between the RNA sample and DEPC water (blank) at a wavelength of 260nm. 
• By using a ratio of A260nm/A280nm an estimation of the purity of the RNA was 
determined, pure RNA reaching an optical density of 2.0, and RNA contaminated 
with ethanol or protein, reaching optical density values less than 1.5. 
• The samples were measured using Starna glass cuvettes (Optiglass limited, Essex, 
UK). The RNA samples were used immediately for reverse transcription (RT) or 
placed at -80
o
C for long term storage. 
 
2.4.3 Reverse Transcription of RNA for production of cDNA 
Reverse transcription (RT) is a simple and sensitive technique for mRNA analysis and 
acts as an enhanced and more rapid alternative to the more conventional methods of 
RNA examination. 
• In this study, RT is carried out by converting 0.5μg/μl of RNA into complementary 
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DNA (cDNA) using the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
California, USA). The protocol that was carried out is outlined below: 
• Each reaction was set up in thin-walled 200μl PCR tubes (ABgene, Surrey, UK) as 
follows: 
Component  Volume per reaction 
5X iScript Reaction Mix 4μl 
iScript Reverse Transcriptase 1μl 
Nuclease-free water xμl 
RNA template (0.5μg/μl) xμl 
Total Volume: 20μl 
 
• The complete reaction was mixed and then incubated in a T-Cy Thermocycler 
(Creacon Technologies Ltd, The Netherlands) at the following temperatures: 
5 minutes at 25
 o
C 
30 minutes at 42
 o
C 
5 minutes at 85
 o
C 
• Once the process was completed, the cDNA was diluted 1:4 with PCR water, and 
either used immediately as a template for conventional PCR, or stored at -20
o
C for 
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further use. 
 
2.4.4 Polymerase Chain Reaction (PCR) 
The Polymerase Chain Reaction (PCR) was initially devised in 1983 by Karey Mullis 
as a method for detecting and amplifying a specific target sequence of nucleic acids. 
• In this study, a particular gene of interest was amplified by PCR using the 
REDTaq™ ReadyMix PCR Reaction mix (Sigma-Aldrich, Inc., Poole, Dorset, 
England, UK). The reactions were set up in PCR tubes in aliquots of 16μl as 
follows: 
Component Volume 
cDNA template 2μl 
Forward primer (working concentration of 1 μM) 1μl 
Reverse primer (working concentration of 1 μM) 1μl 
2X REDTaq
TM
 ReadyMix 8μl 
PCR H2O 4μl 
 
A negative control containing PCR water instead of the template (cDNA) was run 
alongside the test samples to ensure there was no contamination. 
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• The PCR reactions were then briefly mixed before being placed in a 2720 Thermo 
Cycler (Applied Biosystems) set to the following conditions; 
Initial denaturation: 94
o
C for 5-10 minutes 
Followed by 30-42 cycles of: 
Denaturation: 94
o
C for 40 seconds 
Annealing: gene/primer specific temperature (55
 o
C) for 30-40 seconds 
Extension: 72
o
C for 40 seconds 
And finally: 
Final extension: 72
o
C for 7-10 minutes 
The cycling conditions are dependent on different sets of primers and the size of the 
PCR product. 
• The products were stained with ethidium bromide and visualised using agarose gel 
electrophoresis system (section 2.4.5). In order to demonstrate a representative and 
reliable expression pattern, each RT-PCR was repeated three times. 
 
2.4.5 Agarose gel electrophoresis and DNA visualisation 
Agarose gel electrophoresis is the simplest and the most common method of DNA 
separation and analysis. It works by using an electrical current to separate the amplified 
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DNA according to charge and size. Depending on the product size, the samples were 
either run on a 0.8% agarose gel (used for large DNA fragments 1-10kb) or a 2% gel 
(used for smaller fragments less than 1kb). 
• The agarose gels were prepared by adding the required amount of agarose (Melford 
Chemicals, Suffolk, UK) to 400ml of (1x) TBE solution before being heated to 
completely dissolve the agarose. An appropriate amount of this solution was then 
poured into electrophoresis cassettes (Scie-Plas Ltd., Cambridge, UK) containing 
well forming combs, before the gel was left to set at room temperature for 30-40 
minutes. 
• Once gel set, (1X) TBE buffer was poured over the gel until it reached to a level 
5mm above the gel surface. The comb was removed, and approximately 8μl of 1Kb 
DNA ladder (Cat No. M106R; GenScript USA Inc.), or 8-10μl of each PCR reaction, 
was loaded into the wells by placing the gel loading tip just over the well and 
dispensing the product into it. 
• A power pack (Gibco BRL, Life Technologies Inc.) was then used to run the 
samples electrophoretically through the gel at a constant voltage of around 100V for 
approximately 30-50 minutes until the samples had migrated to as far as required 
for that particular product size. 
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• The DNA was then visualised by the addition of ethidium bromide which acts as a 
DNA intercalator and fluoresces once intercalated, thereby absorbing invisible UV 
light and transmitting the energy into visible orange light. The gel was placed in 
ethidium bromide stain diluted in the (1X) TBE buffer and left for 15 minutes with 
constant agitation to ensure even staining, before being visualised under UV light 
using a VisiDoc-It imaging system (UVP). 
• Images were captured with the use of an UV camera imaging system (UVP), and 
printed with a SONY thermo printer (SONY UK, London, UK) or saved as a TIFF 
file. If insufficient staining was found, the gel was returned to the ethidum bromide 
stain for additional staining or destaining in water to remove any background 
staining if required. 
 
2.4.6 Quantitative RT-PCR (Q-PCR) 
Unlike conventional RT-PCR, which only allows for semi-quantification, Q-PCR is a 
method of detecting extremely small amounts of cDNA template within a sample while 
also determining an accurate and reliable value of the template copy number in each 
sample. This method works due to the use of a sequence specific DNA based 
fluorescent reporter probe which only quantifies the levels of DNA containing the probe 
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sequence, thereby greatly increasing specificity. 
This current study uses the Amplifluor™ Uniprimer™ Universal system (Intergen 
company® , New York, USA) to quantify transcript copy number. The amplifluor probe 
consists of a 3’ region specific to the Z-sequence (ACTGAACCTGACCGTACA) 
present on the target specific primers and a 5’ hairpin structure labelled with a 
fluorophore (FAM). When in this hairpin structure, the fluorophore is linked to an 
acceptor moiety (DABSYL) which acts to quench the fluorescence emitted by the 
fluorophore, preventing any signal from being detected.  
During PCR, the probe becomes incorporated and acts as a template for DNA 
polymerisation in which DNA polymerase uses its 5’-3’ exonuclease activity to degrade 
and unfold the hairpin structure, thereby disrupting the energy transfer between 
fluorophore and quencher, allowing sufficient floorescence to be emitted and hence 
detected. The fluorescent signal emitted during each PCR cycle can then be directly 
correlated to the amount of DNA that has been amplified. This process is illustrated in 
Figure 2.1. 
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• Each reaction to be amplified was set up as follows: 
Component Volume 
Forward primer 0.3μl (10pmol/μl) 
Reverse Z primer 0.3μl (1pmol/μl) 
Amplifluor probe 0.3μl (10pmol/μl) 
2X iQ
TM
 Supermix 5μl 
cDNA and PCR H2O 4μl 
 
• Each sample was then loaded into a 96 well plate (BioRad laboratories, Hemel 
Hampstead, UK), alongside standards (ranging from copy numbers of 10
1
-10
8
), 
covered with optically clear Microseal®  (Biorad laboratories, California, USA) and 
this was placed in an iCyclerIQ thermal cycler and detection software (BioRad 
laboratories, Hemel Hampstead, UK) at the following conditions: 
Initial denaturation: 94
o
C for 5 minutes 
Followed by 80-90 cycles of: 
Denaturation: 94
o
C for 10 seconds 
Annealing: 55
o
C for 35 seconds 
Extension: 72
o
C for 20 seconds 
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• The fluorescent signal is detected at the annealing stage by a camera where its 
geometric increase directly correlates with the exponential increase of product. This 
is then used to determine a threshold cycle (TC) for each reaction and the transcript 
copy number depends on when fluorescence detection reaches a specific threshold. 
• The degree of fluorescence emitted by a range of standards with a known transcript 
copy number is used to compare the amount emitted by each sample, allowing for 
the transcript copy number in each sample to be accurately calculated. 
• Furthermore, the transcript copy number of each sample was normalised against the 
detection of β-actin or GAPDH copy numbers. The procedure was repeated at least 
three times, and representative data are demonstrated as expressional trends. Figure 
2.2 shows how transcript levels are quantified. 
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Figure 2.1 Diagram showing function of the u-probe during DNA amplification 
using Q-PCR. 
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Figure 2.2 (A) Detection of transcript levels from a range of standard samples (10
8
 to 
10
1
 copy number) using the iCyclerIQ thermal cycler. (B) Subsequent generation of a 
standard curve from these samples. 
 
100 
 
2.5 Methods for protein detection 
2.5.1 Protein extraction and preparation of cell lysates 
• Once cells had reached an adequate confluency, the cell monolayer was scraped off 
in BSS using a cell scraper. The cell suspension was then transferred into a universal 
tube. 
• This was followed by centrifugation at 1,800rpm for 8 minutes before the 
supernatant was poured off, and the cell pellet resuspended in 200-300μl (depending 
on total cell number, approximately 100μl/106 cells) of lysis buffer. 
• This was transferred into a 1.5ml eppendorf tube and placed for an hour at room 
temperature on a Labinco rotating wheel (Wolf laboratories, York, UK) to allow for 
cell lysis. 
• The resulting suspension was then centrifuged at 13,000rpm for 15 minutes so any 
unwanted cell debris formed a pellet. The supernatant was transferred to a fresh 
eppendorf tube and the pellet discarded. 
• The protein samples were then either quantified for SDS-PAGE as explained below, 
or stored at -20
o
C until further use. 
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2.5.2 Protein quantification and preparation of samples for SDS-PAGE 
In order to standardise the protein sample concentration for western blotting, the 
amount of protein in each sample was quantified following the protocol outlined in the 
Bio-Rad DC Protein Assay kit (Bio-Rad laboratories, Hemel Hampstead, UK). 
• In a 96 well plate, 50mg/ml of bovine serum albumin (BSA) standard (Sigma, 
Dorset, UK) was serially diluted in lysis buffer to a concentration of 0.78mg/ml and 
used to set up a standard curve of protein concentration. 
• Five microliters of either protein sample or standard was added into well, before 
25μl of ‘working reagent A’ (prepared by adding 20μl of reagent S per millilitre of 
reagent A), followed by 200μl of reagent B to each well. 
• After samples were mixed, the plate was left at room temperature for 30-45 minutes 
to allow the colorimetric reaction to take place. Once this was complete, the 
absorbance of each sample was measured at 620nm using the ELx800 plate reading 
spectrophotometer (Bio-Tek, Wolf laboratories, York, UK). 
• A standard curve and an equation to calculate protein concentration based on 
absorbance were established using the scatter line chart of Excel. Protein 
concentration of each sample was determined using the corresponding absorbance 
and the equation of the standard curve. The samples were then diluted in an 
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appropriate amount of lysis buffer in order to normalise them to the required final 
concentration of 1.0-2.0mg/ml. 
• This was then further diluted with 2X Lamelli sample buffer concentrate 
(Sigma-aldrich, St Louis, USA) in a ratio of 1:1 before the samples were denatured 
by boiling at 100
o
C for 5-10 minutes and either loaded onto a SDS-PAGE gel or 
stored at -20
o
C until further use. 
 
2.5.3 Preparing immunoprecipitates 
Immunoprecipitation (IP) can be used for analysing intracellular phosphorylation that 
occurs in downstream signalling cascades. The process involves adding a specific 
antibody targeting a protein of interest within a cell lysate. This is then mixed with 
sepharose or agarose bonded staphylococcal protein A, protein G, or both, in order to 
collect the resulting protein-antibody complexes. These complexes are then centrifuged 
to precipitate the protein-IgG-proteinA/G beads. After being denatured at 100
 o
C for 10 
minutes, the samples were separated on an SDS-PAGE gel, and evaluated using 
immunoprobing. The process was carried out as follows:  
• Antibody targeted against a protein of interest was added to the cell lysate samples 
before being incubated at 4
o
C for 1 hour on a Labinco rotating wheel. 
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• Following incubation, 20μl of conjugated A/G protein agarose beads (Santa Cruz 
Biotechnology, supplied by Insight Biotechnologies Inc, Surrey, England, UK) were 
added to each sample and placed back on the wheel for another hour to allow for the 
antibody-protein complexes to bind to the beads. 
• Centrifugation at 8,000rpm for 5 minutes then acts as a way of removing any 
unbound protein or excess antibodies present in the supernatant. The protein pellet 
was subsequently washed twice with 300μl of lysis buffer before being resuspended 
in 40-60μl of 1x sample buffer and boiled for 10 minutes. The resulting samples 
were then run on SDS-PAGE gels as explained below. 
 
2.5.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
• The system used to carry out SDS-PAGE in this study was the OmniPAGE VS10 
vertical electrophoresis system. Resolving gels of a required percentage (depending 
on protein size) were prepared in 15ml aliquots (enough for 2 gels) by adding all the 
constituents at the amounts indicated below: 
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Table 2.5 Ingredients for resolving gel. 
Component 8% Resolving gel 
(proteins size over 
100kDa) 
10% Resolving gel 
(proteins size below 
100kDa) 
Distilled water 6.9ml 5.9ml 
30% acrylamide mix 
(Sigma-Aldrich, St 
Louis, USA) 
4.0ml 5.0ml 
1.5M Tris (pH 8.8) 3.8ml 3.8ml 
10% SDS 0.15ml 0.15ml 
10% Ammonium 
persulphate 
0.15ml 0.15ml 
TEMED (Sigma-Aldrich, 
St Louis, USA) 
0.009ml 0.006ml 
 
• The resulting mixture was then poured in between two glass plates held in place by 
a loading cassette, until at a level 1.5cm below the top edge of the plate, to prevent 
gel oxidation the top of the resolving gel was covered with a 0.1% SDS solution. 
• The gels were then left to polymerise at room temperature for approximately 30 
minutes, or until fully set. The excess SDS solution was then poured off before 
adding a sufficient amount of stacking gel in its place, prepared as shown below: 
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Table 2.6 Ingredients for stacking gel. 
Component Stacking gel 
Distilled water 3.4ml 
30% acrylamide mix (Sigma-Aldrich, 
St Louis, USA) 
0.83ml 
1.0M Tris (pH 6.8) 0.63 ml 
10% SDS 0.05ml 
10% Ammonium persulphate 0.05ml 
TEMED (Sigma-Aldrich, St Louis, 
USA) 
0.005ml 
 
• After the addition of the stacking gel, a well forming Teflon comb was inserted 
before allowing the gel to polymerise at room temperature for around 20 minutes. 
• Once set, the loading cassette was transferred into an electrophoresis tank and 
covered with 1X running buffer before the well comb was removed, and by use of a 
50μl syringe (Hamilton),  10μl of Broad range markers were loaded (Santa Cruz 
Biotechnology, supplied by Insight Biotechnologies Inc, Surrey, England, UK), 
followed by 10-15μl of the required protein samples. 
• The gels were then run at 100-120V, 50mA, and 50W for a length of time 
appropriate for the size of the protein of interest, in order to separate the proteins 
according to charge and molecular weight. 
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2.5.5 Western blotting: transferring proteins from gel to nitrocellulose membrane 
• Once SDS-PAGE was completed, the protein samples were transferred onto a 
nitrocellulose membrane by western blotting. The electrophoresis equipment was 
disassembled and the gel pried out from the two glass plates before discarding of the 
stacking gel. The resolving gel was then placed on the bottom graphite base 
electrode in a SD20 SemiDry Maxi System blotting unit (SemiDRY, Wolf 
Laboratories, York, UK) on top of 3 pieces of 1X transfer buffer pre-soaked filter 
paper (Whatman International Ltd., Maidstone, UK), and 1 sheet of Hybond 
nitrocellulose membrane (Amersham Biosciences UK Ltd., Bucks, UK). 
• An additional 3 sheets of pre-soaked filter paper were placed on top of the gel to 
form a sandwich arrangement in an order as from anode to cathode; filter paper- 
membrane- gel- filter paper, as shown in Figure 2.3. Electroblotting was then 
carried out at 15V, 500mA, and 8W for 20-60 minutes (depending on protein size). 
Once the proteins had been sufficiently transferred, the membranes were blocked 
over night at 4
o
C in 10% skimmed dry milk solution (10% milk powder and 0.1% 
polyoxyethylene (20) sorbitan monolaurate (Tween 20) (Sigma-Aldrich, St Louis, 
USA) in TBS. This acts to block the proteins onto the membrane to avoid forming 
non-specific binding of primary antibody. 
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Figure 2.3 Diagram depicting process of western blotting; the transferring of 
proteins onto a nitrocellulose membrane. 
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2.5.6 Protein staining 
2.5.6.1 Staining membranes in Ponceau S 
Ponceau S is a reversible and re-usable protein stain that does not interfere with any 
subsequent immuno-probing. Its main use is to confirm a successful transfer of proteins 
from the polyacrylamide gel onto the nitrocellulose membrane, but can also be used to 
aid in membrane sectioning for multiple immune-probing. The protocol was carried out 
as follows: 
• After the transfer was completed and before probing began, the membrane was 
immersed in Ponceau S solution for a few minutes at room temperature. 
• The solution was then washed off with distilled water until the bands become visible. 
If required, the membrane was then cut into several sections using a sharp and 
sterile scalpel. 
• Once the staining was completely washed off it was placed in 10% milk solution. 
 
2.5.6.2 Coomasie blue staining of polyacrylamide gels 
Coomasie blue is used to stain polyacrylamide gels following SDS-PAGE. This allows 
for visualisation of protein bands if no immuno-probing is required and can be used as a 
way of semi-quantifying the volume of the protein bands. The protocol was carried out 
109 
 
as follows: 
• The gel was immersed in Coomassie blue stain solution for approximately 30 
minutes before being repeatedly washed in destaining solution until the background 
staining disappeared, and the protein appeared as blue bands. The gel was then 
photographed or analysed. 
 
2.5.7 Protein detection using specific immuno-probing 
• Once staining was completed, the membrane was transferred into 50ml falcon tubes 
(Nunc, Fisher-Scientific, Leicestershire, UK) ensuring that the membrane surface 
that had been in contact with the gel was facing upwards. 10% milk blocking 
solution was added to the membranes and incubated for an hour at room 
temperature on a roller mixer (Stuart, Wolf-Laboratories, York, UK). 
• Once this was done, the 10% milk solution was poured off and replaced with 10ml 
of 3% milk solution (3% milk powder, 0.1% Tween 20 in TBS) for 15 minutes. This 
was followed by incubation of the membranes for an hour at room temperature, with 
primary antibody diluted 1:500 in 5mls of 3% milk solution. 
• After the probing with primary antibody, any remaining unbound antibody was then 
washed off twice in 3% milk solution at 15 minute intervals. 
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• The membranes were further incubated with 5ml of 1:1000 HRP conjugated 
secondary antibody diluted in 3% milk for one hour with continuous rotation.  
• This was followed by two 15 minute washes in 10ml of 3% milk solution, and two 
15 minute washes with Tween TBS (0.2% Tween 20 in TBS), in order to wash off 
any unbound secondary antibody. 
• The membrane was then washed twice in TBS before the chemiluminescent 
detection. 
 
2.5.8 Chemiluminescent protein detection 
Chemiluminescent protein detection was carried out using the chemiluminescence 
detection kit (Luminata, Millipore), which consists of a highly sensitive 
chemiluminescent substrate that detects the horseradish peroxidise (HRP) used during 
the western blot procedure. The protocol was carried out as follows: 
• 1ml regent was added on to the membrane and incubated for 5 minutes at room 
temperature with constant agitation. 
• Excessive solution on the membrane was then drained over a piece of tissue paper 
and the membrane was transferred into a plastic tray. The chemiluminescent signal 
was detected using an UVITech Imager (UVITech Inc., Cambridge, UK) which 
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contains both an illuminator and a camera linked to a computer. 
• Each membrane was subjected to varying exposure times until the protein bands 
were sufficiently visible. These images were then captured and further analysed 
with the UVI band software package (UVITEC, Cambridge, UK), which allows for 
protein band quantification. 
• In this study, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a 
loading control and ran alongside any other proteins to be detected, so as to allow 
for additional normalisation of the samples and to compensate for any other 
biological variaions which may have occurred during the process. The GAPDH is 
used due to its highly abundant and conserved nature within eukaryotic cells, and is 
one of the most widely employed and accepted internal controls in determining 
mRNA and protein expression. 
• In order to verify the results, each western blot was carried out three times and the 
protein bands quantified and standardised separately. 
 
2.5.9 Immunohistochemical staining 
This study followed a previously reported immunohistochemical staining procedure.  
• The cryosection was taken from -80oC freezer then the cryosection was laid on 
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bench wrapped in foil and allowed it adapt to room temperature. 
• The foil was removed and slides were labled in pencil with the appropriate 
information. 
• Slides were fixed in acetone for 15 minutes followed by three 5 minutes washes 
with 1X TBS. 
• After the fixing and washing, the slide was blocked with a blocking solution 
containing horse serum (Vector Laboratories Inc., Burlingame, USA) for 30 minutes 
at room temperature. To make a blocking solution, 1-2 drops of horse serum were 
added into 5ml of 1x OptiMax Wash Buffer (BioGenex, San Ramon, USA). 
• After blocking, the cells were washed three times with wash buffer before being 
incubated for an hour at room temperature with primary antibody (1:100, the 
dilution may vary depending on a specific antibody used) diluted in blocking 
solution. 
• Any unbound antibody was subsequently washed off with wash buffer. This was 
repeated three times before incubating the cells for a further 30 minutes at room 
temperature, with the corresponding secondary antibody diluted 1:1000 in blocking 
solution. 
After three washes with wash buffer, the cells were incubated with 200μl of 
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working VECTASTAIN®  Universal ABC complex (Vector Laboratories Inc., 
Burlingame, USA). The ABC complex was made up 30 minutes before use by 
mixing 4 drops of the supplied reagent A, with 4 drops of reagent B. 
• The ABC solution was subsequently removed by washing three times with wash 
buffer before a few drops of DAB chromogen (Vector Laboratories Inc., Burlingame, 
USA) were added to the cells and left to incubate for 5 minutes in darkness. DAB 
was made up as follows; 2 drops of the provided buffer (pH 7.5), 4 drops of DAB, 
and 2 drops of hydrogen peroxide diluted in 5ml of distilled water. 
• Following DAB addition, the solution should turn brown and once this had occurred, 
the DAB was washed off using distilled water before the cells were counterstained 
with Mayer’s haemotoxylin for approximately 5 minute. 
• After three washes with distilled water, slides need to be dehydrated for 5 minutes 
in each condition including 50% ethanol, 70% ethanol, 90% ethanol, 100% ethanol, 
50% ethanol/ 50% xylene, 100% xylene. 
• After dehydration, slides were mounted with DPX and leaved to dry. 
 
2.5.10 Immunochemical staining 
This study followed a previously reported immunohistochemical staining procedure 
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(Jiang et al.2005).  
• 20,000 cells in 200μl DMEM medium were seeded into each well of a chamber 
slide (Nalge, NUNC International, LAB-TEK® , USA) and incubated overnight at 
37
 o
C with 5% CO2. 
• The cells were then fixed in ice-cold pure ethanol for 30 minutes at 4 oC, before 
being rehydrated with BSS for 30 minutes at room temperature. 
• This was followed by cell permeabilisation in 0.1% TritonX100 in TBS for 5-10 
minutes at room temperature.  
• Following the permeabilisation, the slide was blocked with a blocking solution 
containing horse serum (Vector Laboratories Inc., Burlingame, USA) for 30 minutes 
at room temperature. To make a blocking solution, 1-2 drops of horse serum were 
added into 5ml of 1× OptiMax Wash Buffer (BioGenex, San Ramon, USA). 
• After blocking, the cells were washed three times with wash buffer before being 
incubated for an hour at room temperature with primary antibody (1:100, the 
dilution may vary depending on a specific antibody used) diluted in blocking 
solution. 
• Any unbound antibody was subsequently washed off with wash buffer. This was 
repeated three times before incubating the cells for a further 30 minutes at room 
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temperature, with the corresponding secondary antibody diluted 1:1000 in blocking 
solution. 
• After three washes with wash buffer, the cells were incubated with 200μl of 
working VECTASTAIN®  Universal ABC complex (Vector Laboratories Inc., 
Burlingame, 
USA). The ABC complex was made up 30 minutes before use by mixing 4 drops of 
the supplied reagent A, with 4 drops of reagent B. 
• The ABC solution was subsequently removed by washing three times with wash 
buffer before a few drops of DAB chromogen (Vector Laboratories Inc., Burlingame, 
USA) were added to the cells and left to incubate for 5 minutes in darkness. DAB 
was made up as follows; 2 drops of the provided buffer (pH 7.5), 4 drops of DAB, 
and 2 drops of hydrogen peroxide diluted in 5ml of distilled water. 
• Following DAB addition, the solution should turn brown and once this had occurred, 
the DAB was washed off using distilled water before the cells were counterstained 
with Mayer’s haemotoxylin for approximately 1 minute. 
 
2.5.11 Gelatine zymography 
• Cells were counted and 1x106 seeded in a tissue culture flask and incubated 
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overnight. 
• Following incubation, samples were washed once with 1x BSS followed by a wash 
with serum-free DMEM and then either incubated in serum-free DMEM control or 
treated medium for 4 hours. 
• After 4 hours the conditioned medium was collected and samples were prepared in 
non-reducing sample buffer. 
• Protein samples were separated using SDS-PAGE on gels containing 1% gelatine 
(Sigma-Aldrich Inc, USA). 
• After SDS-PAGE, gels were renatured for 1 hour at room temperature in washing 
buffer then incubated at 37
o
C in incubation buffer for 36 hours. 
• Following incubation, the gels were stained with coomassie blue for 1 hour and 
washed in destain buffer for another 1 hour. The brightness of clear bands where 
MMP2 and MMP9 were located and gelatine was degraded. 
 
2.6 Alteration of gene expression 
2.6.1 Knocking down gene expression using Ribozyme Transgenes 
In order to knockdown the expression of PTPRK, hammerhead ribozyme transgenes 
which specifically target and cleave the PTPRK mRNA transcript are employed. The 
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hammerhead ribozyme was first described by Forster and Symons in 1987 as a 
self-cleaving region in the RNA genome of various plant viroids and virusoids. The 
hammerhead motif was subsequently integrated into short synthetic oligonucleotides, 
transforming it into a turnover catalyst capable of cleaving various RNA targets 
(Uhlenbeck, 1987; Haseloff and Gerlach, 1988). 
 
Hammerhead motifs contain a conserved secondary structure that consists of three 
helical stems (I, II, and III) enclosing a junction known as the catalytic core, typified by 
various invariant nucleotides. The best codons demonstrated to be suitable for cleavage 
are AUC, GUC and UUC (Figure 2.4). In order to generate a ribozyme transgene 
specific to PTPRK, primers were designed using Zuker’s RNA mFold programme 
(Zuker, 2003) according to the secondary structure of the gene (Figure 2.5). 
Subsequently, an appropriate GUC ribozyme target site was chosen according to the 
secondary structure of PTPRK mRNA and the ribozyme created to specifically bind the 
sequence adjacent to this GUC codon (Figure 2.4). This made it possible for the 
hammerhead catalytic region of the ribozyme to bind to and specifically cleave the 
GUC sequence within the target mRNA transcript. 
Following ribozyme design, the sequences were ordered from invitrogen as 
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sense/antisense strands (as shown in Table 2.4) and the transgenes were then 
synthesised using touchdown PCR of the following conditions: 
Initial denaturation: 94
 o
C for 5 minutes 
Followed by 8 cycles of each annealing temperature (total of 48 cycles): 
Denaturation: 94
 o
C for 10 seconds 
Various annealing steps: 70
o
C for 15 seconds, 65
o
C for 15 seconds, 
60
o
C for 15 seconds, 57
o
C for 15 seconds, 54
o
C for 15 seconds and 50
o
C for 15 
seconds. 
Extension: 72
o
C for 20 seconds 
Final extension: 72
o
C for 7 minutes 
• Subsequently, the transgenes were run on a 2% agarose gel in order to verify their 
presence as well as size before being cloned into the pEF6/His plasmid as described 
in section 2.7. 
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Figure 2.4 Secondary structure of hammerhead ribozyme with bound substrate. 
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Figure 2.5a The predicted secondary structure of human PTPRK mRNA. dG: free 
energy; which is the default parameters that are used by the mfold programme. 
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Figure 2.5b The predicted secondary structure of human PTPRM mRNA. dG: free 
energy; which is the default parameters that are used by the mfold programme. 
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2.7 TOPO TA gene cloning and generation of stable transfectants 
The TOPO TA expression system provides a highly efficient and simple one step 
cloning approach without the requirement of ligases, specific PCR primers, or any post 
PCR procedures. The process involves the direct insertion of Taq polymerase amplified 
PCR products into a plasmid vector suited for high level and constitutive expression in 
mammalian host cell lines, following transfection. 
 
The current study uses the pEF6/V5-His-TOPO plasmid vector (Invitrogen Inc., Paisley, 
UK) which is provided linearised with a single 3’ Thymidine (T) overhang for TA 
cloning, and a covalently bound Topoisomerase (Figure 2.6). Due to its template 
independent terminal transferase activity, Taq polymerase catalyses the addition of a 
single deoxyadenosine (A) to the ends of PCR products this allows for efficient ligation 
of the PCR product into the plasmid vector due its 3’ T overhang mentioned above  
(the process of cloning is summarised in Figure 2.7).    
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Figure 2.6 Schematic of the pEF6 plasmid (taken from pEF6/V5-His TOPO TA 
Expression Kit protocol). 
 
2.7.1 TOPO cloning reaction 
• The following reagents were placed in a pre-labelled eppendorf tube and mixed 
gently before being incubated for 5 minutes at room temperature. 
4µl of PCR product 
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1µl salt solution 
1µl TOPO vector 
 
2.7.2 Transformation of chemically competent E. coli 
• A 5μl cloning reaction was set up (section 2.7.1) and was mixed in a vial with 
chemically competent One Shot™ TOP10 E.Coli (Invitrogen Inc., Paisley, UK) 
before being incubated on ice for 30 minutes. 
• This was followed by a heat-shock at 42oC for 30 seconds in a water bath, and 
immediate incubation back onto ice for 2 minutes. 
• SOC medium (250μl warmed to room temperature) was then added to the cell 
suspension and left to shake horizontally at 200rpm on an orbital shaker (Bibby 
Stuart Scientific, UK) at 37
o
C for an hour. 
• Following this incubation period, the E.coli mixture was spread onto pre-warmed 
selective LB-agar plates (with 100μg/ml ampicillin) at high and low seeding 
densities, before being incubated at 37
 o
C over night. 
• As the pEF plasmid has antibiotic resistance genes to both ampicillin and blasticidin, 
only the cells that contain the plasmid are capable of growing on the agar. This is a 
way of selecting only the colonies positive for the plasmid containing a gene of 
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interest. However, to confirm that the gene sequence has been inserted in the correct 
orientation, the colonies need to be further tested (explaining in section 2.7.3). 
 
2.7.3 Colony selection and analysis 
• In order to confirm that a right product will be produced, the colonies were analysed 
to verify that the gene sequence had been ligated into the vector in the correct 
orientation. 
• Two PCR reactions were performed to analyse each of 10 isolated colonies. The 
first reaction used a reverse primer specific for the plasmid vector (BGHR) and a 
forward primer specific for the insert (RbTPF). BGHR primer ends around 173bp 
downstream of the inserting site and so if the insert has been ligated in the correct 
orientation, the resulting product should be around 50bp bigger than the predicted 
product size. The second reaction contains a forward primer specific for the plasmid 
vector (T7F) and a forward primer specific for the insert (RbTPF). If a product was 
seen in the second reaction, it indicated the insert was ligated in the wrong 
orientation. If a band is seen for both reactions then the colonies contain a mixture 
of plasmids with both correctly and incorrectly inserted sequences. Finally, in order 
to verify that the full sequence has been inserted without degradation, a further 
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reaction with T7F and BGHR is carried out on the colonies. 
• Individual colonies were examined by lightly touching a labelled colony with a 
pipette tip, and mixing it into each PCR reaction before specific amplification of the 
desired sequence. The thermal cycler was set to the following conditions: 
Initial denaturation: 94
 o
C for 10 minutes 
Followed by 35 cycles of: 
Denaturation: 94
 o
C for 30 seconds 
Annealing: 56
 o
C for 40 seconds 
Extension: 72
 o
C for 1.5 minutes 
And finally: 
Final extension: 72
o
C for 7 minutes 
 
2.7.4 Plasmid purification and amplification 
• Following colony analysis, the ones deemed to have the insert in the correct 
orientation were picked from the plate and inoculated in 10ml of LB broth with 
100μg/ml ampicillin and then being incubated at 37oC over night with constant 
agitation. 
• The amplified E.coli were then pelleted by centrifugation at 4oC for 15 minutes at 
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6,000rpm, and then used for plasmid extraction. This was carried out using the 
Sigma GenElute Plasmid MiniPrep Kit (Sigma-Aldrich, USA) according to the 
provided protocol, outlined below. 
• The bacterial pellet was resuspended in 200μl of resuspension fluid (containing 
RNase A) before being mixed thoroughly and transferred into the provided 2ml 
collection tubes. 
• This was followed by the addition of 200μl lysis solution and gentle mixing by 
inverting the tubes 5-6 times. The resulting mixture was left at room temperature for 
5 minutes before adding 350μl of neutralisation solution. 
• The tubes were inverted several times, and centrifuged at 12,000rpm for 10 minutes. 
The resulting supernatant was then transferred into a fresh collection tube 
containing a Mini Spin Column, which binds the plasmid DNA after centrifugation 
at 12,000rpm for 1 minute. 
• The flow through was discarded before the column was washed with 700μl of wash 
solution (containing ethanol) and centrifuging at 12,000rpm for 1 minute. The flow 
through was discarded once more, before the column was dried by another 
centrifugation of one minute. 
• The column was then transferred into a fresh collection tube for elution. This was 
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carried out by adding 100μl of elution solution and centrifuging at 12,000rpm for 1 
minute. The resulting flow through containing the purified plasmid was collected, 
and around 4μl was run on a 0.8% agarose gel in order to confirm the presence and 
purification of the plasmid. 
 
2.7.5 Transfection of mammalian cells using electroporation 
• Following plasmid extraction, the empty plasmid, and the plasmid containing the 
ribozyme transgene was used to transfect both PC-3 and DU-145 prostate cancer 
cell lines, MDA-MB-231 and MCF-7 breast cancer cell lines, and HECV 
endothelial cell line respectively. 
• The method of transfection used in this study was electroporation using an 
electroporator (Easyjet, Flowgene, Surrey, UK). 
• Once the cells had reached confluency they were detached from their tissue culture 
flasks, counted, and approximately 1x10
6
 cells were resuspended in 1ml of media. 
• 300μl of the cell suspension was then added into an electroporation cuvette 
(Eurgenetech, Southampton, UK), and following the addition of 3-5μl of plasmid, 
left at room temperature for 5 minutes. 
• The cuvette was placed into the electroporator and subjected to an electrical pulse of 
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290-310V before immediately being transferred into a fresh tissue culture flask 
containing media. 
 
2.7.6 Establishment of a stable expression mammalian cell line (Figure 2.7) 
• Following transfection, in order to obtain a stable cell line carrying the constructed 
vector, the cultured cells needed to be selected. 
• As mentioned before, the pEF plasmid contains a resistance gene against blasticidin 
and this is used as a selection of mammalian cell. Therefore, the cells were cultured 
in selection media containing 5μg/ml blasticidin for around 1-2 weeks which only 
allowed the cells containing the plasmid to survive. 
• After selection, the cells were transferred into maintenance media containing 
0.5μg/ml blasticidin. In order to verify the knockdown of the gene of interest, the 
cells were analysed using RT-PCR and western blotting. 
• Once the cells had been verified to stably express the desired molecule; they were 
subjected to various in vitro assays in order to test the effect of altering the 
expression of that molecule on the biological properties of the cells. These assays 
are outlined in section 2.8. 
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Figure 2.7 Flow chart summarising cloning and production of a stable expression 
mammalian cell line. 
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2.8 In vitro cell function assays 
These assays can be used to quantify cell density as they adhere to multi-well plates, 
with or without Matrigel (a basement membrane substitute). After a set amount of time, 
the cells are stained with crystal violet (0.2% mixed with 2% ethanol, and dissolved in 
distilled H2O), which stains DNA. The cells can then either be counted, or the amount 
of crystal violet that the cells have absorbed can be quantified, by solubilising the dye 
and measuring the absorbance at 540nm using a spectrophotometer. 
 
2.8.1 In vitro cell growth assay 
• The protocol by Jiang et al. was followed (Jiang et al., 2005). 200μl of media 
containing 3,000 cells was seeded into four 96 well plates and if required, cells were 
treated with a protein of interest in serum free media. 
• These plates were then left to incubate at 37oC, with 5% CO2, for a period of 24 
hours and 120 hours respectively. 
• After the incubation, the cells were fixed with 4% formalin for 10-20 minutes, 
before being subsequently stained with 0.5% crystal violet for 10 minutes. The dye 
was washed off with water, and the plates left to dry. 
• The dye was then solubilised using 200μl acetic acid, and cell growth was assessed 
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by measuring the absorbance at 540nm using a spectrophotometer (BIO-TEK, 
Elx800, UK). The growth rate was calculated as a percentage, using the absorbance 
taken at 24 hours as a baseline. 
 
2.8.2 In vitro adhesion assay 
• Wells in a 96 well plate were coated with 100μl of serum free media with 5μg (stock 
concentration 0.05μg /μl) Matrigel (BD Matrigel™ Matrix, Magrigel™ Basement 
Membrane Matrix, Biosciences). The Matrigel was then left to dry for 2 hours at 
55
o
C. 
• To rehydrate the Matrigel, 200ul of sterile water was added to each well and left for 
45 minutes at room temperature. 
• The media was aspirated and 20,000 cells diluted in 200μl media, were seeded into 
each well and left to adhere on the Matrigel over a 40-minute culture at 37
o
C, with 
5% CO2. 
• After the incubation, the wells were washed with BSS to remove any non-adherent 
cells. The adherent cells were fixed with 4% formalin for 10-20 minutes, and then 
stained with 0.5% crystal violet for 10 minutes. Following washes, the plates were 
left to dry before counting the adherent cells and taking photos under a microscope. 
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Due to the fluid dynamics within the small sized wells of a 96 well plate, matrigel 
sets unevenly, causing cell aggregation around the edges of the well. Therefore, in 
order to avoid these areas, only the cells which had adhered to the central area of the 
well were counted. 
 
2.8.3 In vitro invasion assay 
• 8μm pore Transwell inserts (FALCON®, pore size 8.0μm, 24 well format, Greiner 
Bio one, Germany) were placed into wells of a 24 well plate (NUNC™, Greiner Bio 
one, Germany), using sterile forceps in order to prevent contamination. 
• Each insert was subsequently coated with 100μl serum free media containing 50μg 
Matrigel, and left to dry for 2 hours at 55
 o
C. 
• The Matrigel was then rehydrated with 100μl sterile water for an hour at room 
temperature. 
• The water was discarded, and 20,000 cells in 200μl media were seeded into each 
insert. 600μl media was then added to the lower chamber of each well (outside the 
inserts) and the cells were incubated for a maximum of 96 hours, with 5% CO2 at 37
 
o
C. This setup is shown in Figure 2.8. 
• After 72 hours incubation, the invasive cells migrate through the Matrigel, and the 
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porous membrane to the other side of the insert. The Matrigel layer and the 
non-invasive cells were then removed from inside the insert using tissue paper. If 
this step is not carried out, the Matrigel would also be stained with crystal violet, 
making it difficult to distinguish between the background and invading cells. 
• The invasive cells were then fixed with 4% formalin for 10-20 minutes, and then 
stained with 0.5% crystal violet for 10 minutes. The crystal violet was washed off, 
the plates left to dry, and the stained cells photographed and counted under a 
microscope. 
 
 
Figure 2.8 Schematic diagram showing in vitro invasion assay. 
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2.8.4 In vitro motility assay 
• The protocol by Jiang et al. was followed (Jiang et al., 1995). 700μl of media 
containing 200,000-300,000 cells are seeded into a 24 well plate and cells were 
treated with a protein of interest in serum free media if required. 
• These plates were then left to incubate at 37oC, with 5% CO2, for a period of 24 
hours to allow cells to form a confluent monolayer then the cells were wounded and 
took photos using a microscope with camera at 0.25, 1, 2, and 3 hours after 
wounding. Migration distances were measured using ImageJ software (National 
Institutes of Health, USA). 
 
2.8.5 Electrical cellular impedance sensing (ECIS) 
• Electrical Cellular Impedance Sensing (ECIS) is a novel method used as an 
alternative to the conventional function assays mentioned above. It works using an 
array of 96 wells, each containing a gold electrode. These measure the current and 
voltage across this electrode, calculating the impedance and resistance. From the 
impedance changes, effects on cell attachment and motility can be examined (Keese 
et al., 2004). Using 96W1E arrays (ECIS™ cultureware, Applied Biophysics, Inc., 
NY, USA), each well was stabilised at room temperature for around 20 minutes 
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using 200μl electrode stabilising solution (ECIS™, Applied Biophysics, Inc., NY, 
USA). 
 
• The solution was then aspirated and replaced with 200μl DMEM F12 media 
containing Hepes buffer (Lonza, Verviers, Belgium) and left until needed. 
• The media was aspirated, and 40,000 cells diluted in 200μl DMEM were seeded 
into each well, and treated with a protein of interest if required. 
• The array was then placed into an ECIS™ CO2 incubator (RS biotech 9600, R 
galaxy R+) which is connected to the ECIS™ Model 9600 Controller (Applied 
Biophysics, Inc., NY, USA). The software was set up so that resistance to the 
current flow was measured at 400Hz. Data was normalised using resistance from 
the first time point. 
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2.8.6 Analysing apoptosis using flow cytometer 
Phosphatidylserine (PS), a phospho-lipid component of the cell membrane is normally 
located on the cytoplasmic side of cell membranes in normal live cells. However, when 
the cells become apoptotic, PS translocates from the inner to the outer leaflet of the cell 
membrane, resulting in it being exposed to the external cellular membrane. In 
leukocytes, this functions as a trigger for macrophages to phagocytose the apoptotic 
cells. 
 
In order to detect apoptotic cells, this current study uses the Annexin V Kit (Santa Cruz 
Biotechnology) to carry out an apoptosis assay. This kit contains recombinant 
fluorescent conjugated annexin V (FITC annexin V) and Propidium Iodide (PI) solution. 
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The calcium dependent phospholipid-binding protein annexin V, binds to PS with a high 
affinity, and hence when labelled with a fluorophore or biotin, can be used to detect 
apoptotic cells by binding to the PS on the outer leaflet of the cell membrane. PI on the 
other hand, is a red-fluorescent intercalating dye, capable of permeating only through 
cell membranes of non-viable cells and binding to their nucleic acids. Therefore, any 
cells that have lost their membrane integrity will be stained red by the PI, whereas the 
apoptotic cells, which are impermeable to PI, will be stained green by the FITC annexin 
V only. Any live cells present in the solution will show little or no fluorescence. This 
partial staining allows for easy identification with the Partec CyFlow®  SL flow 
cytometer and the accompanying FloMax software package (Partec GmbH, Munster, 
Germany). The protocol was carried out as follows: 
• Both the adherent cells and those floating in the culture medium, were harvested 
and washed in PBS. The cell solution was then centrifuged, before 5x10
5
 cells were 
resuspended in 200μl 1X annexin-binding buffer, sufficient for 100μl per assay. 
• 1µl of FITC annexin V (0.01μg/ml) and 1μl of PI working solution (100μg/ml) were 
subsequently added to each 100μl cell fraction and the cells were left at room 
temperature for 30 minutes. 
• Following incubation, 400μl of 1X annexin binding buffer was added and mixed 
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gently then placed on ice. 
• The stained cells were analysed immediately using the flow cytometer and 
FlowMax software package, measuring any fluorescence emission at 530nm (FL1) 
and 575nm (FL3). 
 
2.9 Clinical cohort study 
2.9.1 Breast cancer 
A total of 160 breast samples were collected immediately after surgery and stored at 
-80
o
C until use, with approval of the Bro Taf Health Authority local research ethics 
committee. All patients were informed and participated with written consent. The cohort 
included 127 breast cancer tissues and 33 background normal breast tissues (Table 2.7). 
All the specimens were verified by a consultant pathologist. A routine follow-up was 
carried out after surgery. The median follow-up period was 120 months. 
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Table 2.7 Sample numbers of breast cohort study. 
Clinical/pathological features  Sample numbers 
Tissue sample  
  Normal 33 
  Tumour 127 
Grade   
  1  23 
  2  41 
  3  56 
NPI   
  1 (<3.5)  68 
  2 (3.5-5.4)  38 
  3 (>5.4)  16 
TNM   
  1  61 
  2  40 
  3  7 
  4  4 
Clinical outcome   
  Disease-free  87 
  Poor outcome  28 
    With metastasis  7 
    With local recurrence  5 
    Died of breast cancer  16 
Histology  
Ductal 88 
Lobular 14 
Others 8 
Lymph node status        
  Negative 65 
  Positive 55 
Estrogen receptor  
ERα (-) 75 
ERα (+) 38 
ERβ (-) 91 
ERβ (+) 24 
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2.10 Statistical analysis 
Statistical analysis was performed using SPSS18 (SPSS Inc., Chicago, USA). Data 
were calculated as the mean ± SD and Mann-Whitney U-test was used for analysis of 
non-normally distributed data, while the Student’s t-test was used for normally 
distributed data. Each assay was performed at least three times. Chi-squared test was 
used for comparison of two independent groups and Fisher’s exact test was used for 
certain samples analysis. Survival data was analysed using the Kaplan-Meier survival 
analysis. P-value＜0.05 were considered statistical significant. 
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Chapter 3 
 
PTPRK expression in prostate 
tissues and cell lines 
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3.1 Introduction 
Protein tyrosine phosphatase kappa (PTPRK or PTPκ) belongs to the MAM-subfamily 
of the classic protein tyrosine phosphatases (PTPs). PTPRK was identified in 1993 by 
Jiang et al. (Jiang, Wang et al. 1993) and it contains a MAM (Meprin/A5/ PTPmu) 
domain in the extracellular region followed by one Ig-like domain and four fibronectin 
type III repeats. The MAM-subfamily has two cytoplasmic PTP domains (the second 
PTP domain is a pseudophosphatase) and an intracellular juxtamembrane region 
homologous to the intracellular domain of cadherin (Zondag et al., 1995). PTPRK is 
expressed in normal tissues such as spleen, prostate, ovary, brain, and has also been 
found in melanocyte and keratinocyte epidermal cell lines (Jiang et al., 1993; McArdle 
et al., 2005).  
 
Recently it has been suggested that PTPs have already been shown to act as tumour 
suppressors, such as PTEN (MMAC1, a tumour suppressor which is mutated in various 
human cancers) and PTPρ (PTPRT, a potential tumour suppressor in colorectal cancers) 
(Tonks 2006). PTPRK has been demonstrated to act as a potential tumour suppressor in 
primary central nervous system lymphomas (Nakamura et al., 2003). However, the role 
played by PTPRK in cancer remains largely unknown.  
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The study presented in this chapter was aimed to investigate the implication of PTPRK 
in prostate cancer, by examining its expression profile in prostate cancer tissues and cell 
lines, and subsequently to establish in vitro cell models to further explore its effect on 
functions of the cancerous cells.  
 
3.2 Materials and methods 
3.2.1 Prostate cancer tissues 
Prostate samples were collected immediately after surgery and stored at -80°C until 
further use, with approval of the Bro Taf Health Authority local research ethics 
committee. All patients were informed and participated with written consent. All the 
specimens were verified by a consultant pathologist. 
 
3.2.2 Antibody and primers 
Polyclonal rabbit anti-PTPRK antibody (SC-28906) was obtained from Santa Cruz 
Biotechnology (Santa Cruz, California, USA). All the primers used were synthesised 
and provided by Invitrogen (Paisley, UK). Primer sequences are shown in Tables 2.2 
and 2.3. 
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3.2.3 Cell lines 
PC-3, DU-145, LNCaP, CAHPV-10, PZHPV7, PNT1A, PNT2C2 and MRC-5 cells 
were routinely cultured in DMEM-F12 medium as described in section 2.3. 
 
3.2.4 RNA isolation, cDNA synthesis, and RT-PCR 
RNA was isolated from cells using Tri Reagent (Sigma-Aldrich, Inc., Poole, Dorset, 
England, UK), and converted into cDNA by reverse transcription using the iScript™ 
cDNA Synthesis Kit (Bio-Rad Laboratories, California, USA), as described in section 
2.4. RT-PCR was carried out at the following conditions; 94˚C for 5 minutes, followed 
by 30 to 42 cycles of 94˚C for 30 seconds, 56˚C for 30 seconds, and 72˚C for 1 minute 
and a final extension of 7 minutes at 72˚C. The products were run on an agarose gel and 
visualised using ethidium bromide. 
 
3.2.5 Protein extraction, SDS-PAGE, and Western blot analysis 
Protein was extracted and was then quantified using the DC Protein Assay kit 
(BIO-RAD, USA). After SDS-PAGE, the proteins were transferred onto nitrocellulose 
membranes which were then blocked and probed with the specific primary 
(anti-PTPRK 1:500) and the corresponding peroxidise-conjugated secondary antibodies 
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(1:1000). All of the antibodies used in this study are listed in Table 2.4. The protein 
bands were eventually visualised using the chemiluminescence detection kit (Luminata, 
Millipore). 
 
3.2.6 Immunochemical staining of PTPRK 
Immunochemical staining of PTPRK in prostate cancer cells and tissues were carried 
out using specific primary antibody for the protein, followed by secondary antibody. 
For the detailed procedure refer to Section 2.5.9. 
 
3.3 Results 
3.3.1 Prostate tissues and cell lines screened for PTPRK expression 
The expression of PTPRK was examined in seven prostate cell lines, including PC-3, 
DU-145, LNCaP, CA-HPV-10, PZ-HPV-7, PNT-1A and PNT-2C2 and fibroblast cell 
line, MRC-5. The first four are prostate cancer cells. PC-3 is derived from bone 
metastatic lesions originating from prostate cancer. DU-145 is from a brain metastasis 
of prostate cancer. LNCaP is from lymphatic metastasis and CA-HPV-10 from a 
localised prostate carcinoma. The remaining three are immortalised prostatic epithelial 
cells. 
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Figure 3.1 shows that PTPRK is consistently expressed in all the prostate cell lines, 
except PNT-1A, where it appears to have a lower level of PTPRK mRNA. Figure 3.2 
shows that PTPRK is more frequently expressed in prostate cancer tissues (12/18, 
66.7% positive, p=0.143 vs. normal using Fisher exact test) than normal prostate tissues 
at mRNA level (4/11, 36.7% positive). Furthermore, Figure 3.3 also shows a higher 
PTPRK expression level in prostate cancer tissues compared with normal prostate 
tissues using IHC staining. Figure 3.4 shows the overall PTPRK protein expression in 
two prostate cancer cell lines (PC-3 and DU-145) and one fibroblast cell line (MRC-5) 
using ICC staining. Figure 3.5 shows PTPRK protein expression in different cell lines 
using western blot. PTPRK was consistently expressed in all the cell lines except in 
PNT-1A and PNT-2C2 where a lower protein expression level of PTPRK was seen. 
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Figure 3.1 Cell line screen for PTPRK mRNA expression. Seven prostate cell lines 
and one fibroblast cell line were screened for mRNA expression of PTPRK using 
conventional PCR techniques. 
 
 
Figure 3.2 Prostate tissues screen for PTPRK. 29 prostate tissues were screened for 
mRNA expression of PTPRK using conventional PCR techniques. Different nombers 
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were stood for different patients. 
 
Figure 3.3 IHC staining for PTPRK in normal prostate and prostate cancer tissues. 
Three normal prostate tissues and three prostate cancer tissues were screened for the 
PTPRK protein expression in tissues using IHC staining. 
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Figure 3.4 ICC staining for PTPRK in cell lines. Two prostate cancer cell lines (PC-3 
and DU-145) and one fibroblast cell line (MRC-5) were screened for the PTPRK 
expression in tissues using ICC staining. A-B show PC-3 cells, C-D show DU-145 cells 
and E-F show MRC-5 cells.  
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Figure 3.5 Cell line screen for PTPRK protein expression. Five prostate cell lines 
and one fibroblast cell line were screened for protein expression of PTPRK using 
western blot.
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3.4 Discussion 
PTPRK is a poorly studied protein phosphatase in the field of cancer progression. The 
limited information available in the literature indicates that PTPRK probably behaves in 
a similar manner with its closest homologue: PTPRM. In fact, PTPRM and PTPRK 
both prefer homophilic binding; PTPRM not only binds to PTPRM but also recognises 
other subfamily members, such as PTPRK and PTPRT to mediate cell-cell aggregation. 
However, PTPRK does not interact with PTPRM. Expression of PTPRK only promoted 
homophilic interactions which include cell aggregation and cell-cell adhesion. 
Furthermore, it has been reported that PTPRK-mediated intercellular adhesion does not 
need PTPase activity or post-translational modification of PTPRK protein and is 
calcium independent (Brady-Kalnay et al., 1993; Sap et al., 1994; Zondag et al., 1995; 
Becka et al., 2010). Additionally, PTPRM has been shown to drive cancer progression 
(Gyorffy et al., 2008), however PTPRK has been reported as a tumour suppressor in the 
primary lymphoma of central nervous system and associated with colorectal cancer and 
pancreatic islet tumour (Lu et al., 1998; Nakamura et al., 2003; Cady et al., 2008; Starr 
et al., 2009). No other studies have attempted to define the function of PTPRK in 
prostate cells and its potential involvement in cancer metastasis.  
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In the current study, we firstly demonstrated the presence of PTPRK expression in 
seven prostatic cell lines and one human endothelial cell line. The cell lines used here 
have extensively been used as models for in vitro studies on prostate cancer. PC-3, 
DU-145 and LNCaP are aggressive prostatic carcinomas derived from metastatic sites 
of the bone, brain and lymph nodes respectively. CA-HPV-10 represents a less 
aggressive prostatic adenocarcinoma cell line immortalised with HPV-18. PZ-HPV-7, 
PNT-1A, and PNT-2C2 are immortalised prostatic epithelial cell lines.  
 
Its expression in tissues shows that PTPRK expression slightly higher in prostate cancer 
tissues than in normal prostate tissue samples in both mRNA and protein levels but the 
stastical analysis dose not reach significant difference. According to the mRNA levels 
of PTPRK, its expression appears at a similar level of that seen in prostate cell lines. 
The only exception was PNT-1A which appeared to have lower PTPRK expression. 
Furthermore, the protein levels of PTPRK in cell lines are similar with mRNA 
expression as well. PTPRK expression in PNT-1A and PNT-2C2 are both very weak 
compared with other cell lines. However, the current assessment of PTPRK expression 
in prostate cancer is limited and not sufficient to reach any solid conclusion. Hopefully, 
the implication of PTPRK in disease development and progression of prostate cancer 
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can be elucidated by further investigations using a large clinical cohort of prostate 
cancer. 
 
The staining location of PTPRK was seen in all pictures to be located mainly at the cell 
nuclei using ICC staining. As PTPRK is believed to be a transmembrane protein 
phosphatase, the location of the staining appears to against this belief. It may be due to 
the distribution change PTPRK even if no certain contact with ECM suggesting PTPRK 
itself may be a molecule which is participated in regulation of down-stream signalling 
pathway. However, the activation and changes should be further investigated.  
 
This screening process also aided the determination of which cell lines to use for the 
remainder of the study. As previously mentioned, PTPRK is a cell surface tyrosine 
phosphatase with a possible role in intracellular signal transduction, as well as being in 
place to inactivate other cell surface proteins. Since the mRNA expression levels are 
similar in all prostate cells, we chose aggressive prostate cancer cell lines, PC-3 (highly 
tumourigenic) and DU-145; these cell lines were selected to transfect with the ribozyme 
transgene to determine the consequences of PTPRK knockdown on in vitro cellular 
functions. The findings of the function based studies are presented in the next chapter. 
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Chapter 4 
 
Knockdown of PTPRK and 
the effect on the functions of 
prostate cancer cells 
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4.1 Introduction 
A cancer cell relies on varying vital biological processes to establish itself in its 
environment and to subsequently metastasise. The most important of these include 
aberrations in cell proliferation, adhesion, invasion and migration. Cancer cells can 
influence these processes in several ways, most significantly by altering the expression 
of molecules that play key roles in controlling these cellular functions. PTPRK has been 
previously shown to inhibit cell proliferation by regulating EGFR and the TGF-β 
signalling pathway in different cells. The homophilic binding ability of PTPRK is 
similar to PTPRM. Furthermore, PTPRK regulates cell migration by TGF-β signalling 
pathway via positively regulated Src. This chapter attempts to determine whether the 
knockdown of PTPRK can affect the behaviour of prostate cancer cells.  
PTPRK was knocked down in PC-3 and DU-145 cells using a ribozyme transgene and 
the effect on cellular functions was subsequently investigated.  
 
4.2 Materials and methods 
4.2.1 Cell lines 
PC-3 and DU-145 prostate cancer cell lines were used in this chapter, including empty 
plasmid control and transfected cell lines. Cells were continuously maintained in 
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DMEM media with 10% FBS and antibiotics. The stable transfected cells were 
maintained in the same media and supplemented with 0.5μg/ml blasticidin. 
 
4.2.2 Generation of PTPRK ribozyme transgenes 
Hammerhead ribozymes targeting PTPRK were designed using Zuker’s mRNA Fold 
programme (Zuker, 2003), based on the secondary structure of PTPRK mRNA. Primers 
containing restriction sites were then generated (Table 2.3). The ribozymes were then 
synthesised using a touch-down PCR procedure at the following conditions; 94˚C for 5 
minutes, followed by 8 cycles at each annealing temperature (total of 48 cycles): 94˚C 
for 10 seconds, 70˚C, 65˚C, 60˚C, 57˚C, 54˚C, and 50˚C for 15 seconds, 72˚C for 20 
seconds and a final extension of 7 minutes at 72˚C. Subsequently, the transgenes were 
run on a 2% agarose gel in order to verify their presence as well as size, before being 
cloned into a plasmid vector. 
 
4.2.3 TOPO TA cloning of PTPRK fragments or transgenes into a pEF6/His 
TOPO plasmid vector 
Following verification, the PTPRK transgene was cloned into a pEF6/V5-His-TOPO 
plasmid (Invitrogen Inc., Paisley, UK), followed by transformation of constructed 
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plasmid into E.Coli. The correct constructs were then amplified and purified using the 
Sigma GenElute Plasmid MiniPrep Kit (Sigma-Aldrich, USA). 
 
4.2.4 Prostate cancer cell transfection and generation of stable transfectants 
Following plasmid verification using DNA electrophoresis, the plasmids were 
transfected into target cells using the electroporation at 310V. The transfectants were 
then selected with 5μg/ml blasticidin for a period of two weeks. Empty plasmid vectors 
were also used to transfect the same cells and used as a control for the following 
experiments. After the selection, the cells were verified for PTPRK knockdown using 
RT-PCR, Q-PCR, and Western blotting. Full details of the cloning process have been 
given in section 2.7. 
 
4.2.5 RNA isolation, cDNA synthesis, RT-PCR, and Q-PCR 
RNA was isolated from the cells using the Tri Reagent kit (Sigma-Aldrich, Inc., Poole, 
Dorset, England, UK) and converted into cDNA by reverse transcription using the 
iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, California, USA), as described in 
section 2.4. RT-PCR was carried out at the following conditions; 94
 o
C for 5 minutes, 
followed by 30 to 35 cycles of 94
 o
C for 30 seconds, 56
 o
C for 30 seconds, and 72
 o
C for 
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1 minute, and a final extension of 7 minutes at 72
 o
C. The products were run on an 
agarose gel and visualised using ethidium bromide. Q-PCR was performed following 
the conditions; 94
o
C for 5 minutes, followed by 80 to 90 cycles of 94
o
C for 10 seconds, 
55
o
C for 15 seconds, and 72
o
C for 20 seconds. 
 
4.2.6 Protein extraction, SDS-PAGE, and Western blot analysis 
Protein was extracted and was then quantified using the DC Protein Assay kit 
(BIO-RAD, USA). After the SDS-PAGE, the proteins were transferred onto 
nitrocellulose membranes which were then blocked and probed with the specific 
primary (anti-PTPRK 1:500) and the corresponding peroxidise-conjugated secondary 
antibodies (1:1000). All of the antibodies used in this study are listed in Table 2.4. The 
protein bands were eventually visualised using the chemiluminescence detection kit 
(Luminata, Millipore). 
 
4.2.7 In vitro cell growth assay 
The cells were seeded into three 96 well plates, and incubated for 1 and 5 days 
respectively, as described in section 2.8.1. Following incubation, the cells were fixed 
and stained with crystal violet before the absorbance was measured in order to 
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determine cell number.  
 
4.2.8 In vitro cell Matrigel adhesion assay 
The cells were seeded into a 96 well plate coated with matrigel as described in section 
2.8.2. The cells were left to adhere for a period of 40 minutes, before being fixed and 
stained with crystal violet and the cells counted. 
 
4.2.9 In vitro cell motility assay 
The protocol followed is described by Jiang (Jiang et al., 1995b). Cells are seeded into a 
24 well plate and these plates were then left to incubate at 37
o
C, with 5% CO2, for a 
period of 24 hours to allow cells to form a confluent monolayer then the cells were 
wounded and  photos taken using a microscope with camera at 0.25, 1, 2 and 3 hours 
after wounding. Migration distances were measured using ImageJ software (National 
Institutes of Health, USA) 
 
4.2.10 In vitro cell Matrigel invasion assay 
The cells were seeded into transwell inserts with 8μm pores coated with 50 μg matrigel, 
in a 24 well plate and were incubated for a period of 3 days. Following incubation, the 
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cells which had migrated through the matrigel to the other side of the insert were fixed 
in formalin, stained with crystal violet and counted. 
 
4.3 Results 
4.3.1 Generation of a PTPRK ribozyme transgene 
In order to silence the expression of PTPRK in prostate cancer cells, ribozyme 
transgenes targeting PTPRK were generated based on the secondary structure of human 
PTPRK mRNA (figure 2.5a) and cloned into a pEF6/His plasmid. Figure 3.6 depicts the 
series of PCR reactions carried out to construct a plasmid containing a PTPRK 
ribozyme transgene. Based on the secondary structure of PTPRK, an appropriate 
targeting site for the ribozyme was first ascertained. 
 
This was followed by ribozyme synthesis through touchdown PCR, and cloning into a 
pEF6/His plasmid. In order to verify correct orientation of the ribozyme transgene, 
primers RbTPF and RbBMR were paired with T7F, respectively. These primers were 
specific to the ribozyme transgenes. 
 
If the transgene is correctly orientated, a PCR product of around 140bp (T7F promoter 
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starts 90bp before insert and ribozyme sequence is around 50bp) should arise for the 
T7F+RbBMR reaction. However, if it is incorrectly orientated, a product of a similar 
size should appear for the T7F+RbTPF reaction. Following colony analysis, all those 
found to be positive for the transgenes underwent further amplification and finally, 
plasmid extraction. Colonies 2 and 10 were shown to have the highest levels of 
correctly orientated ribozyme transgene. The plasmids were then verified using DNA 
electrophoresis, in order to demonstrate successful isolation of correctly sized plasmids 
(Figure 4.1). 
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Figure 4.1 Ribozyme transgene synthesis. A. The ribozymes were generated using 
touchdown PCR and run on an agarose gel. B. After transformation into E.coli cells, the 
colonies were analysed using PCR in order to verify correct orientation of the transgene. 
P for correct orientation (50bp ribozyme sequence plus 173bp sequence downstream of 
the insert site), which refers to a PCR reaction that uses a plasmid specific reverse 
primer (BGHR) and a ribozyme specific reverse primer (RbTPF) and N stands for 
incorrect orientation (50bp ribozyme sequence plus 90bp sequence upstream of the 
insert site), where a plasmid specific forward primer (T7F) is coupled with a ribozyme 
forward primer (RbTPF), in a PCR reaction. C. The plasmids were extracted from the 
correct colonies and verified with DNA electrophoresis.
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4.3.2 Verification of PTPRK knockdown in PC-3 and DU-145 cells 
RT-PCR, Q-PCR and western blots were carried out to ensure that the knockdown of 
PTPRK was successful at both mRNA and protein levels using conventional RT-PCR, 
quantitative real time PCR and Western blot in both PC-3 (Figure 4.2) and DU-145 
(Figure 4.3) cells. Figure 4.3A shows knockdown of PTPRK in mRNA level using 
RT-PCR. Figure 4.3B shows PTPRK mRNA volume of four repeats which was 
normalised against corresponding internal control (GAPDH) using Quantitative real 
time PCR. PTPRK expression was decreased in PTPRK knockdown cells compared 
with empty plasmid pEF control. Figure C shows knockdown of PTPRK in protein 
level using western blots. Figure 4.3D shows PTPRK protein bands volume of three 
repeats which is normalised against corresponding internal control. PTPRK expression 
was decreased in PTPRK knockdown cells compared with pEF control. 
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Figure 4.2 Confirmation of knockdown of PTPRK in PC-3 cells. A. RT-PCR 
showing reduced levels of PTPRK in mRNA in PC-3 cell compared with PC-3
pEF
 
control cell. B. Quantitative real time PCR shows PTPRK mRNA volume of four 
repeats which is normalised against corresponding internal control (GAPDH). PTPRK 
expression was decreasing in PC-3
PTPRKkd
 cells compared with PC-3
pEF
 (p<0.05). C. 
Western blot showing reduced levels of PTPRK protein in the PC-3
PTPRKkd
 cell 
compared to the PC-3
pEF
 control cell. D. PTPRK protein bands volume of three repeats 
which is normalised against corresponding internal control (GAPDH). PTPRK 
expression was decreasing in PC-3
PTPRKkd
 cells compared with PC-3
pEF
 (p<0.05).  
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Figure 4.3 Confirmation of knockdown of PTPRK in DU-145 cells. A. RT-PCR 
showing reduced levels of PTPRK in mRNA in DU-145 cell compared with DU-145
pEF
 
control cell. B. Quantitative real time PCR shows PTPRK mRNA volume of four 
repeats which is normalised against corresponding internal control (GAPDH). PTPRK 
expression was decreasing in DU-145
PTPRKkd
 cells compared with DU-145
pEF
 (p<0.05). 
C. Western blot showing reduced levels of PTPRK protein in the DU-145
PTPRKkd
 cell 
compared to the DU-145
pEF
 control cell. D. PTPRK protein bands volume of three 
repeats which is normalised against corresponding internal control (GAPDH). PTPRK 
expression was decreasing in DU-145
PTPRKkd
 cells compared with DU-145
pEF
 (p<0.05).  
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4.3.3 Effect of PTPRK knockdown on the growth of prostate cancer cells 
The cell lines displaying knockdown of PTPRK were used in an in vitro cell growth 
assay along with the empty plasmid controls. There was a significant decrease in the 
growth of the PC-3
PTPRKkd
 cells (Figure 4.4). Cell growth at 5 days was significantly 
reduced in the PC-3
PTPRKkd
 cells (634.33±58.76) p<0.001, compared with the control 
PC-3
pEF
 (739.35±24.14).  
 
There was also a significant decrease in the growth seen in the DU-145
PTPRKkd
 cells 
(Figure 4.5). The growth rate at 5 days was significantly reduced in the DU-145
PTPRKkd
 
cells (667.23±6.91) compared with the control DU-145
pEF
 (817.22±46.69) p<0.001. 
 
4.3.4 Effect of PTPRK knockdown on in vitro cell-matrix adhesion 
The PC-3 cells were further analysed for their adhesive capacity using an in vitro 
matrigel adhesion assay. The cells with a knockdown of PTPRK displayed a significant 
decrease in adhesive capability compared to its controls. Representative images of 
adhered PC-3 cells (Figure 4.6A). There was a significant decrease in cell adhesion of 
PC-3
PTPRKkd
 cells (23.95±7.47) p<0.001 compared to the control PC-3
pEF
 (53.95±11.94) 
(Figure 4.6B). 
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The DU-145 cells were also analysed for their adhesive capacity. The cells with a 
knockdown of PTPRK displayed a significant decrease of adhesive capability compared 
to its controls. Figure 4.7A was representative images of adhered DU-145 cells. Figure 
4.7B demonstrated that there was a significant decrease in cell adhesion with 
DU-145
PTPRKkd
 cells (18.87±3.95) compared to the control DU-145
pEF
 (29.67±8.16) 
p=0.008. 
 
4.3.5 Effect of knockdown of PTPRK in the cell motility 
The cells were further analysed for their motility using scratch or wounding assay. The 
cells with knockdown of PTPRK displayed a significant increase in motility compared 
to control cells. Figure 4.8 shows that there was a significant increase in cell motility 
with PC-3
PTPRKkd
 cells (96.9±27.9) compared to the PC-3
pEF
 cells (62.1±16.0) p<0.05. 
There was no significant difference in cell motility of DU-145
PTPRKkd
 cells compared 
with the control DU-145
pEF
 (Figure 4.9). 
 
4.3.6 Effect on invasion of prostate cancer cells by PTPRK knockdown 
PTPRK knockdown cells displayed a significant reduction of invasion compared to the 
controls. The number of invaded cells were 168.72±15.25 after PTPRK knockdown 
169 
 
p<0.05 compared to that of the control (190.83±12.25). However, an increase of 
invasion was seen in DU-145
PTPRKkd
 cells (207.67±40.26), p<0.001 compared to the 
control DU-145
pEF
 (92.42±18.37). 
 
170 
 
 
Figure 4.4 Knockdown of PTPRK has a significant decrease in the growth of the 
PC-3
PTPRKkd
 cells. After 5 days incubation there was a significant decrease in the 
PC-3
PTPRKkd
 cells (634.33±58.76) compared with the control PC-3
pEF
 (739.35±24.14) 
(p<0001). Data shown is representative of at least 6 independent repeats. Error bars 
represent standard deviation. The 1 day time point was used as a baseline to normalise 
the data. Growth rate (%) = Day1 absorbance/ Day 5 absorbance x100. 
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Figure 4.5 Knockdown of PTPRK has a significant decrease in the growth of the 
DU-145
PTPRKkd
 cells. After 5 days incubation there was a significant decrease in the 
DU-145
PTPRKkd
 cells (667.23±6.91) compared with the control DU-145
pEF
 
(817.22±46.69) (p<0001). Data shown is representative of at least 6 independent repeats. 
Error bars represent standard deviation. The 1 day time point was used as a baseline to 
normalise the data. Growth rate (%) = Day1 absorbance/ Day 5 absorbance x100. 
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Figure 4.6 Knockdown of PTPRK in PC-3 cells displayed a significant decreasing 
in adhesive capability compared to its controls. A. Representative images of cells 
following staining. B. After 40 minutes incubation of the cells on an artificial matrigel 
basement membrane, there was a significant decrease in adhesion was seen between the 
PC-3
PTPRKkd
 cells (23.95±7.47) compared to the control PC-3
pEF
 (53.95±11.94) 
(p<0.001). Data shown is representative of at least 6 independent repeats. Error bars 
represent standard deviation.  
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Figure 4.7 Knockdown of PTPRK in DU-145 cells also displayed a significant 
decreasing in adhesive capability compared to its controls. A. Representative images 
of cells following staining. B. After 40 minutes incubation of the cells on an artificial 
matrigel basement membrane, there was a significant decrease in adhesion was seen 
between the DU-145
PTPRKkd
 cells (18.87±3.95) compared to the control DU-145
pEF
 
(29.67±8.16) (p=0.008). Data shown is representative of at least 6 independent repeats. 
Error bars represent standard deviation.  
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Figure 4.8 Knockdown of PTPRK increases the motility of PC-3 prostate cells. The 
knockdown of PTPRK caused a significant increase in the motility of the PC-3
PTPRKkd
 
cells (96.9±27.9) compared to the PC-3
pEF
 cells (62.1±16.0) (p<0.05). Data shown is 
representative of at least 6 independent repeats. Error bars represent standard deviation. 
175 
 
 
Figure 4.9 Knockdown of PTPRK has no effect in the motility of DU-145 prostate 
cells. There was no significant difference in cell motility of DU-145
PTPRKkd
 cells 
(44.6±6.6) compared with the control DU-145
pEF
 (54.5±28.7). Data shown is 
representative of at least 6 independent repeats. Error bars represent standard deviation. 
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Figure 4.10 Knockdown of PTPRK decreases the invasive ability of PC-3 prostate 
cancer cells. A. Representative images of cells following staining. B. Following a 3 day 
incubation of the cells on an artificial matrigel basement membrane there was a 
significant decrease in the invasion of the PC-3
PTPRKkd
 cells (168.72±15.25) compared 
to the control PC-3
pEF
 cells (190.83±12.25) (p<0.05). Data shown is representative of at 
least 3 independent repeats. Error bars represent standard deviation. 
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Figure 4.11 Knockdown of PTPRK increases the invasive ability of DU-145 
prostate cancer cells. A. Representative images of cells following staining. B. 
Following a 3 day incubation of the cells on an artificial matrigel basement membrane 
there was a significant decrease in the invasion of the DU-145
PTPRKkd
 cells 
(207.67±40.26) compared to the control DU-145
pEF
 (92.42±18.37) (p<0.001). Data 
shown is representative of at least 3 independent repeats. Error bars represent standard 
deviation. 
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4.4 Discussion 
Several members of the PTP proteins have been linked to cancer progression. PTPRM 
has been reported to play a role in cancer cell migration and adhesion and associated 
with ovarian carcinoma carcinogenesis (Zondag et al., 1995; Gyorffy et al., 2008). 
PTPRK is in the same sub-family with PTPRM and has similar structure of cell 
adhesion molecule (CAM). PTPRK has been identified as a possible tumour suppressor 
in primary lymphoma of central nervous system lymphomas, in which the locus that the 
PTPRK gene resides is frequently deleted (Nakamura, Kishi et al. 2003). 
Over-expression of PTPRK in Hodgkin Lymphoma cells resulted in a decrease in cell 
proliferation and survival and knockingdown PTPRK caused the opposite effect 
(Flavell et al 2008). A similar suppressing role was observed in human keratinocyte, 
adding extra TGF-β1 to treat HaCaT cell induced PTPRK expression and final lead to 
anti-proliferation phenomenon (Yang et al., 1996). In contrast, another study 
demonstrated that blocking of PTPRK expression accelerated cell cycle progression, 
enhanced response to EGF-induced EGFR tyrosine phosphorylation, then increased 
downstream ERK activation, and abrogated TGF-β-mediated antimitogenesis (Wang et 
al., 2005; Xu et al., 2005). Together, the limited available literature has presented a 
rather mixed, if not confusing, picture with regard the role of PTPRK in cancer and 
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cancer development. 
 
The present study attempted to investigate the role of PTPRK in prostate cancer. The 
ribozyme transgene proved effective at knockdown the expression of PTPRK at both 
the mRNA and protein level. These tools of genetic manipulation aid in the generation 
of useful in vitro models allowing for the subsequent investigations of the impact on 
cellular functions. 
 
When PTPRK was knocked down in PC-3 and DU-145 cells lines, they demonstrated 
decreased cell growth and adhesion compared to their controls. However, knockdown 
of PTPRK in PC-3 cells showed significant increases of cell motility. There was no 
effect on the motility in DU-145 PTPRK knockdown cells compared with their control 
cells. Furthermore, in the cell invasion assay, knockdown of PTPRK in PC-3 and 
DU-145 showed completely different trends. In PC-3 cells, knockdown of PTPRK 
reduces the invasiveness compared with control cells, while PTPRK knockdown in 
DU-145 cells promotes the invasive ability. The exact reason for the differential effect 
of PTPRK on the cell migration and invasion is currently unknown but is likely to be 
due to differences in the expression patterns of other proteins between PC-3 and 
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DU-145, particularly the interacting molecules and pathways of PTPRK.  
 
The inhibition of cell growth in PC-3 and DU-145 cells by PTPRK knockdown is 
probably linked to the balance between EGFR proliferation and TGF-β 
anti-proliferation pathways. It has been shown that PTPRK directly dephosphorylates 
EGFR in vitro and increased PTPRK expression decreases both basal and 
ligand-stimulated EGFR tyrosine phosphorylation, and reduced PTPRK expression 
leads to an increase in EGFR tyrosine phosphorylation (Xu et al., 2005). Moreover, 
PTPRK is up-regulated by TGF-β1 which is probably involved in mediation TGF-β 
dependent anti-proliferation and cell migration effects
 
(Yang et al., 1996). Furthermore, 
co-localisation of PTPRK with β-catenin at adhesion junctions has been revealed in 
human embryonic kidney cells (HEK293) which stabilise E-cadherin/ β-catenin 
complexes. It suggests that β-catenin might be a substrate of PTPRK-mediated 
phosphatase activity. The stabilisation of β-catenin /E-cadherin complexes can suppress 
wnt/ β-catenin-induced transcription of target genes, such as cyclin D1 and c-Myc, 
leading to an inhibition of proliferation and migration in cancer cells. It provides 
evidence that PTPRK may be a potential tumour suppressor
 
(Novellino et al., 2008). 
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In addition, knockdown of PTPRK decreases cell adhesion in both PC-3 and DU-145 
cells due to the extracellular region of PTPRK, which contains one Ig-like domain. 
Some molecules of the Ig superfamily can mediate both homophilic and heterophilic 
interactions. However, PTPRK fails to interact with PTPRM which belong to the same 
subfamily of PTP. Expression of PTPRK only promoted homophilic interactions which 
include cell aggregation and cell-cell adhesion. Furthermore, it has been reported that 
PTPRK-mediated intercellular adhesion does not need PTP activity or post-translational 
modification of PTPRK protein and is calcium independent (Sap et al., 1994; Zondag et 
al., 1995). 
 
This study suggests that PTPRK is an important regulator of the biological properties of 
prostate cancer cells, which is possibly involved in the disease progression. In order to 
further determine the role of PTPRK in cancer, the following chapter will focus on the 
mechanisms of the inhibitory effect on growth of prostate cancer cells. 
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Chapter 5 
 
Knockdown of PTPRK 
induces apoptosis in prostate 
cancer cells and the 
involvement of the MAPK 
pathway 
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5.1 Introduction 
The previous chapter has shown that knockdown of PTPRK reduces cell proliferation in 
prostate cancer cell lines. Unlimited cell proliferation is essential for cancer progression. 
Most oncogenic factors can regulate cell proliferation via two different ways; disrupting 
the cell cycle and/or inhibiting apoptosis. 
 
PTP deficiency leads to several physiologic abnormalities such as embryonic 
developmental defect (PTP-PEST), impairment of the immune system (TC-PTP), 
inhibition of tumourigenesis and metastasis (PTP1B) and others (Sirois et al., 2006; 
Bourdeau et al., 2007; Julien et al., 2007). Dysregulation of apoptosis is one of the 
mechanisms underlying these conditions. PTP-PEST renders cells more sensitive to 
anti-Fas and TNFα apoptotic stimulation. PTP-PEST is cleaved by caspase-3, leading to 
an increased catalytic activity and simultaneous changes in its protein structure. 
Furthermore, PTP-PEST proteolysis facilitates cellular detachment during apoptosis 
(Halle et al., 2007). In contrast to PTP-PEST, PTP1B does not possess a 
caspase-cleavage site. Activated PTP1B contributes to STAT3 dephosphorylation and 
results in apoptosis in human glioma cells (Akasaki et al., 2006; Halle et al., 2007). In 
the breast cancer cell line MCF-7, overexpression of PTPRB induces apoptosis via a 
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direct increase in the expression of Apaf-1 and the pro-apoptotic α-isoform of caspase-1 
(Radha et al., 1999; Gupta et al., 2002). 
 
The previous chapter has shown that PTPRK knockdown resulted in inhibition of in 
vitro growth of prostate cancer cells. Together with the role of PTP family proteins in 
the regulation of apoptosis, it was hypothesised that one of the mechanisms by which 
PTPRK influence the growth rate of prostate cancer cells is vis the action on apoptosis.  
 
5.2 Materials and methods 
5.2.1 Materials 
The primers used in this chapter are shown in Table 2.2, including caspase-3, caspase-8, 
caspase-9, p53, c-Myc, ID1, and cyclin-D1. The antibodies used in this chapter 
including anti-caspase-3, caspase-8, caspase-9, p38, JNK, ERK, and phospho-tyrosine 
are shown in Table 2.4. 
 
5.2.2 Investigating the expression of apoptotic molecules using PCR and Western 
blotting 
Both RNA and protein were extracted from stable transfected cells and were used in 
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either Western blot analysis or RT-PCR in order to investigate expression levels of 
molecules involved in apoptosis. These methods were carried out as previously 
described in sections 2.4 and 2.5. 
 
5.2.3 Immunoprecipitation and detection of tyrosine phosphorylated ERK, JNK 
and p38 
Protein extracted from PC-3 cells was immunoprecipitated with anti-p38, JNK, and 
ERK antibody in order to detect phosphorylation of these proteins. These 
immunoprecipitated protein samples were then run on an SDS-PAGE and blotted with 
anti-phosphotyrosine antibody. Please refer to section 2.5.3 for further details on 
immunoprecipitation method. 
 
5.2.4 Apoptosis analysis using flow cytometry 
Both the transfected PC-3
pEF
 cells and PC-3
PTPRKkd
 cells were treated with or without 
100nM p38 and JNK inhibitor over 72-hour culture before analysis of apoptosis. In 
order to detect apoptotic cells, the current study used an Annexin V Kit (Santa Cruz 
Biotechnology) which contained recombinant flourescein conjugated annexin V (FITC 
annexin V) and propidium iodide (PI) solution. The cells were stained with both FITC 
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annexinV and PI solution, followed by the detection of apoptotic cells using a flow 
cytometer (PartecCyFlow®  SL, Partec GmbH, Munster, Germany). This was achieved 
by measuring any fluorescence emission at 530nm (FL1) and>575nm (FL3). 
 
5.3 Results 
5.3.1 PTPRK knockdown affected apoptosis in prostate cancer cells 
There were an increased proportion of apoptotic cells (both early and late) in 
PC-3
PTPRKkd
 cells (34.90%) compared to the PC-3
pEF
control (16.14%) and PC-3 
wild-type (8.05%) cells (Figure 5.1). 
 
5.3.2 Expression of caspases in the PTPRK knockdown cells 
Caspase-3 is an indicator of apoptosis at the end-stage. Caspase-8 and caspase-9 are 
up-stream key factors of apoptosis; caspase-8 is normally activated by external 
signalling, and caspase-9 is activated by internal signalling. Therefore, in order to 
further determine whether PTPRK knockdown has an effect on prostate cancer cell 
apoptosis, levels of caspase-3, caspase-8, and caspase-9 were examined in the 
transfected PC-3 cells using PCR, Q-PCR, and western blotting analysis.PC-3
PTPRKkd 
cells demonstrated significantly higher expression levels of caspase-3 and caspase-8, 
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but not caspase-9, compared with PC-3
pEF
 controls cells in both mRNA and protein 
levels (Figure 5.2 and 5.3). 
 
5.3.3 Expression of other genes/molecules relevant to apoptosis and/or the cell 
cycle 
As PTPRK knockdown was shown to promote the progression of apoptosis, the 
expression of a number of relevant genes was examined using RT-PCR. An 
up-regulation of p53 was also seen in the PTPRK knockdown cells, whilst a 
down-regulation of ID1 appeared in the same cells (Figure 5.4). No effect on the 
expression of c-Myc was observed in the PC-3
PTPRKkd
 cells compared with the control. 
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Figure 5.1 The apoptotic population in PC-3 cells was analysed using flow 
cytometry after 72 hours incubation, in order to induce apoptosis. Segment Q1 of 
the quadrants refers to non-specific PI staining which are alive cells ; Q2 indicates late 
apoptotic and necrotic cells which are stained with both annexinV and PI; Q3 includes 
healthy and alive cells with low staining of both PI and annexinV; and Q4 to early 
apoptotic cells with high annexinV but low PI staining. Apoptotic index refers to total 
apoptotic population including both late apoptotic cells (Q2) and early apoptotic cells 
(Q4). The positive control was PC-3
WT
 cells treated with H2O2. H2O2 will induce 
peroxidation of cell membrane and break lipid bilayer structure resulting in aopotosis. 
Data shown are representative data of three independent experiments. 
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Figure 5.2 The effect of PTPRK knockdown on Caspase-3, -8, and -9 expressions 
were analysed in mRNA level using PCR and Q-PCR. A. PCR results of Caspase-3, 
-8, and -9 mRNA expressions. Expression of caspase-3 (B) and caspase-8 (C) was 
increased in PC-3
PTPRKkd
 cell vs. PC-3
pEF
 control using Q-PCR. However, there is no 
significant difference ofcaspase-9 (D) seen inPC-3
PTPRKkd
 cell using Q-PCR. Q-PCR 
result was normalised with GADPH. **p<0.01. 
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Figure 5.3 The effect of PTPRK knockdown on Caspase-3, -8, and -9 expressions 
were analysed in protein level using western blot. A. The protein expression of 
Caspase-3 and -8 were also increased in PC-3 cells by PTPRK knockdown, and also no 
similar change was seen in the Caspase-9 expression. Intensity of bands from three 
western blots was analysed using Image J software for caspase-3 (B), caspase-8 (C), 
and caspase-9 (D).Bar graphs shown quantifications of three Western blots of each 
molecule. The intensity shown is integrated band intensity (intensity×area) and was 
normalised against the corresponding GAPDH signal. **p<0.01.
191 
 
 
Figure 5.4 The effect of PTPRK knockdown on p53, ID1, and c-Myc expressions 
were analysed in mRNA level using PCR and Q-PCR. A. PCR results of p53, ID1, 
and c-Myc, it demonstrated that expression of p53 was increased and expression of ID1 
was decreased in PC-3
PTPRKkd
 cell compared with their controls. B. Expression of p53 
was increased in PC-3
PTPRKkd
 cell vs. PC-3
pEF
 control using Q-PCR. C. Expression of 
ID1 was decreased in PC-3
PTPRKkd
 cell vs. PC-3
pEF
 control using Q-PCR. D. There is no 
significant difference in c-Myc expression of PC-3
PTPRKkd
 cell using Q-PCR. Q-PCR 
result was normalised with GADPH expression. *p<0.05 and ***p<0.001.
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5.3.4 The role of JNK in PTPRK knockdown-associated apoptosis 
The mitogen-activated protein kinase (MAPK) pathway is the major signalling pathway 
involved in cellular proliferation and it affects both apoptosis and the cell cycle. As 
knockdown of PTPRK has been shown to impact on the apoptosis, its effect on the 
expression of three key molecules of the MAPK pathway, p38, JNK, and ERK in PC-3 
cells was analysed. The PC-3
PTPRKkd
 cell showed a similar level of protein expression in 
overall p38, JNK and ERK compared with their pEF control. Furthermore, levels of 
phosphorylated p38, JNK, and ERK were analysed using immunoprecipitation and 
Western blotting. A marked increase inactive p-JNK (Tyr) was seen in the PTPRK 
knockdown cells and also to a less degree, an increased level of active p38, suggesting 
that JNK and p38 may play a role in the regulation of apoptosis in the PC-3
PTPRKkd
 cell 
(Figure 5.5). 
Additionally, PC-3 cells were treated with p38 and JNK inhibitors for 48 hours and 
analysed for apoptosis using flow cytometry. The PC-3
pEF
 control cells showed no 
effect on treatment of cells with p38 and JNK inhibitors, but apoptosis of untreated 
PC-3
PTPRKkd
 cells (26.70%±2.87) was dramatically increased compared with PC-3
pEF
 
cells (14.61%±1.74), p<0.001. The PC-3
PTPRKkd
 cells treated with p38 inhibitor 
(26.75%±4.80) exhibited similar apoptotic levels to the untreated cells (13.36%±2.69). 
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However the PC-3
PTPRKkd
 cells treated with JNK inhibitor (18.76%±4.28) exhibited 
significant reduction of apoptotic cells compared with untreated PC-3
PTPRKkd
 cells, 
p<0.001 (Figure 5.6). The addition of the p38 inhibitor did not inhibit the effect on 
apoptosis, suggesting that p38 was unlikely to be involved. However, the addition of the 
JNK inhibitor diminished the apoptotic effect of PTPRK knockdown. This suggests that 
PTPRK knockdown may utilise a signalling pathway via JNK to impact on apoptosis 
and to thereby inhibit cell proliferation. 
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Figure 5.5 PTPRK signalling via MAPK pathway in PC-3 cells. A. The overall expression 
of p38, JNK, and ERK in PC-3
PTPRKkd
 cells were showed similar amount in protein levels 
compared with their pEF controls. In addition, there is no change in both active p-38 and 
p-ERK; however, the active p-JNK was increased significantly compared with the PC-3
pEF
 cells. 
Relative intensity of bands from three Western blots was analysed using Image J software for 
p38 (B), JNK (C), and ERK (D). **p<0.01. 
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Figure 5.6 The role of p38 and JNK in PTPRK knockdown associated apoptosis. 
PC-3
PTPRKkd
 cells treated with JNK inhibitors exhibited a significantly decreased 
apoptotic population compared with untreated control, p<0.001. There was no change in 
apoptotic effect induced by PTPRK knockdown seen in the cells treated with the p38 
inhibitor. The bar graph demonstrates the mean apoptotic percentage of four 
independent experiments. Error bars represent standard deviation. ***p<0.001. 
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5.4 Discussion 
PTPs have been shown to exhibit different effects on tumour apoptosis (Julien et al., 
2011). In the case of PTPRK, the previous chapter has shown that it is capable of 
inhibiting the growth of prostate cancer cells through endogenous alteration of 
expression. This current chapter further investigates the mechanisms behind this growth 
reduction. 
 
In general, cell population is control by the regulation and balance between cell 
proliferation (cell cycle) and cell death (necrosis and apoptosis). PTPRK knockdown 
promoted the apoptosis in prostate cancer cells and suppressed in vitro growth.  
Moreover, apoptosis was associated with the activation of Caspase-3, -8, and -9 and an 
increasing Bax:Bcl-2 ratio, followed by a releasing of cytochrome-c (Halle et al., 2007). 
Caspase-3 is a key molecule in the late stage of apoptosis; caspase-8 normally is 
activated by extrinsic receptor-mediated pathway; caspase-9 is activated by intrinsic 
mitochondrial-mediated pathway (Lee et al., 2011). In order to analyse how these 
molecules were affected in PC-3
PTPRKkd
 cells, the expression of caspase-3, -8, and -9 
was analysed using PCR, Q-PCR, and western blotting. There was a significant increase 
in both caspase-3 and -8 expressions, but not in caspase-9 following the knockdown of 
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PTPRK. This result showed that the increased apoptosis in PC-3
PTPRKkd
 cells was 
related with extrinsic signalling rather than mitochondrial signalling.  
 
Most PTPs play a role in promoting apoptosis. For example, PTP1B has been reported 
to play a role in the activation of MAPKs. PTP1B activates JNK and P38 pathway via 
inositol-requiring kinase 1 (IRE1) signalling and lack of PTP1B resulted in decreased 
levels of ER-induced apoptosis (Gu et al., 2004; Sangwan et al., 2006). However, 
SHP-1 dephosphorylates TrkA which in turn inhibits NGF-mediated PLCγ1 and Akt 
phosphorylation, reducing the TrkA survival signal (Marsh et al., 2003). In contrast, 
osteoclastic PTP (PTP-oc) has been reported to promote c-Src-mediated activation of 
NFκB and JNK leading cell protection from apoptosis (Amoui et al., 2007). In the 
present study, the reduction of PTPRK expression in PC-3 cells shows a promotion of 
apoptosis and an involvement of MAPK signalling pathway. The tyrosine 
phosphorylation of JNK was increased in PC-3
PTPRKkd
 cells and promotion of apoptosis 
in PC-3
PTPRKkd
 cells was diminished after treating cells with the JNK inhibitor 
(SP600125). These data suggest that PTPRK down-regulates apoptosis in prostate 
cancer cells by suppressing the JNK pathway.  
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We also investigated other apoptosis-related molecules such as p53, ID1 and c-Myc. 
These molecules play crucial roles in the regulation of cell proliferation. Expression of 
c-Myc in tumours helps cancerous cells pass through check-points and progress to the 
G2/M phase of cell cycle. In addition, expression of ID1 activates NFκB, which then 
induces Bcl-2 to inhibit apoptosis. In contrast to these anti-apoptotic factors, p53 acts as 
a promoter of apoptosis. Furthermore, mRNA expression of p53 was increased and 
expression of ID1 was decreased. p53 regulates both cell cycle and apoptosis. There are 
some reports that show that expression of p53 is associated with the induction of 
apoptosis in different cancer cells (Pietsch et al., 2008). p53 silencing was able to 
suppress cadmium-induced apoptosis in prostate cells (Aimola et al., 2012). 
Additionally, activation of JNK can also up-regulatep 53 expression, leading to the 
accumulation of Bax which induces cell apoptosis in HeLa cells (Cao et al., 2010). In 
contrast, ID1 expression increases NF-κB expression which is associated with the 
anti-apoptotic pathway. NF-κB activates Bcl-2 to initiate the mitochondrial mediated 
anti-apoptotic effect and also activates XIAP to inhibit the activities of caspase-3 and -9 
(Ling et al., 2003; Peng et al., 2012). These results indicate a complex network affected 
by PTPRK which participates in the coordination of cellular functions, making further 
investigations into the protein interactions between PTPRK and the network protein an 
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interesting area to explore in future. 
 
In conclusion, PTPRK knockdown resulted in increased apoptosis leading to the 
inhibition of in vitro growth of prostate cancer cells. PTPRK is a key factor in 
coordinating apoptosis via the regulation of MAPK pathways, in particular the JNK 
pathway in prostate cancer cells. 
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Chapter 6 
 
PTPRK is negative regulator 
of adhesion and invasion of 
breast cancer cells and is 
associated with poor prognosis 
of breast cancer 
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6.1 Introduction  
It has been demonstrated that most PTPs act as tumour suppressors in cancer, such as 
PTPRT and LAR in colorectal cancer (Wang et al., 2004). However, certain PTPs have 
been shown as oncogenic factors, for example PTPRA in breast and colon cancers 
(Tabiti et al., 1995; Ardini et al., 2000). 
 
PTPRK has been reported to regulate cell proliferation by coordinating EGFR pathway 
and TGF-β pathway (Xu et al., 2005). Activation of EGFR may trigger downstream 
cascades including MAPKs, PI3K/ Akt, and PLC/PKC. PTPRK affects the activation of 
both EGFR (ErbB1) and HER2 (ErbB2) by suppressing phosphorylation of the 
receptors and consequently reduces the basal and ErbB ligand-induced proliferation 
(Wang et al., 2005; Xu et al., 2005).  
 
The previous chapters have shown that PTPRK knockdown resulted in an inhibition of 
the in vitro growth of prostate cancer cells by promotion of apoptosis via JNK. To 
investigate if this pathway is a general phenominan and applicable to other tumour 
type(s) and if the PTPRK regulation of cancer cell functions may have a clinical 
relevance, we chose another tumour type, namely breast cancer, due to the hypothesised 
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impact of PTPRK on the tumour type and the available tumour cohort. The current 
chapter aims to investigate the role played by PTPRK in breast cancer, particularly the 
link to disease progression and impact on functions of breast cancer cells. 
 
6.2 Materials and methods 
6.2.1 Breast cancer tissues 
Breast samples were collected immediately after surgery and stored at -80°C until use, 
with approval of the Bro Taf Health Authority local research ethics committee. All 
patients were informed and participated with written consent. All the specimens used in 
the current study were verified by a consultant pathologist. A routine follow-up was 
carried out after surgery and details were stored in a database. The median follow-up 
period was 120 months. 
 
6.2.2 Antibody and primers 
Polyclonal rabbit anti-PTPRK antibody (SC-28906) was obtained from Santa Cruz 
Biotechnology (Santa Cruz, California, USA). All the primers used were synthesised 
and provided by Invitrogen (Paisley, UK). Primer sequences are located in Tables 2.2 
and 2.3. 
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6.2.3 Cell lines 
MDA-MB-231, MCF-7, MDA-MB-436, BT474 and BT483 were routinely cultured in 
DMEM-F12 medium as described in section 2.3. 
 
6.2.4 Generation of PTPRK ribozyme transgenes 
Hammerhead ribozymes targeting PTPRK were designed based on the secondary 
structure of PTPRK mRNA, and synthesised following a previously described method 
in section 2.7. Primer details are listed in the Table 2.3. 
 
6.2.6 Breast cancer cell transfection and generation of stable transfectants 
Anti-PTPRK hammerhead ribozyme transgenes and empty plasmids were transfected 
into the breast cancer cells, followed by a selection using blasticidin (5µg/ml). The 
transfectants were verified for PTPRK knockdown using RT-PCR, Q-PCR and Western 
blotting. Full details of the cloning process have been given in section 2.7. 
 
6.2.7 RNA isolation, cDNA synthesis, and RT-PCR 
RNA was isolated from the cells using the Tri Reagent kit (Sigma-Aldrich, Inc., Poole, 
Dorset, England, UK). For tissue RNA extraction, all frozen tissues were sectioned 
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using a cryostat (Leica DM40). Up to 50 frozen sections from each sample were 
collected, combined and homogenised in 1ml Tri Reagent solution, using a handhold 
homogenizer (Fisher Scientific). Total RNA was extracted according to the 
manufacturer's instruction. cDNA was synthesised by reverse transcription using the 
iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, California, USA), as described in 
section 2.4. RT-PCR was carried out at the following conditions; 94˚C for 5 minutes, 
followed by 30 to 42 cycles of 94˚C for 30 seconds, 56˚C for 30 seconds, and 72˚C for 
1 minute and a final extension of 7 minutes at 72˚C. The products were run on an 
agarose gel and visualised using ethidium bromide. 
 
6.2.8 Protein extraction, SDS-PAGE, and Western blot analysis 
Protein was extracted and was then quantified using the DC Protein Assay kit 
(BIO-RAD, USA). After SDS-PAGE, the proteins were transferred onto nitrocellulose 
membranes which were then blocked and probed with the specific primary 
(anti-PTPRK 1:500) and the corresponding peroxidise-conjugated secondary antibodies 
(1:1000). All of the antibodies used in this study are listed in Table 2.4. The protein 
bands were eventually visualised using the chemiluminescence detection kit (Luminata, 
Millipore). 
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6.2.9 Immunochemical staining of PTPRK 
Immunochemical staining of PTPRK in breast cancer tissues were carried out using the 
anti-PTPRK antibody for the protein (1:100), followed by secondary antibody. For the 
detailed procedure refer to Section 2.5.9. 
 
6.2.10 In vitro cell growth assay 
The cells were seeded into two 96 well plates, and incubated for 1 and 5 days 
respectively, as described in section 2.8.1. Following incubation, the cells were fixed 
and stained with crystal violet before the absorbance was measured in order to 
determine cell number. 
 
6.2.11 In vitro cell Matrigel adhesion assay 
The cells were seeded into a 96 well plate coated with matrigel as described in section 
2.8.2. The cells were left to adhere for a period of 40 minutes, before being fixed and 
stained with crystal violet. The adherent cells were then photographed and counted 
under a microscope. 
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6.2.12 In vitro cell motility assay 
The protocol followed is described by Jiang (Jiang et al., 1995b). Cells are seeded into a 
24 well plate and cells were treated with a protein of interest in serum free media if 
required. These plates were then left to incubate at 37
o
C, with 5% CO2, for a period of 
24 hours to allow cells to form a confluent monolayer. Subsequently, the cells were 
wounded and photos taken using a microscope with camera at 0.25, 1, 2 and 3 hours 
after wounding. Migration distances were measured using ImageJ softwear (National 
Institutes of Health, USA) 
 
6.2.13 In vitro cell Matrigel invasion assay 
The cells were seeded into transwell inserts with 8μm pores coated with 50 μg matrigel, 
in a 24 well plate and were incubated for a period of 3 days. Following incubation the 
cells which had migrated through the matrigel to the other side of the insert were fixed 
in formalin, stained with crystal violet and counted. 
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6.3 Results 
6.3.1 Expression of PTPRK in breast cancer. 
The expression of PTPRK was examined in breast cancer cell lines and a cohort of 
breast cancer tissues. The expression of PTPRK mRNA in breast cancer cell lines was 
determined using RT-PCR. PTPRK was expressed similarly in five different breast 
cancer cell lines (Figure 6.1A). We quantified PTPRK transcript levels in the breast 
specimens using Q-PCR, in which expression of PTPRK appeared to be higher in breast 
tumour tissues compared with the normal mammary background tissues (Figure 6.1B).  
IHC revealed a stronger staining of PTPRK in tumour tissues compared with normal 
background tissues (Figure 6.1C) which is consistent with PTPRK mRNA expression. 
Staining intensity analysis confirmed higher PTPRK expression in breast cancer (Figure 
6.1D).  
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Figure 6.1 Expression of PTPRK in breast cancer. A, Expression of PTPRK mRNA 
in breast cancer cell lines using RT-PCR. B, PTPRK transcript levels were increased in 
human breast cancer compared with normal breast tissues. C, The 
immunohistochemical staining revealed an increase staining of PTPRK in breast cancer 
tissues compared with normal tissues. C1, Normal breast. C2, Ductal carcinoma in situ. 
C3 and C4, Ductal carcinoma. C5, negative control. *, P < 0.05.
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6.3.2 Correlation of PTPRK expression with histological type, tumour grade, 
lymph node involvement, and tumour-node-metastasis stage. 
Levels of PTPRK transcripts were analysed against the corresponding clinical and 
pathological data (Table 6.1). PTPRK levels appeared to be lower in well differentiated 
tumours, but there was no significant differences compared with its expression in 
moderately differentiated tumours and poorly differentiated tumours. There was no 
correlation observed between PTPRK expression and lymph node involvement. 
Furthermore, PTPRK levels were lower in tumours of early TNM stage and were 
up-regulated in the advanced tumours, particularly the most advanced tumours of 
TNM4, p= 0.0096 compared with TNM1.  
 
6.3.3 Prognostic relevance and clinical outcomes of PTPRK in breast cancer. 
According to the Nottingham Prognostic Index (NPI) which takes into consideration of 
tumour grade, tumour size and nodal status, we further analysed the relationship 
between prognosis and PTPRK expression. PTPRK was expressed at similar levels in 
the groups of NPI 1 (NPI score<3.5, good prognosis) and NPI 2 (NPI score=3.5-5.4, 
moderate prognosis). A decreased expression of PTPRK was seen in the tumour of NPI 
3 (NPI score>5.4, poor prognosis) compared with NPI 1, p= 0.039. PTPRK transcript 
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levels were decreased in patients who had metastases or died from breast cancer 
p=0.0039 and p= 0.0075 compared respectively with that of patients being disease free. 
Furthermore, the relationships between PTPRK expression and oestrogen receptors 
(ERs) had also been analysed. There was no difference observed in PTPRK transcript 
levels among tumours with different ERα expression. PTPRK expression appeared to be 
higher in ERβ positive group which was not statistically significant (Table 1). The 
Kaplan-Meier survival model was used to analyse the overall survival and disease-free 
survival status of patients. The average level of PTPRK transcripts in NPI 2 group was 
used as threshold. It was found that patients with higher PTPRK transcript levels had a 
longer overall survival (n=35, 138.8 months, 95% CI= 130.1-147.5 months), p= 0.016 
vs. that of patients with lower transcript levels (n= 49, 122.0 months, 95% CI= 
105.3-138.6 months) (Figure 6.2A). The patients displaying higher expression of 
PTPRK also had longer disease-free survival (n=35, 135.5 months, 95% CI= 
124.9-146.1 months), p= 0.014 vs. that of patients with lower transcript levels (n= 49, 
114.6 months, 95% CI= 97.5-131.8 months) (Figure 6.2B). 
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Table 6.1 Transcript levels of PTPRK in breast cancer 
Clinical/pathological features  Mean± SD (copy no.) P-value 
Tissue sample   
  Normal 41727±29372  
  Tumour 94853±29454 0.20 
Grade    
  1  49406±26362  
  2  58798±30155 0.82 
  3  91732±79298 0.15 
NPI    
  1 (<3.5)  101232±35303  
  2 (3.5-5.4)  133681±76599 0.70 
  3 (>5.4)  21029±14034 0.039 
TNM    
  1  66529±24657  
  2  138704±78190 0.38 
  3  91732±79298 0.77 
  4  402±131 0.0096 
Clinical outcome    
  Disease-free  93337±29257  
  Poor outcome  104467±87823 0.91 
    With metastasis  5327±4270 0.0039 
    With local recurrence  604691±533976 0.41 
    Died of breast cancer  10392±7684 0.0075 
Histology   
Ductal 114036±36747  
Lobular 4542±2265  
Others 86319±74256 0.75 
Lymph node status         
  Negative 101232±35303  
  Positive 97728±52643 0.96 
Estrogen receptor   
ERα (-) 96298±32787  
ERα (+) 96323±71111 1.00 
ERβ (-) 78492±26375  
ERβ (+) 164555±118437 0.49 
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Figure 6.2 The Kaplan-Meier survival model demonstrated the impact of PTPRK 
expression in breast cancer. Higher levels of PTPRK expression (n=35; vs lower 
expression, n=49) in primary breast tumours correlate with longer overall survival (A) 
and disease free survival (B). Groups of PTPRK expression level were divided by 
NPI2. 
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6.3.4 Knockdown of PTPRK in breast cancer cell lines. 
The expression of PTPRK was knocked down using ribozyme transgenes targeting 
human PTPRK mRNA. This was performed in two breast cancer cell lines, 
MDA-MB-231 (ER negative) and MCF-7 (ER positive), which expressed PTPRK 
(Figure 6.1A). The knockdown of PTPRK was verified in the transfectants using 
RT-PCR (Figure 6.3A), real-time quantitative PCR (Figure 6.3B) and Western blot 
(Figure 6.4). Decreased expression of PTPRK was seen in both MDA-MB-231
PTPRKkd
 
and MCF-7
PTPRKkd
 cells which were transfected with ribozyme transgenes, compared to 
their corresponding controls.  
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Figure 6.3 Knockdown of PTPRK transcript levels in breast cancer cells. 
Knockdown of PTPRK was seen in both MDA-MB-231
PTPRKkd
 (A1) and 
MCF-7
PTPRKkd
 (A2) cells using RT-PCR compared with their empty plasmid 
control (MDA-MB-231
pEF
 and MCF-7
pEF
) cells. Knockdown of PTPRK in 
MDA-MB-231 (B1) and MCF-7 (B2) cells was also verified using real-time 
quantitative PCR compared with pEF control cells. **, P < 0.01 and ***, P < 
0.001.
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Figure 6.4 Knockdown of PTPRK protein levels in breast cancer cells. A, 
Knockdown of PTPRK in MDA-MB-231 and MCF-7 cells was confirmed using 
western blot in comparison with pEF control. B, The Western blot band intensity of 
PTPRK. **, P < 0.01. 
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6.3.5 Knockdown of PTPRK promotes in vitro cell functions.  
The effect on in vitro cell functions by PTPRK knockdown was examined including 
cell growth, adhesion, invasion and migration. Knockdown of PTPRK in both 
MDA-MB-231 and MCF-7 cells exhibited an impact on cell growth. The 
MDA-MB-231
PTPRKkd
 cells showed an increased growth rate at day 3 (621.94±12.87, 
P<0.001) compared with MDA-MB-231
pEF 
(502.87±23.51) (Figure 6.5A1). Similarly, 
MCF-7
PTPRKkd
 cells showed the same trend, with a marked increase of growth rate at 
day 3 (326.36±23.29, P<0.001) compared with MCF-7
pEF 
(223.16±16.49) (Figure 
6.5A2). Knockdown of PTPRK in both MDA-MB-231 and MCF-7 cells had a 
significant influence on cell matrix adhesion. The MDA-MB-231
PTPRKkd
 cells 
(237.64±52.55 cells) exhibited an increased adhesion, P<0.05 compared with 
MDA-MB-231
pEF
 cells (154.17±23.67) (Figure 6.5B1). An enhanced adhesion was also 
seen in MCF-7
PTPRKkd
 cells (315.17±28.34 cells, p<0.001) compared with MCF-7
pEF
 
(233.67±30.10 cells) (Figure 6.5B2). Invasiveness of both MDA-MB-231 and MCF-7 
cells were also promoted after knockdown of PTPRK. Both MDA-MB-231
PTPRKkd
 and 
MCF-7
PTPRKkd
 cells showed a remarkably increased invasive capacity compared with 
respective controls (Figure 6.6A). Finally, in MDA-MB-231 cells, knockdown of 
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PTPRK increased motility compared with MDA-MB-231
pEF
 (Figure 6.6B). No obvious 
effect of PTPRK knockdown was seen on the migration of MCF-7. 
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Figure 6.5 The effects of PTPRK knockdown on cell growth and adhesion of breast 
cancer cells. Knockdown of PTPRK increased the in vitro growth of breast cancer cells, 
MDA-MB-231 (A1) and MCF-7 (A2). Knockdown of PTPRK promoted cell-matrix 
adhesion in both MDA-MB-231 (B1) and MCF-7 (B2) cells. *, P < 0.05 and ***, P < 
0.001. Growth rate (%) = Day1 absorbance/ Day 3 absorbance x100.
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Figure 6.6 The effects of PTPRK knockdown on cell invasion and motility of 
breast cancer cells. Knockdown of PTPRK in MDA-MB-231 (A1) and MCF-7 (A2) 
cells increased cell invasive ability. B1, Knockdown of PTPRK in MDA-MB-231 cells 
increased cell motility. B2, Knockdown of PTPRK had no effects on cell motility in 
MCF-7 cells ***, P < 0.001. 
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6.4 Discussion 
Previous studies have already shown that breast cancer is associated with different PTPs, 
such as PTPγ, LAR, PTPα, PTP1B, and DEP-1. PTPγ has been report as a tumour 
suppressor in kidney and lung adenocarcinoma and its expression has also been seen to 
be reduced in breast cancer tissues compared with normal tissues. Furthermore, 
expression of PTPγ is reduced in tumours compared with normal tissues, which is also 
related to higher ERα and lower ERβ expression. It is suggested that PTPγ may be an 
estrogen-regulated tumour suppressor in human breast cancer (LaForgia et al., 1991; 
Zheng et al., 2000; Liu et al., 2002). However other PTPs may play very different roles 
in malignancies. For example, LAR expression is increased and detected as a 
neuronal-type splicing format in breast tumours (Yang et al., 1999). PTPα is able to 
induce fibroblast transformation via regulation of Src, in which overexpression of PTPα 
in cells is accompanied with increased Src activity and blockage of PTPα leads to a 
reduced activity of Src (Su et al., 1999). Overexpression of PTPα has also been 
indicated in poorly differentiated breast cancer and also the ER positive tumours. 
Overexpression PTPα in MCF-7 resulted in increased Src activity and an inhibition of 
cell growth which may due to an arrest of cell at G0/G1 phase (Zheng et al., 1992; 
Ponniah et al., 1999; Su et al., 1999; Ardini et al., 2000). Moreover, PTP1B is 
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up-regulated in human breast cancer cells by neu oncogene.  PTP1B also activates 
c-Src in breast cancer cells (MDA-MB-435) (Zhai et al., 1993; Wiener et al., 1994; 
Bjorge et al., 2000). 
 
Although the levels of PTPRK transcript were higher in tumour versus normal (Table 
6.1), there was a distinct association between loss of PTPRK and increasing NPI within 
the tumour tissues themselves. This supports a role for PTPRK in tumours as a potential 
tumour suppressor. In the current study, levels of PTPRK transcript in a breast cancer 
cohort were analysed against the corresponding clinical and pathological data. The 
results showed that patients with advanced breast cancer and poor prognosis, especially 
patients with metastases and who died from breast cancer had relatively lower levels of 
PTPRK expression. Moreover, the patients with lower expression of PTPRK had 
shorter overall survival and disease-free survival compared with those with higher 
expression. Certain PTPs have been shown to be differentially expressed in breast 
tumours with links to oestrogen receptors (LaForgia et al., 1991; Zheng et al., 2000; Liu 
et al., 2002). Although PTPRK expression is slightly higher in ERβ positive than ERβ 
negative, there was no statistical difference. Similarly, there was no correlation between 
PTPRK and ERα status seen in the current study.  
222 
 
 
Our present study has indicated that there is a profound role played by PTPRK in breast 
cancer cells. In line with the findings from the breast cancer cohort, knockdown of 
PTPRK, in both MDA-MB-231 and MCF-7 cell lines leads to increased in vitro cell 
proliferation, adhesion and invasion. Currently there are a few studies indicating that 
overexpression PTPs, such as PTPα, LAR, and DEP-1, inhibit cell proliferation (Zhai et 
al., 1993; Keane et al., 1996; Ardini et al., 2000). Furthermore, recent studies have 
shown that PTPRK is up-regulated by TGF-β and probably involved in TGF-β 
dependent anti-proliferation and cell migration effects. Co-localisation of PTPRK with 
β-catenin at adhesion junctions has been revealed in human embryonic kidney cells 
which stabilise E-cadherin/β-catenin complexes. The stabilisation of 
β-catenin/E-cadherin complexes can suppress wnt/β-catenin-induced transcription of 
target genes, such as cyclin D1 and c-Myc, leading to an inhibition of proliferation and 
migration in cancer cells (Yang et al., 1996; Novellino et al., 2008). In addition, it has 
been shown that PTPRK directly dephosphorylates EGFR and increased PTPRK 
expression decreases both basal and ligand-stimulated EGFR tyrosine phosphorylation, 
and reduced PTPRK expression leads to an increase in EGFR tyrosine phosphorylation. 
Blocking PTPRK expression accelerated cell cycle progression which may due to the 
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enhanced EGF-induced tyrosine phosphorylation of EGFR and HER2 (ErbB2), and the 
downstream ERK activation (Wang et al., 2005; Xu et al., 2005). However, the 
involvement of these pathways in the inhibitory effect of PTPRK on the growth, 
adhesion and invasion of breast cancer cells has yet to be investigated. 
 
In conclusion, lower expression levels of PTPRK are correlated with poor prognosis 
and reduced overall survival and disease free survival. Moreover, knockdown of 
PTPRK resulted in increased adhesive and invasive abilities and promoted the cell 
proliferation and motility of breast cancer cells. This suggests that PTPRK may be a 
potential tumour suppressor in breast cancer. 
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Chapter 7 
 
PTPRM is a negative regulator 
of proliferation and invasion 
of breast cancer cells and is 
associated with disease 
prognosis in breast cancer 
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7.1 Introduction 
PTPs are characterised by variable extracellular multiple domains and exhibit features 
of cell adhesion molecules in their extracellular segment. It has been implicated in 
cell-cell and cell-matrix contact via dimerisation, phosphorylation and reversible 
oxidation (Angers-Loustau et al., 1999; Stoker 2005). PTPRM belongs to the same PTP 
R2B subfamily with PTPRK and its basically shares the some extracellular domains 
including Ig-like domain, MAM domain, and fibronectin type-III repeats. 
 
PTPRM has a similar structure to cell-cell adhesion molecules and has been shown to 
exhibit homophilic binding and confer cell-cell adhesion in cells including epithelial 
and cancer cells. Moreover, PTPRM also recognises other subfamily members to 
mediate cell-cell aggregation (Brady-Kalnay et al., 1993; Becka et al., 2010). Like 
other PTPs, PTPRM is regulated by the balance between the actions of protein tyrosine 
kinases (PTKs) and PTPs. Reduced expression of PTPRM resulted in an increased 
phosphorylation of tyrosine 992 of EGFR (pY992) by EGF, a docking site for PLCγ1 to 
activate PLCγ1, thus leading to increased cell migration in both wounding and 
chemotaxis assays (Phillips-Mason et al., 2008; Hyun et al., 2011). 
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The previous chapters have shown the effects of PTPRK knockdown in breast cancer 
cells and PTPRK expression associates with prognosis in breast cancer. It has been 
reported that PTPRM is associated with carcinogenesis of ovarian carcinoma (Gyorffy 
et al., 2008). However, the role played by PTPRM in breast cancer remains unknown. 
In order to investigate the PTPRM in breast cancer, the disease progression and impact 
of PTPRM on functions of breast cancer cells were analysed. 
 
7.2 Materials and methods 
7.2.1 Breast cancer tissues 
The collection and preparation of breast tissue samples have been introduced in the 
previous chapter section 6.2.1. 
 
7.2.2 Antibody and primers 
The primers used in this chapter are shown in Table 2.2 including PTPRM and MMP9. 
The antibodies used in this chapter including anti-PTPRM, PLCγ, JNK, ERK and 
phospho-tyrosine are shown in Table 2.4. 
 
 
227 
 
7.2.3 Cell lines 
MDA-MB-231 and MCF-7 were routinely cultured in DMEM-F12 medium as 
described in section 2.3. 
 
7.2.4 Generation of PTPRM ribozyme transgenes 
Hammerhead ribozymes targeting PTPRM were designed based on the secondary 
structure of PTPRM mRNA and synthesised following a previously described method 
in section 2.7. Primers’ details are listed in the Table 2.3.  
 
7.2.6 Breast cancer cell transfection and generation of stable transfectants 
Following plasmid verification using DNA electrophoresis, the plasmids were 
transfected into target cells using the electroporation at 310V. The transfectants were 
then selected with 5μg/ml blasticidin for a period of two weeks. Empty plasmid vectors 
were also used to transfect the same cells in order to use as controls. After the selection, 
the cells were verified for PTPRM knockdown using RT-PCR, Q-PCR, and western 
blotting. Full details of the cloning process have been given in section 2.7. 
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7.2.7 RNA isolation, cDNA synthesis, and RT-PCR 
RNA was isolated from the cells using the Tri Reagent kit (Sigma-Aldrich, Inc., Poole, 
Dorset, England, UK), and converted into cDNA by reverse transcription using the 
iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, California, USA), as described in 
section 2.4. RT-PCR was carried out at the following conditions; 94˚C for 5 minutes, 
followed by 30 to 42 cycles of 94˚C for 30 seconds, 56˚C for 30 seconds and 72˚C for 1 
minute, and a final extension of 7 minutes at 72˚C. The products were run on an agarose 
gel and visualised using ethidium bromide. 
 
7.2.8 Protein extraction, SDS-PAGE, and Western blot analysis 
Protein was extracted and was then quantified using the DC Protein Assay kit 
(BIO-RAD, USA). After the SDS-PAGE, the proteins were transferred onto 
nitrocellulose membranes which were then blocked, and probed with the specific 
primary (1:500) and the corresponding peroxidase-conjugated secondary antibodies 
(1:1000). All of the antibodies used in this study are listed in Table 2.4. The protein 
bands were eventually visualised using the chemiluminescence detection kit (Luminata, 
Millipore). 
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7.2.9 Immunoprecipitation and detection of tyrosine phosphorylated ERK, JNK, 
and PLCγ 
Protein extracted from MDA-MB-231 cells was immunoprecipitated with anti-PLCγ, 
JNK, and ERK antibody in order to detect phosphorylation of these proteins. These 
immunoprecipitated protein samples were then run on an SDS-PAGE and blotted with 
anti-phosph-tyrosine antibody. Refer to section 2.5.3 for further details on 
immunoprecipitation method. 
 
7.2.10 In vitro cell growth assay 
The cells were seeded into three 96 well plates, and incubated for 1 and 5 days 
respectively, as described in section 2.8.1. Following incubation, the cells were fixed 
and stained with crystal violet before the absorbance was measured in order to 
determine cell number.  
 
7.2.11 In vitro cell Matrigel adhesion assay 
The cells were seeded into a 96 well plate coated with matrigel as described in section 
2.8.2. The cells were left to adhere for a period of 40 minutes, before being fixed and 
stained with crystal violet and the cells counted. 
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7.2.12 In vitro cell motility assay 
The protocol followed is described by Jiang (Jiang et al., 1995b). Cells are seeded into a 
24 well plate and cells were treated with a protein of interest in serum free media if 
required. These plates were then left to incubate at 37
o
C, with 5% CO2, for a period of 
24 hours to allow cells to form a confluent monolayer then the cells were wounded and 
took photos using a microscope with camera at 0.25, 1, 2 and 3 hours after wounding. 
Migration distances were measured using ImageJ software (National Institutes of 
Health, USA) 
 
7.2.13 In vitro cell Matrigel invasion assay 
The cells were seeded into transwell inserts with 8μm pores coated with 50 μg matrigel, 
in a 24 well plate and were incubated for a period of 3 days. Following incubation, the 
cells which had migrated through the matrigel to the other side of the insert were fixed 
in formalin, stained with crystal violet and counted. 
 
7.2.14 Electric cell-substrate impedance sensing (ECIS) 
The ECIS system (9600 model, Applied Biophysics Inc., USA) was used to quantify 
cell migration as previously reported (Jiang et al., 2008). 96W1E arrays were used in 
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this study. Cells were seeded at 40,000 cells per well in 200μl of DMEM medium alone 
or medium supplemented with 200nM PLCγ (U-73122), JNK (SP600125), ERK 
(FR180204) small inhibitors (MERCK, Germany). The resistance at 30 kHZ was 
recorded for 6 hours after wounded and the data was analysed using an ECIS-9600 
software package. 
 
7.2.15 Gelatin zymography assay 
1×10
6 
cells were counted and seeded to a tissue culture flask and incubated overnight. 
Following incubation, samples were washed once with 1x balanced salt solution 
followed by a wash with serum-free DMEM and then either incubated in serum-free 
DMEM control or treated medium for 4 hours. The treatments consisted of a 200 nM 
JNK or ERK inhibitors. After 4 hours the conditioned medium was collected. Protein 
samples were prepared in non-reducing sample buffer. Samples were separated using 
SDS-PAGE on gels containing 1% gelatine (Sigma-Aldrich Inc, USA). Gels were 
renatured for 1 hour at room temperature in washing buffer and incubated at 37
o
C in 
incubation buffer for 36 hours. The gel was stained with coomassie blue. The brightness 
of clear bands, where MMP9 was located and gelatine was degraded, was analysed 
using densitometry. 
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7.3 Results 
7.3.1 Expression of PTPRM in breast cancer 
A lower level of transcript expression was seen in breast cancer cells and the breast 
cancer tissue compared with normal mammary background tissue. Although transcript 
levels of PTPRM appeared to be reduced in breast cancer tissue in comparison with 
normal mammary tissues, the difference was not statistically significant (Figure 7.1). 
 
7.3.2 Association of PTPRM with tumour grade and TNM staging 
Levels of PTPRM transcripts were analysed against the corresponding clinical and 
pathological data (Table 7.1). PTPRM levels were higher in well differentiated tumours 
and were decreased in moderately differentiated tumours (p=0.011) and poorly 
differentiated tumours (p=0.031). Furthermore, PTPRM levels were higher in tumours 
of early TNM stage and decreased in the TNM2 (p=0.032). TNM3 and TNM4 tumours 
also tended to have decreased levels of PTPRM, compared to TNM1 tumours, but this 
was not statistically significant. This lack of significance was likely due to a smaller 
number of samples at advanced stages (TNM3, n=7 and TNM4, n=4). Tumours with 
lymphatic involvement appeared to have lower levels of PTPRM transcripts than the 
node negative tumours, but were not statistically significant. 
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Figure 1. Expression of PTPRM in breast cancer tissues. The PTPRM transcript 
level was decreased in human breast cancer compared with normal breast tissues using 
quantitative PCR, p=0.36.  
 
Table 7.1. Transcript levels of PTPRM in breast cancer. 
Clinical/pathological features  Mean± SD (copy no.) P-value 
Tissue sample 
    
   Normal 1687±1337  
   Tumour 428.8±148.8 0.36 
Grade    
   1 472±114  
   2 288.8±110 0.011 
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   3 92.5±279 0.031 
NPI    
   1 (<3.5)  605.4±277  
   2 (3.5-5.4)  339±132 0.39 
   3 (>5.4)  83.8±25.7 0.06 
TNM    
   1 423±105  
   2 172.8±45 0.032 
   3 212.7±208 0.27 
   4 165.5±109 0.13 
Clinical outcome    
   Disease-free  510±209  
   Poor outcome  219±66 0.19 
       With metastasis  209±163 0.27 
       With local recurrence  432±298 0.84 
       Died of breast cancer  170±55 0.012 
Lymph node status         
   Negative 605.4±277  
   Positive 257.7±91.9 0.24 
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7.3.3 Reduced PTPRM is associated with poor prognosis 
According to the Nottingham Prognostic Index (NPI), we further analysed the 
relationship between prognosis and PTPRM expression. Patients with moderate 
prognosis (NPI 3.5-5.4, p=0.39) and poor prognosis (NPI >5.4, p=0.06) exhibited lower 
levels of PTPRM compared to the good prognosis group (NPI<3.5). According to 
clinical outcome from our follow-up data, PTPRM transcript levels were decreased in 
patients who died from breast cancer when compared with that of disease free patients 
(p=0.012). To investigate whether PTPRM expression levels were correlated with 
long-term survival, we divided the patients into two groups according to the average 
PTPRM transcript levels of patients with moderate prognosis of NPI 3.5-5.4. 
Kaplan-Meier survival analysis demonstrated that the expression of PTPRM transcripts 
was significantly associated with disease free survival (Figure 7.2). The patients with 
lower expression of PTPRM had shorter survival (median=109.5 months, 95% 
CI=94.1-124.9), p=0.029 vs. that of patients with higher expression levels 
(median=142.5 months, 95% CI=129.6-155.4 months). 
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Figure 7.2 The Kaplan-Meier survival model of PTPRM in breast cancer. Higher 
levels of PTPRM expression (n=35; vs lower expression, n=49) in primary breast 
tumours correlate with longer disease free survival. *, p < 0.05. Groups of PTPRM 
expression level were divided by NPI2.
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7.3.4 Knockdown of PTPRM in breast cancer cells  
The expression of PTPRM was knocked down using ribozyme transgenes targeting 
human PTPRM mRNA. Two different breast cancer cell lines were employed in the 
current study. MDA-MB-231 cells are oestrogen receptor (ER) negative and appear to 
be more aggressive compared to MCF-7 cells which are ER positive. The knockdown 
of PTPRM in these two cell lines was verified in the transfectants using RT-PCR, 
real-time quantitative PCR and Western blot (Figure 7.3). Marked reduction of PTPRM 
expression was seen in both MDA-MB231
ΔPTPRM
 and MCF-7
ΔPTPRM
 cells which were 
transfected with ribozyme transgenes, compared to their corresponding wild type and 
empty plasmid control. 
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Figure 7.3 Knockdown of PTPRM in breast cancer cells. Knockdown of PTPRM was seen 
in both MDA-MB-231
ΔPTPRM
 (A) and MCF-7
ΔPTPRM
 (B) cells using RT-PCR compared with 
their wild type and (MDA-MB-231
WT
 and MCF-7
WT
) empty plasmid control (MDA-MB-231
pEF
 
and MCF-7
pEF
) cells. Knockdown of PTPRM in MDA-MB-231
ΔPTPRM
 (C) and MCF-7
ΔPTPRM
 
cells (D) was also verified using real-time quantitative PCR compared with pEF control cells. 
Knockdown of PTPRM in MDA-MB-231
ΔPTPRM
 (E) and MCF-7
ΔPTPRM
 (F) cells was confirmed 
using Western blot in comparison with wild type and pEF control. *, p < 0.05. 
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7.3.5 Effect on breast cancer cell functions by knockdown of PTPRM 
The effect on in vitro cell functions (cell growth, adhesion, invasion and migration) by 
PTPRM knockdown was examined. Knockdown of PTPRM in both MDA-MB-231 and 
MCF-7 cells exhibited a significant impact on in vitro cell growth. Both 
MDA-MB-231
ΔPTPRM
 and MCF-7
ΔPTPRM
 cells showed an increased growth rate at day 3 
compared with empty plasmid control (Figure 7.4A and 4B). Knockdown of PTPRM in 
both cell lines had a significant influence on cell matrix adhesion. Both cell lines 
exhibited a significantly stronger ability to adhere to matrix compared to empty plasmid 
control (Figure 7.4C and 4D). The invasiveness of both MDA-MB-231
ΔPTPRM
 and 
MCF-7
ΔPTPRM
 cells were also enhanced after knockdown of PTPRM. In vitro, both 
MDA-MB-231
ΔPTPRM
 and MCF-7
ΔPTPRM
 cells shown an increased invasive capacity 
compared with respective controls (Figure 7.5A and 5B). Finally, MDA-MB-231 cells, 
knockdown of PTPRM also enhanced cell motility (p<0.001) compared with 
MDA-MB-231
pEF
 (Figure 7.5C).  
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Figure 7.4. The effects of PTPRM knockdown on biological functions of breast 
cancer cells. A and B, Knockdown of PTPRM increased the in vitro growth of breast 
cancer cells. C and D, Knockdown of PTPRM promoted cell-matrix adhesion in both 
MDA-MB-231 and MCF-7 cells. ** p < 0.01 and *** p < 0.001. Growth rate (%) = 
Day1 absorbance/ Day 3 absorbance x100. 
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Figure 7.5. The effects of PTPRM knockdown on biological functions of breast 
cancer cells. A and B, Invasiveness of both MDA-MB-231 and MCF-7 cells were also 
promoted after knockdown of PTPRM. C, in vitro wounding assay showed that 
MDA-MB-231
ΔPTPRM
 cells promoted cell migration. ** p < 0.01 and *** p < 0.001. 
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7.3.6 Tyrosine phosphorylation of JNK and ERK were increased by PTPRM 
knockdown 
Recent reports have shown that a reduction in expression of Protein Tyrosine 
Phosphatase-1B (PTP1B) and T-Cell Protein Tyrosine phosphatase (TC-PTP) reduced 
ERK phosphorylation in MCF-7 cells (Blanquart et al., 2010) and PTPRM suppressed 
glioma cell migration by dephosphorylation of PLCγ1 (Phillips-Mason et al., 2011). To 
determine the relationship between these proteins, immunoprecipitation (IP) and 
western blotting was used to investigate the impact of PTPRM on the tyrosine 
phosphorylation of PLCγ1, JNK and ERK in MDA-MB-231 cells (Figure 7.6A). 
Results showed that tyrosine phosphorylation of both ERK (Figure 7.6B) and JNK 
(Figure 7.6C) were increased in MDA-MB-231
ΔPTPRM
 cells compared with 
MDA-MB-231
pEF
 cells (p<0.05). Our data also suggests that there is no change in 
tyrosine phosphorylation of PLCγ1 in PTPRM knockdown cells compared to control 
cells (Figure 7.6D). 
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Figure 7.6 Impact on tyrosine phosphorylation of JNK and ERK. A, 
immunoprecipitation and western blot showed tyrosine phosphorylation of JNK and 
ERK were increased in PTPRM knockdown cells, which exhibited no effect on PLCγ 
phosphorylation. Relative intensity of bands from three western blots was analysed 
using Image J software for PLCγ (B), JNK (C), and ERK (D). *, p < 0.05.
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7.3.7 Involvement of JNK and ERK pathway in PTPRM impact on cell migration  
In order to investigate breast cancer cell migration we used the ECIS system to analyse 
cell motility. MDA-MB-231 cells were treated with 200nM PLCγ1, ERK and JNK 
small inhibitors. As shown in Fig. 7.7, a decrease in cell motility was observed in 
MDA-MB-231
ΔPTPRM
 following incubation with JNK (Figure 7.7A) and ERK (Figure 
7.7B) small inhibitors compared to control cells, as shown by a slower rise in resistance 
compared to untreated knockdown cells, indicative of reduced migration onto the 
electrode. No effect was seen following the addition of PLCγ1 inhibitor (Figure 7.7C). 
Figure 7.7D shows the statistical analysis of resistance on the fifth hour following 
wounding and indicates that MDA-MB-231
ΔPTPRM
 cells migrated faster than 
MDA-MB-231
pEF
 cells in both control and PLCγ1 inhibitor treated groups, p<0.05. 
However, this effect on the migration was diminished in MDA-MB-231
ΔPTPRM
 cells 
when exposed to JNK or ERK inhibitors. 
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Figure 7.7 The knockdown of PTPRM in MDA-MB-231 cell resulted in increased 
cell motility via JNK and ERK pathways. Incubation of MDA-MB-231
ΔPTPRM
 cells 
with JNK small inhibitor (A) and ERK small inhibitor (B) diminished such effect. C, 
incubation of MDA-MB-231
ΔPTPRM
 cells with PLCγ small inhibitor had no effect on 
cell migration using ECIS. D, Overall changes of resistance on the fifth hour with 
statistical analysis. *, p < 0.05 and ***, p < 0.001. 
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7.3.8 Enzyme activity of MMP9 was increased via ERK in PTPRM knockdown 
cells. 
Recently, several reports have shown that MMP9 expression and activity were 
up-regulated by the ERK signalling pathway in different human cells (Liu and Wilson 
2012). In order to investigate MMP9 activity in breast cancer cells, we used gelatine 
zymography to analyse enzyme activity. Knockdown of PTPRM resulted in an increase 
of both active MMP9 and MMP2 in MDA-MB-231 cells, which was consistent with 
increased invasiveness. We further treated MDA-MB-231 cells with 200 nM JNK and 
ERK small inhibitor, respectively. The elevated MMP9 and MMP2 activity in PTPRM 
knockdown cells was reduced to a similar level seen in the control cells, especially after 
treatment with ERK inhibitor (Figure 7.8A). Furthermore, MMP9 gene expression is 
also increased in PTPRM knockdown cells (Figure 7.8B and 8C). 
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Figure 7.8 MMP9 expression and activity in MDA-MB-231 cell. A, gelatine 
zymography indicated the reduced enzyme activity of MMP9 in cells treated with ERK 
inhibitors.The overall MMP9 gene expression was increased in MDA-MB-231
ΔPTPRM
 
cells using (B) RT-PCR and (C) real-time quantitative PCR. 1: pro-MMP9, 2: MMP9, 
and 3: MMP2. * p < 0.05.
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7.4 Discussion 
Previous studies looking at the different PTPs have in general indicated that increased 
expression of PTPs is associated with breast cancer (Hiscox and Jiang 1998). This 
finding is not universal as Zheng et al (Zheng et al., 2000) showed that PTPRG was 
more highly expressed in normal tissue than in breast tumour tissue. PTPRM appears to 
have a similar tumour suppressing role and, for the first time, we demonstrate that in 
breast cancer there is a significant reduction in transcript levels. In the current study, 
levels of PTPRM transcript in a breast cancer cohort were analysed against the 
corresponding clinical and pathological data. The results showed that patients with 
higher tumour grade had relatively lower levels of PTPRM expression. Furthermore, 
the patients with lower expression of PTPRM had shorter disease-free survival 
compared with those with higher expression. 
 
Our present study has indicated profound roles played by PTPRM in breast cancer cells. 
Knock-down of PTPRM in both MDA-MB-231 and MCF-7 cell lines led to increased 
in vitro cell proliferation, adhesion and invasion. There was a study indicating that PKC 
is involved in PTPRM-dependent signalling. PTPRM, RACK1, and PKCδ exist in a 
complex in cultured retinal cells and retinal tissue. PKCδ is required for neurite 
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outgrowth of retinal ganglion cells on a PTPRM substrate (Rosdahl et al., 2002). 
Furthermore, PTPRM regulates the PKC pathway to restore E-cadherin-dependent 
adhesion via its interaction with RACK1 (Hellberg et al., 2002). Activation of PLCγ1 
is associated with increased invasion of cancer cells. A recent study has shown that 
PLCγ1 is a target of PTPRM and dephosphorylation of PLCγ1 is a major pathway by 
which PTPRM suppresses glioma cell migration (Phillips-Mason et al., 2011). However, 
in our current study no change in the activated PLCγ1 was seen in the PTPRM 
knockdown cells and the promoted migration was not affected by a PLCγ1 small 
inhibitor. This suggests that the PLCγ1 pathway is not involved in the effect on these 
breast cancer cells by knockdown of PTPRM. 
 
In addition to the PLCγ1 pathway, ERK and JNK pathways have been indicated in the 
functions of certain PTPs. It has been shown that reduction in expression of Protein 
Tyrosine Phosphatase-1B (PTP1B) and T-Cell Protein Tyrosine phosphatase (TC-PTP) 
reduced ERK phosphorylation in MCF-7 cells to regulate cell migration (Blanquart et 
al., ). Inhibition of JNK and ERK1/2 reduced PTP1B protein expression (Sarmiento et 
al., ) and the absence of PTP1B in endoplasmic reticulum (ER) resulted in an activation 
of JNK leading to a suppression of apoptosis (Gu et al., 2004). Moreover, a 45kDa 
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variant of TC-PTP (TC45) exits in the nucleus upon EGFR activation and inhibits the 
EGFR-dependent activation of JNK and consequent activation of PI3K/Akt pathway, 
but elicits no impact on activation of ERK2 (Tiganis et al., 1999). To examine the 
involvement of ERK and JNK pathways in the effect of PTPRM knockdown on breast 
cancer cell motility, we treated the cells with small inhibitors for these pathways. The 
effect of PTPRM knockdown on cell migration was diminished by blocking these 
pathways individually. This indicates that the dephosphorylation of ERK and JNK by 
PTPRM plays a critical role in coordinating functions of breast cancer cells. 
 
It has been suggested that MMP9 activity is related to the ERK pathway, as tumour 
necrosis factor (TNF) stimulates proMMP9 production in human chorionic trophoblast 
cells through ERK1/2 pathway but not JNK and p38 pathway (Li et al., 2010) and 
miR-520c and miR-373 up-regulated MMP9 expression by activation of 
Ras/Raf/MEK/ERK in human fibrosarcoma cells (Liu and Wilson 2012). Our data has 
thus indicated that MMP9 activity in MDA-MB-231
ΔPTPRM
 was increased compared 
with pEF control and this increase was diminished by the treatments with ERK and 
JNK inhibitors. MMP9 activity in the JNK inhibitor-treated PTPTM knockdown cells 
was reduced to a level similar to the corresponding control cells. This implies that 
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activation of JNK pathway resulting from PTPRM knockdown has contributed to the 
increased MMP9 activity. Surprisingly, in the ERK inhibitor-treated PTPRM 
knockdown cells, MMP9 activity was reduced to a level lower than the control cells and 
that this appeared to be much less affected by the small inhibitors. This may be due to 
the dual actions by the ERK pathway on the MMP9, i.e. activation and transcriptional 
regulation. It also suggests that the activity of MMP9 tends to be more dependent on the 
MAPK pathway in the PTPRM knockdown cells. Additionally, the potency and 
unknown effect of the small inhibitors used in the current study may also be a reason 
for such a difference. However, the exact mechanism and other unknown interacting 
molecules involved in this effect require further investigation.   
 
In summary, results from this study suggest lower expression levels of PTPRM to be a 
characteristic of breast cancer. Lower expression levels of PTPRM are correlated with 
poor prognosis and reduced disease free survival. Moreover, knockdown of PTPRM 
resulted in elevated adhesion, invasion and proliferation of breast cancer cells. 
Activation of ERK and JNK by tyrosine phosphorylation and consequent elevated 
MMP9 activity is involved in increased cell migration and invasion by PTPRM 
knockdown. 
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Chapter 8 
 
General discussion 
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Tyrosine phosphorylation is essential and dispensable for the signal transductions of 
many pathways involved in the tumourigenesis and metastasis. For example, tyrosine 
phosphorylation is important for EGFR, cMet and MAPK pathways to fulfil their 
regulation on cell proliferation, apoptosis, migration and morphology. EGFR is one of 
the most common targets of cancer therapy due to the involvement of EGFR in tumour 
growth and metastasis. The PI3K/ Akt pathway, downstream of EGFR, plays an 
important role in cell growth, apoptosis, and cell motility (Vivanco and Sawyers 2002). 
It has also been reported that PTEN (phosphatase with tensin homology), a well-known 
tumour suppressor and a phosphatase, negatively regulates the PI3K/ Akt pathway 
(Stambolic et al., 1998). It indicates that protein tyrosine phosphatases also play crucial 
roles cancer. 
 
8.1 PTPRK, PTPRM, and cancer 
PTPRK has been reported that PTPRK participates in the regulation of cell functions, 
mainly via EGFR and TGF-β pathways. These two pathways are involved in the 
regulation of most biological functions, for example, the EGFR pathway regulates cell 
proliferation via downstream PI3K/ Akt pathway and cell motility by FAK and also 
affects the MAPK pathway. PTPRM and PTPRK belong to the same subfamily and it 
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has been reported that PTPRM regulates cell migration by dephosphorylation of PLCγ1, 
consequently suppressing the cytoskeletal changes of migration (Rosdahl et al., 2002; 
Ensslen and Brady-Kalnay 2004; Phillips-Mason et al., 2008; Phillips-Mason et al., 
2011).  
 
Recent studies have shown that PTPRK and PTPRM both play important roles in 
cancer development (Nakamura et al., 2003; Gyorffy et al., 2008). The molecular 
mechanisms involved in the activation of PTPRK and PTPRM in prostate and breast 
cancer remain largely unknown. There is very little information in the literature 
concerning the specific involvement of PTPRK and PTPRM in cancer. This project 
aimed to provide more information about the function of PTPRK, PTPRM and the 
mechanism by which it exerts its effects on cancer cells.  
 
8.2 The role of PTPRK in prostate cancer 
Human PTPRK is widely expressed in different organs such as spleen, prostate and 
ovary and the expression of some PTPs is increased in prostate cancer patients such as 
PAcP (human prostatic acid phosphatase, a neutral PTP) (Yang et al., 1997; Veeramani 
et al., 2005). The IHC staining of PTPRK in tumour tissues appeared to be more 
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intensive compared to the normal prostate tissues. However, such difference was not 
statistically significant, when determined semi-quantitively. This may be due to the 
limited number of specimens available at the time of the study. The staining of PTPRK 
was seen mainly at the cell nuclei. Although PTPRK is a transmembrane protein 
phosphatase, there is a report that the post-translational modification of PTPRK is 
through cleavage of its extracellular domain (N-terminal) and RPTPs, PTPRM and 
LAR have also been shown to undergo post-translational modification (Gebbink et al., 
1991; Streuli et al., 1992; Jiang et al., 1993). The anti-PTPRK antibody we used was 
raised against amino acids 27-101, mapping within an N-terminal extracellular domain 
of PTPRK of human origin. Due to most of the PTPRK ICC staining being located at 
the cell nuclei, it indicated that after post-translational modification of PTPRK, the 
extracellular domain may be a molecule which participated in regulation of 
down-stream signalling pathways. However, the location of PTPRK should be further 
examined using IF staining with confocal microscopy analysis. The mechanism of this 
phenomenon warrants further investigation. 
 
PTPRK knockdown inhibited the growth and adhesion of both PC-3 and DU-145 cells. 
Moreover, knockdown of PTPRK resulted in a significant promotion of cell motility in 
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PC-3 cells, but not in DU-145 cells. In cell invasion assays, knockdown of PTPRK in 
PC-3 and DU-145 cells showed a completely different cell response. In PC-3 cells, 
knockdown of PTPRK reduced the invasiveness compared with control cells, while 
PTPRK knockdown in DU-145 cells promoted the invasive ability. The exact reason for 
the differential effect of PTPRK on the cell migration and invasion is currently 
unknown, but is likely to be due to differences in the expression patterns of other 
proteins involved in PTPRK function. Recent studies shows that JNK and ERK play 
important roles in regulation of metastasis, JNK and ERK activation is associated with 
promotion of MMPs activities in prostate cancer cells (Sekine et al., 2010; Chen et al., 
2011). In the current study, the phosphorylation of JNK was increased in PC-3 PTPRK 
knockdown cells however there was no effects on ERK phosphorylation. The mirgation 
mechanisms between PC-3 and DU-145 cells needs to be further investigated, with 
particular focus on the interacting molecules and pathways of PTPRK.  
 
Cell growth is important for cancer development. In order to elucidate the mechanism(s) 
by which PTPRK can inhibit the growth of prostate cancer cells, the apoptotic 
population was analysed using a flow cytometric assay. PC-3
PTPRKkd
 cells showed a 
significant promotion in the percentage of apoptotic cells under serum starvation 
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compared to the control PC-3
pEF
 cells, suggesting that PTPRK may act as an 
anti-apoptotic factor protecting PC-3 cells from undergoing apoptosis. Most PTPs play 
promoting roles in apoptosis. PTP1B has been reported that to be associated with 
MAPKs activation. PTP1B activates JNK and p38 pathways via IRE1 
(inositol-requiring kinase 1) signalling (Gu et al., 2004). However, the osteoclastic PTP 
(PTP-oc) has been reported to promote c-Src-mediated activation of NFκB and JNK 
leading to a protection of the cells from apoptosis (Amoui et al., 2007). In this study, 
PTPRK knockdown in PC-3 cells resulted in promotion of apoptosis. Moreover, the 
tyrosine phosphorylation of JNK was increased in PC-3 knockdown cells and the 
increased apoptosis in PC-3
PTPRKkd
 cells was diminished through treatment with a JNK 
inhibitor (SP600125). This suggests that PTPRK suppresses the apoptosis in prostate 
cancer cells by deactivating the JNK pathway. 
 
In general, apoptosis is associated with the activation of the caspase cascade (Halle et 
al., 2007). PC-3
PTPRKkd
 cells showed significantly higher expression levels of caspase-3 
compared to the empty plasmid control. Additionally, the upstream caspase-8, of the 
extrinsic cascade, was also increased in the cells. No change was seen in the expression 
of caspase-9. It has been demonstrated that caspase-8 is normally activated by extrinsic 
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receptor-mediated pathway and caspase-9 is activated by intrinsic 
mitochondrial-mediated pathway (Lee et al., 2011). The present study showed that the 
increased apoptosis in PC-3
PTPRKkd
 cells was more related with extrinsic signalling 
rather than mitochondrial apoptosis signalling. At the same time, we also investigated 
other apoptosis-related molecules including p53, ID1 and c-Myc. There are reports in 
the literature showing that expression of p53 is associated with the induction of 
apoptosis in different cancer cells (Pietsch et al., 2008). Silencing of p53 was able to 
suppress cadmium-induced apoptosis in prostate cells. Additionally, the activation of 
JNK can also up-regulate p53 expression leading to the accumulation of Bax which 
induces apoptosis of HeLa cell (Cao et al., 2010; Aimola et al., 2012). In contrast, ID1 
expression increases NF-κB expression, which is associated with the anti-apoptotic 
pathway (Ling et al., 2003; Peng et al., 2012). In PTPRK knockdown cells, the 
expression of p53 was increased whilst the expression of ID1 was reduced. These 
results indicate a complex network affected by PTPRK which participate in the 
coordination of apoptosis. 
 
In summary, activation of JNK by tyrosine phosphorylation and consequently increased 
p53, caspase-8/caspase-3 expression, and reduced ID1 expression are involved in the 
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differential rates of apoptosis of prostate cancer cells following PTPRK knockdown 
(Figure 8.1). 
 
Figure 8.1 Potential interacting pathways and molecules involved in the functions 
of PTPRK in prostate cancer cells. 
 
8.3 The role of PTPRK in breast cancer 
Previous studies have already demonstrated that breast cancer is associated with 
different PTPs, for example PTPγ, LAR, PTPα, PTP1B and DEP-1. However, the 
expression of PTPs exhibits certain variations in different malignancies. For example, 
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PTPγ expression is reduced in breast cancer tissues and is associated with higher ERα 
and lower ERβ expression (Zheng et al., 2000; Liu et al., 2002), whilst the expression 
of LAR is increased in the breast cancer (Yang et al., 1999). According to the current 
study, PTPRK expression appears to be increased in breast cancer which is yet to be 
validated larger cohort of breast cancer tissues. The clinical findings have been 
supported by the in vitro results in the present study. PTPRK knockdown promoted 
most cell functions of breast cancer cells including cell growth, adhesion, invasion and 
migration.  
 
However and interestingly, in vitro data showed almost completely opposite effects on 
the cellular functions of breast cancer cells compared with the prostate cancer cells 
tested. The sharp contrasts for the functions of PTPRK in the two tumour types are 
intriguing. There are previous studies which have indicated that ERK1/2 is the most 
relevant MAPK to breast cancer (Santen et al., 2002) and JNK is more relevant to 
prostate cancer (Kumar et al., 2010; Hubner et al., 2012; Sielicka-Dudzin et al., 2012). 
Thus, different downstream and upstream pathways to PTPRK in different tumour types 
and indeed in different cell lines of the same tumour type, may respond to PTPRK in a 
different fashsion, as seen in the present study. This can at least partially explain the 
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different effects of PTPRK knockdown seen in the breast cancer cells and prostate 
cancer cells. However, whether and how the ERK pathway is involved in the effect of 
PTPRK knockdown in breast cancer cells would be an exciting study to pursue in 
future. 
 
PTPRA expression is also increased in the poorly differentiated breast cancer and ER 
positive tumours. Overexpression of PTPRA in MCF-7 cells resulted in increased Src 
activity and an inhibition of cell growth (Ponniah et al., 1999; Ardini et al., 2000). The 
current study showed that patients with advanced breast cancer and poor prognosis, 
especially patients with metastases and who died from breast cancer, had low levels of 
PTPRK expression. Patients who had lower expression of PTPRK had shorter overall 
survival and disease-free survival compared with those with higher expression. Certain 
PTPs have been shown to be differentially expressed in breast tumours with links to 
oestrogen receptor status (LaForgia et al., 1991; Zheng et al., 2000; Liu et al., 2002). 
PTPRK expression was slightly higher in ERβ positive tumours than the ERβ negative 
tumours though this was not found to be statistically significant. Similarly, there was no 
correlation between PTPRK and ERα status seen in the current cohort of breast cancer. 
 
262 
 
Above all, lower expression levels of PTPRK were correlated with poor prognosis, 
reduced overall survival and disease free survival. Moreover, knockdown of PTPRK 
resulted in increasing adhesive and invasive abilities and promoted cell proliferation 
and motility of breast cancer cells. Together, this data suggests that PTPRK may be a 
negative regulator in breast cancer progression. 
 
8.4 The role of PTPRM in breast cancer 
PTPs expression is seen to vary in cancers, for example, the expressions of certain PTPs 
are increased in breast cancer but PTPRG expression is decreased (Hiscox and Jiang 
1998; Zheng et al., 2000). In the current study, we demonstrated a significant reduction 
of PTPRM transcripts in breast cancer. The results showed that patients with higher 
tumour grade had relatively lower levels of PTPRM expression. Furthermore, patients 
with lower expression of PTPRM had shorter disease-free survival compared with those 
with higher expression. 
 
PTPRM Knockdown in both MDA-MB-231 and MCF-7 cell lines led to increased in 
vitro cell proliferation, adhesion and invasion. Currently, PTPRM has been identified to 
interact with molecules such as PKC, PLCγ and EGFR. Firstly, PTPRM, RACK1 and 
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PKCδ exist in a complex form in cultured retinal cells and retinal tissue (Rosdahl et al., 
2002) and secondly PLCγ1 has been reported as a target of PTPRM and activation of 
PLCγ1 is associated with increased invasion of cancer cells. It has been reported that 
PTPRM reduces glioma cell migration via inactivation of PLCγ1 (Phillips-Mason et 
al., ). Thirdly, EGFR is dephosphorylated by PTPRM at pY992, the docking site for 
PLCγ1 activation. If this tyrosine is dephosphorylated by PTPRM, the activation of 
PLCγ1 is reduced and this may finally lead to a decrease in cell migration (Hyun et al., 
2011; Phillips-Mason et al., 2011). However, in the current study, PTPRM knockdown 
exhibited little effect on the activation of PLCγ1 and the promoted cell migration was 
also not affected by the PLCγ1 inhibitor. Apart from the PLCγ1 pathway, ERK and 
JNK pathways have also been demonstrated to play a role in the regulation of the cell 
functions which can be coordinated by PTPs. For example, PTP1B and TC-PTP have 
been reported to regulate the migration of breast cancer cells (MCF-7) via ERK 
pathway (Blanquart et al., 2010). In the current study, the tyrosine phosphorylation of 
ERK and JNK were increased in the PTPRM knockdown cells but not the PLCγ1. We 
further treated PTPRM knockdown cells with ERK and JNK inhibitors and found the 
promotion of cell migration was diminished by inhibition of these pathways. Taken 
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together, the data suggests that PTPRM can regulate the migration of breast cancer cells 
via ERK and JNK rather than PLCγ1. 
 
MMPs are zinc dependent proteolytic enzymes that can cleave their target ECM and 
non-matrix substrates such as growth factors. MMPs are crucial for tumour metastasis 
due to their ECM degrading activity. It has been indicated that MMP9 activity is related 
to the ERK pathway. This has been implicated in a study where TNF (tumour necrosis 
factor) was found to stimulate proMMP9 production in human chorionic trophoblast 
cells through ERK1/2 pathway but not JNK and p38 pathway (Li et al., 2010). 
miR-520c and miR-373 also up-regulate MMP9 expression by activation of 
Ras/Raf/MEK/ERK in human fibrosarcoma cells (Liu and Wilson 2012). The ERK 
pathway regulates proliferation, invasion, and MMP9 expression in colon cancer cells 
(CT-26) and a similar effect has also been seen with the JNK pathway which regulates 
the expression of both MMP2 and MMP9 (Son et al., 2010). In this study, we found the 
MMP9 activity wass increased in PTPRM knockdown cells and this increase was 
diminished by treating cells with ERK and JNK inhibitors. Treating cell with JNK and 
ERK individually both resulted in decreased MMP9 activity. MMP9 activity in PTPRM 
knockdown cells was reduced to a similar level of the control cells when treated by the 
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JNK inhibitor. However, the MMP9 activity in the PTPRM knockdown cells was 
reduced to a lower level compared with the control. Together, it indicates that MMP9 
activity is regulated by both JNK and ERK pathways in PTPRM knockdown cells but 
may be more dependent on ERK pathway. This may be due to the dual actions of the 
ERK pathway on MMP9, i.e. activation and transcriptional regulation. However, the 
exact mechanism and other unknown interacting molecules involved in this effect 
require further investigation.  
 
In summary, results from this study suggest lower expression levels of PTPRM to be a 
characteristic of breast cancer. Lower expression levels of PTPRM are correlated with 
poor prognosis and reduced disease free survival. Moreover, knockdown of PTPRM 
resulted in elevated adhesion, invasion, and proliferation of breast cancer cells. 
Activation of ERK and JNK by tyrosine phosphorylation and consequent elevated 
MMP9 activity is involved in increased cell migration and invasion by PTPRM 
knockdown (Figure 8.2). 
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Figure 8.2 Potential interacting pathways and molecules involved in the functions 
of PTPRM in breast cancer cells. 
 
8.5 Future work 
Further investigation into the relationship between PTPRK and prostate cancer is 
essential. The findings from this study have added further weight to the theory that 
PTPRK is a potential oncogene/proto-oncogene in prostate cancer but the precise 
mechanism of action is yet to be fully understood. First of all, from the results of this 
study and previous studies, the interplay between PTPRK and EGFR and TGF-β should 
be investigated. The present study on PTPRK in prostate cancer only used a small 
number of clinical samples, making it difficult to draw a solid clinical conclusion. This 
was limited by the number of quality samples available to this study. A large cohort 
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study supported by full clinical, pathological and followup information will be highly 
desirable.  
 
The different impacts on in vitro cell functions between prostate and breast cancer 
should be further investigated. ERs, ARs, and MAPKs play an important role in breast 
and prostate cancer development. In the current study, we already demonstrated that 
tyrosine phosphorylation of JNK was increased in prostate cancer cells and it has been 
reported JNK activation is more relevant to prostate cancer. Further investigation of 
MAPK and the crosstalk with hormones such as oestrogen and androgen and their 
receptors may shed further light on the differential responses to PTPRK and PTPRM 
seen in the breast and prostate cancer cells.  
 
The relationship between PTPRM and breast cancer is important as well. The findings 
from this study indicate that PTPRM is a potential tumour suppressor in breast cancer 
and its mechanism of action must be fully investigated. Previous studies indicated that 
PLCγ1, a proposed substrate of PTPRM, may be the key molecule to regulate cell 
migration in cancers. In this study, however, ERK and JNK play crucial roles in the 
regulation of cell migration in breast cancer cells. Further investigations focusing on the 
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ERK and JNK pathways in other cell functions and in relationship to the PTP family 
will be very valuable.  
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